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1. Abstract 
 
Adeno-associated virus type-2 (AAV2) is a member of the genus Dependovirus and the family 
Parvoviridae. In order to enter a lytic replication cycle, AAV2 requires the simultaneous co-
infection of a helper virus such as adenovirus (Ad), herpes virus or papillomavirus. In absence of 
a helper virus AAV2 establishes a latent infection by integrating its genome into the host cell 
genome, preferentially at a distinct site termed AAVS1on human chromosome 19. In the past, it 
has been documented that AAV2 is inhibiting replication of its helper viruses in the co-infected 
cell. Moreover, it has been shown that the non-structural AAV2 Rep proteins are responsible for 
the AAV2-mediated inhibition of helper virus replication. While the mechanism of Rep-mediated 
inhibition of Ad replication has been described explicitly, less is known about the mechanism 
how Rep inhibits herpes virus replication. In particular, although the herpes simplex virus type-1 
(HSV-1), a prominent human pathogen, has experimentally been used as the preferred helper 
virus for AAV2 replication among the herpesviruses, to date interference of the Rep protein with 
the HSV-1 replication cycle has been poorly understood. Therefore, the goal of this work was to 
identify the mechanism of AAV2 Rep-mediated inhibition of HSV-1 replication. We demonstrate 
by using a set of plasmids encoding mutant and wild-type (wt) Rep that the DNA-binding and 
helicase domains in cis are necessary and sufficient for inhibition of HSV-1 replication, while the 
endonuclease domain is dispensable. Moreover, we show that Rep is inhibiting HSV-1 at the 
stage of DNA replication. Assessment of the HSV-1 protein levels revealed that Rep proteins are 
not diminishing HSV-1 immediate-early (IE) and early (E) gene expression which are required for 
HSV-1 DNA replication, but cause a clear reduction in the levels of the late (L) proteins, 
indicating that inhibition indeed occurs at the stage of DNA replication. The Rep activities 
required for inhibition of HSV-1 DNA replication precisely coincide with the activities that were 
required for the induction of apoptosis and DNA-damage response (DDR) in the cell. More 
precisely, the AAV2 Rep proteins induce a DDR in cells that includes the hyper-phosphorylation 
of replication protein A (RPA) which is not activated upon infection with HSV-1 alone. Therefore, 
we tested whether either the Rep-mediated induction of apoptosis or the activation of RPA are 
responsible for the Rep-mediated inhibition of HSV-1 DNA replication. However, the results of 
these experiments revealed that neither pathway is directly responsible for inhibition of HSV-1 
replication; rather they are downstream effects resulting from the DNA-binding and helicase 
activities of Rep. We therefore hypothesized that the AAV2 Rep proteins can interfere with the 
HSV-1 DNA replication process directly. The Rep proteins may bind to putative Rep-binding 
sites (pRBS) on the HSV-1 genome and modify the bound DNA substrate via the helicase 
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activity. Of note, the Rep-binding site (RBS) is a specific nucleotide sequence motif within the 
AAV2 genome and the AAVS1 site required to direct the Rep proteins to the AAV2 or host DNA 
during replication, transcription and integration. The very same RBS nucleotide characteristics 
were used to identify putative (p)RBS on the HSV-1 genome. We identified nine pRBS motifs on 
the HSV-1 genome and demonstrated that the Rep proteins indeed are capable of binding to 
these sites in silico and in vitro. Moreover, we demonstrated that the helicase activity per se can 
inhibit DNA replication. The AAV2 Rep-helicase activity is inhibiting any replicating dsDNA 
substrate if it can bind to it, independently of the AAV2 DNA-binding domain. Our results suggest 
the following mechanism that contributes to Rep-mediated inhibition of HSV-1 DNA replication: 
the Rep proteins bind to pRBS motifs on the HSV-1 genome and modify the dsDNA via the 
helicase activity which is ultimately resulting in a stalled replication fork (RF). This mechanism is 
in analogy with the MCM2 helicase activity which is continuing to unwind the dsDNA substrate 
when it is uncoupled from the replication complex, e.g. during a stalled RF. This process is 
leading to inhibition of DNA replication, an event necessary to provide a time window for the cell 
to repair the damaged DNA. 
In a second project, we assessed the phenotypic profile of a novel AAV2 Rep protein mutant 
which comprises a Tyrosin substituted for an Asparic acid at position aa-371 (D371Y). This 
mutation lies directly within the Rep-helicase domain and is associated with an intriguing 
phenotype. While the helicase activity necessary for the AAV2 DNA replication is unaffected, the 
helicase activity required for the inhibition of HSV-1 DNA replication is reduced. Moreover, the 
mutant Rep78D371Y proteins exhibit significantly less toxicity in cell culture. Specifically, the 
initiation of a cellular DNA-damage response (DDR) is reduced by 20-60% in cells expressing 
Rep78D371Y compared to cells expressing the wt Rep78. In addition, the mutant Rep78D371Y 
proteins are completely incapable of inducing apoptosis in transfected cells. These data led to 
the hypothesis that this novel AAV2 Rep mutant may augment the performance of HSV/AAV 
hybrid gene-therapy vectors. Essentially, in transduced cells these hybrid vectors rely on the 
expression of the Rep proteins to establish site-specific integration of the AAV2 ITR-flanked 
transgene into the host cell genome. Hence, the necessary existence of the Rep ORF on the 
vector in cis leads to the expression of the Rep proteins during production of the vector stocks 
and therefore the inhibition of the HSV-1 based hybrid vector DNA replication. By introducing the 
novel mutant Rep78D371Y ORF into the hybrid vectors, we improved hybrid vector stock titers 
up to 10-fold. In addition, the low toxicity of Rep78D371Y may have a positive effect on the 
physiology of transduced cells, diminishing safety concerns in clinical trials.  
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2. Zusammenfassung 
 
Das Adeno-assoziierte Virus vom Serotyp-2 (AAV2) gehört zum Genus Dependovirus innerhalb 
der Familie der Parvoviridae. AAV2 ist ein replikations-defektes Virus und benötigt für die 
Replikation die gleichzeitige Anwesenheit eines sogenannten Helfervirus. Zu den Helferviren 
von AAV2 gehören unter anderem Adenoviren, Herpesviren und Papillomaviren. In Abwesenheit 
eines Helfervirus, kann AAV2 sein Genom an einer bestimmten Stelle (AAVS1) des 
menschlichen Chromosoms 19 integrieren. So kann AAV2 mehrere Monate bis Jahre in einer 
latenten Phase verbleiben bis ein potentielles Helfervirus die Zelle infiziert und die nötigen 
Helferproteine für die AAV2 Replikation zur Verfügung stellt. In der Vergangenheit ist gezeigt 
worden, dass AAV2 alle seine Helferviren an der Replikation hindern kann, möglicherweise um 
die Konkurrenz um zelluläre und virale Ressourcen zu minimieren. Der Mechanismus wie AAV2 
die Replikation von Adenoviren inhibiert ist bekannt und wurde bereits detailliert beschrieben. 
Hingegen ist der Mechanismus wie AAV2 Herpesviren inhibiert nur sehr vage bekannt. Man 
weiss lediglich, dass der Mechanismus durch die nicht-strukturellen AAV2 Rep Proteine 
induziert wird. Das Ziel dieser Studie war es, diesen Mechanismus näher zu identifizieren und zu 
beschreiben. In einem ersten Schritt haben wir die funktionellen Domänen der Rep Proteine 
identifiziert, welche für die Inhibition der HSV-1 Replikation verantwortlich sind. Wir haben dazu 
eine Reihe von wild-typ (wt) und mutanten Rep Proteinen getestet und haben herausgefunden, 
dass die DNA-bindungs Domäne zusammen mit der ATPase/Helikase Domäne für die Inhibition 
von HSV-1 verantwortlich ist. Erstaunlicherweise ist die Endonuklease Aktivität von Rep nicht 
notwendig um HSV-1 zu inhibieren. Das Gen-Expressionsprofil von HSV-1 infizierten Zellen hat 
gezeigt, dass die Rep Proteine die Expression der HSV-1 immediate-early (IE) und early (E) 
Gene nicht beeinflussen, hingegen ist die Expression der late (L) Gene stark reduziert. Dies war 
ein erster Hinweis, dass die HSV-1 DNA Replikation selbst betroffen ist, da die Expression der L 
Proteinen von der HSV-1 DNA Synthese abhängig ist. Einen zweiten Hinweis haben Southern 
Blot Experimente ergeben, mit welchen wir die HSV-1 DNA visualisiert haben. Dabei zeigte sich, 
dass die Expression der Rep Gene die Produktion von HSV-1 DNA Kopien stark beeinträchtig 
hat. 
Da die gleichen Rep Domänen, welche für die HSV-1 Inhibition benötigt werden genauso 
verantwortlich sind, um einen sogenannten zellulären DNA-damage response (DDR) auszulösen 
und die Zellen in Apoptose zu versetzen, haben wir angenommen, dass diese Effekte auf die 
Zelle mögliche Mechanismen sein könnten, welche für die Inhibition der HSV-1 DNA Replikation 
verantwortlich sind. Genau gesagt induzieren die Rep Proteine einen DDR welcher unter 
3
anderem durch die Aktivierung der Replikations Proteine A (RPA) charakterisiert ist. Wir haben 
daher untersucht, ob die Aktivierung von RPA unabhängig von Rep einen Einfluss auf die HSV-1 
DNA Replikation hat. Zudem haben wir getestet, ob die Rep-induzierte Inhibition von HSV-1 
verhindert werden kann, wenn wir die Apoptose in Zellen gezielt unterdrücken. Beide 
Experimente haben jedoch gezeigt, dass keine dieser Funktionen für die Inhibition von HSV-1 
verantwortlich sind. Daraus folgerten wir, dass die AAV2 Rep Proteine einen direkten Einfluss 
auf die HSV-1 DNA Replikation haben müssten. Die Rep Proteine könnten theoretisch mit ihrer 
DNA-bindungs Domäne direkt an die doppel-strängige HSV-1 DNA binden und diese mit Hilfe 
der Helikase Aktivität entwinden und so die DNA Replikation verunmöglichen. Die DNA-
bindungs Domäne von Rep bindet nämlich an eine ganz spezifische Nukleinsäure Sequenz, 
welche Rep-binding site (RBS) genannt wird. Solche RBS befinden sich auf der AAV2 DNA und 
auf der AAVS1 Stelle im humanen Chromosom 19. Rep Proteine binden gezielt an diese DNA 
Abschnitte um die AAV2 Replikation, Transkription, oder die Integration zu steuern. Wir haben 
daher das HSV-1 Genom auf das Vorhandensein solcher RBS untersucht und haben neun 
mutmassliche RBS gefunden. In vitro Versuche haben ergeben, dass aufgereinigte Rep 
Proteine tatsächlich an diese RBS Stellen auf der HSV-1 DNA binden können. In einem weiteren 
Versuch haben wir gezeigt, dass die Helikase Aktivität von Rep unabhängig von der DNA-
bindungs Domäne jedes DNA Substrat so manipuliert, dass eine Replikation nicht mehr möglich 
war. Mit diesen beiden Erkenntnissen konnten wir die Theorie bestätigen dass die Rep Proteine 
an die HSV-1 DNA binden und mit der Helikase Aktivität die Replikation inhibieren können. 
Diese Hypothese erhält zusätzliche Unterstützung aus der Tatsache, dass die Zelle einen sehr 
ähnlichen Mechanismus benützt, um die eigene DNA Replikation zu kontrollieren. Wenn die 
replizierenden Polymerasen einen defekten DNA Strang vorfinden, löst sich der mini-
chromosome maintenance 2-7 (MCM2-7) Protein Komplex von den Polymerasen ab und 
entwindet einen Teil der darauf folgenden doppel-strängigen DNA. Dies hat zur Folge, dass 
aktivierte RPA Proteine an diese entwundene DNA rekrutiert werden und eine DDR auslösen, 
welche den Zell Zyklus stoppt damit die Zelle Zeit gewinnt um die beschädigte DNA zu 
reparieren. Solche so genannten blockierten Replikationsgabeln könnten sich so ähnlich auf der 
HSV-1 DNA bilden, wenn die Rep Proteine dort binden und die DNA entwinden aber keine 
Replikation stattfindet. 
In einem zweiten Projekt haben wir den Phänotyp von Rep Proteinen untersucht, welche eine 
neu entdeckte Mutation aufweisen. Diese Mutation betrifft eine Aspartansäure an der 
Aminosäure Position 371, welche mit einem Tyrosin substituiert ist (D371Y). Diese Mutation liegt 
genau zwischen den Walker Motiven A und B der Helikase Domäne von Rep und weist einen 
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interessanten Phänotyp auf. Die Rep Proteine mit dieser Mutation sind einerseits immer noch in 
der Lage die AAV2 Replikation, welche ganz von der Helikase Aktivität abhängig ist zu steuern. 
Andererseits sind diese mutierten Rep Proteine nicht mehr in der Lage die HSV-1 Replikation zu 
inhibieren. Zusätzlich haben wir gezeigt, dass diese mutierten Rep Proteine auch nicht mehr in 
der Lage sind eine zelluläre DDR oder Apoptose auszulösen. Diese Beobachtungen könnten für 
die Konstruktion von HSV/AAV Hybrid Gentherapie Vektoren von grosser Bedeutung sein. 
HSV/AAV Hybridvektoren enthalten unter anderem das AAV2 Rep Gen um die Integration des 
Transgens ins Wirtszellgenom zu ermöglichen, damit eine möglichst lang anhaltender  
therapeutischer Effekt erzielt werden kann. Da jedoch die Rep Proteine die HSV-1 DNA 
Replikation inhibieren und einen toxischen Effekt in der Zelle auslösen, sind diese Vektoren 
nicht sehr vielversprechend. Die Herstellung von Hybridvektoren ist abhängig von der HSV-1 
Replikation und wird somit von den Vektor-kodierten Rep Proteinen unterdrückt, was zur Folge 
hat, dass die Produktion sehr ineffizient ist. Zudem wäre die Toxizität der Rep Proteine nicht 
kompatibel mit einer Verwendeung der Vektoren in klinischen Versuchen. Wir haben deshalb 
das wt Rep Gen in den HSV/AAV Hybrid Vektoren mit dem mutanten RepD371Y Gen ersetzt. 
Die daraus entstandenen Vektor Präparate sind tatsächlich bis zu 10-mal höher konzentriert als 
herkömmliche Hybrid Vektor Präparate. Die höheren Vektor-Titer und die stark reduzierte 
Toxizität führen zu einer verbesserten Effektivität der HSV/AAV Hybrid Vektoren. 
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3. Introduction 
 
3.1. Background 
 
When almost fifty years ago M. David Hoggan discovered the human adeno-associated virus 
(AAV) in contaminated adenovirus preparations by electron microscopy (EM), he and his 
coworkers had no idea that their discovery would result in the emergence of the first licensed 
viral gene therapy product in Europe, named Glybera (53). Basically, Glybera (alipogene 
tiparvovec) is a recombinant AAV (rAAV) consisting of an AAV1 capsid enclosing the 
transgene encoding lipoprotein lipase (LPL), which is flanked by AAV2 inverted terminal 
repeats (ITRs). This vector can be administered intramuscularly and is to be considered as a 
safe and effective treatment of LPL deficiency (15, 18, 157). This amazing development of 
AAV from a negligible contaminant to the most promising gene therapy vector platform 
nowadays is not self-evident. Since its discovery, scientists all over the world contributed 
piece by piece to the knowledge we have today, necessary to develop Glybera.  
Shortly after its discovery it became clear that AAVs are nonpathogenic, rather it was found 
that AAVs showed a tendency to inhibit tumorigenicity of other viruses such as 
adenoviruses, papillomaviruses or herpes viruses. Despite its innocuousness, AAV gained 
immense scientific popularity. So also in the lab of Kenneth I. Berns, who first described the 
AAV life cycle including its property to establish a latent infection by integrating its genome in 
a well-defined locus within the human chromosome 19, termed AAVS1 (10, 11, 25, 65–68, 
114). Driven by pure curiosity and fascination about this novel virus, a number of laboratories 
designated their work in investigating this intriguing virus. The switch from basic AAV 
research to AAV vector development and gene therapy applications was made by the 
laboratories from Muzyczka and Carter in the early 1980s, when they succeeded to clone the 
AAV DNA, which facilitated the engineering of rAAV vectors (73, 112, 113, 135). This 
achievement is considered the beginning of a new era of AAV research, where AAVs were 
studied intensively with the aim to use AAV one day as a gene therapy vector. This was the 
base of most of the knowledge about AAV we have today. 
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3.2. Adeno-associated Virus Type-2 (AAV2) 
 
AAV classification and biology 
The family of the Parvoviridae can be divided into two subfamilies: the Densovirinae and the 
Parvovirinae according to their prevalence in insects and vertebrates respectively. The 
vertebrate parvoviruses itself are classified into two functional groups, which are the 
autonomous parvoviruses and the dependoviruses, which differ fundamentally in their 
biological life cycle (9). The dependoviruses comprise the genus Dependovirus and include 
the species adeno-associated virus (AAV), which are unique among DNA viruses as these 
viruses are in contrast to the autonomous parvoviruses dependent on a co-infection with a 
so called helper virus to enter a lytic replication cycle. Ironically, helper viruses for AAV are 
the very same viruses AAV is inhibiting in co-infected cells, namely adenoviruses (Ad), 
papillomaviruses or herpes viruses (16, 53, 141, 150). In absence of a helper virus however, 
AAV undergoes a latent infection by integrating its genome into a well-defined site in the 
human chromosome 19 at a locus termed AAVS1 (66, 114, 131, 152). While the mechanism 
how AAV integrates its DNA into the host genome is poorly understood, the replication of 
AAV has been studied intensively and is well known. Among the more than 40 AAV 
serotypes, which include primate, avian, bovine, canine, equine and ovine serotypes, the 
human AAV serotype 2 (AAV2) is the most studied and best known dependovirus to date. 
AAV2 structure and genome organization 
The AAV2 particle is a small, non-enveloped, icosahedral capsid, built up by three structural 
proteins termed VP1, VP2 and VP3. The capsid consists of about 60 protein subunits of 
which 90% is made up by VP3. The size of AAV2 capsids vary between 20 and 25 nm and 
enclose a ssDNA genome of about 4.7kb in size (75). The whole genome comprises only 
two open reading frames (ORFs) rep and cap, which are flanked by two inverted terminal 
repeats (ITRs) of about 145nt (Fig. 3.1). The rep ORF is regulated by two promoters (p5 and 
p19) which together with a common splicing site encode four Rep proteins termed Rep40, 
Rep52, Rep68 and Rep78, named according to their apparent molecular weight (23) (Fig. 
3.1). The two major Rep proteins Rep68 and Rep78 are required for AAV2 DNA replication, 
transcription, site-specific integration and for inhibition of helper virus replication, whereas 
the smaller Rep40 and Rep52 are believed to be required for packaging and transcription 
(23, 86). The cap ORF is regulated by the p40 promoter. All three capsid proteins are 
translated from two alternatively spliced mRNA species, which are 2.3 and 2.6 kb in size 
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respectively. The smaller mRNA species is usually the preferred one, where the AUG codon 
from which the synthesis of VP1 starts is cut out, leading to the overall reduced levels of 
VP1. From the next AUG codon within this mRNA species the VP3 protein is synthesized. In 
the same reading frame, upstream of that codon is an ACG start codon located, which is 
responsible for synthesis of VP2 (6, 7, 20, 91, 136) (Fig. 3.1). In addition, it has been 
reported recently that a nested ORF within the cap gene encodes a protein designated 
assembly-activating protein (AAP), which is believed to be required for AAV2 capsid 
assembly in the nucleolus (95, 122). 
The AAV2 life cycle and DNA replication 
Attachment and entry of the virion into the cell is mediated by heparan sulfate proteoglycans 
(HSPG), the primary cell surface receptors (130). In addition, fibroblast growth factor 
receptor-1, integrin alpha-V-beta-5 and hepatocyte growth factor receptor act as co-
receptors (61, 104, 129). Adsorption of the particle at the cell membrane is induced by 
dynamin-dependent endocytosis via a clathrin-coated pit. After AAV2 has escaped the 
endosomal pathway, the capsids are organized in a peri-nuclear pattern, before the genome 
is internalized within the nucleus (5, 31, 46, 115, 151, 156). Once the AAV2 DNA has 
reached the nucleus, low level DNA replication occurs from the ssDNA template to initiate 
expression of the major Rep proteins 68 and 78, which are necessary for repressing all 
AAV2 promoters and initiating integration in the absence of a helper virus (68, 76, 114, 131). 
After integration of the AAV2 genome within the host genome, the virus can remain latent 
during several numbers of cell cycles. Upon infection with a helper virus the latent AAV2 
genome is rescued and synthesis of all AAV2 proteins is induced (113, 145, 147). In the 
case of Ad as a helper virus, the Ad E1A protein is trans-activating transcription from the p5 
promoter and initiates synthesis of Rep68 and Rep78 (21, 72, 106). At the same time, the Ad 
E1A protein induces S-phase, where all cellular replication proteins necessary for AAV2 
replication are produced (92). In the case of herpes virus as a helper virus (e.g. herpes 
simplex virus type-1 (HSV-1)) the ICP0 protein is transactivating the p5 promoter and 
inducing synthesis of the major AAV2 Rep proteins (39). A detailed summary of helper 
factors from HSV-1 and the corresponding mechanisms are discussed in section 3.4 (Helper 
factors provided by HSV-1 for AAV2 replication). 
AAV2 DNA synthesis is very unique among DNA viruses as it consists of a few remarkable 
features. Palindromic sequences at both ends of the genome facilitate folding of the ITRs 
into a T-shaped hairpin structure (Fig. 3.2 A). The ITR hairpins can appear in two 
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orientations, flip and flop, due to inversions within the first 125 nucleotides. Both ends consist 
of a Rep-binding site (RBS), which is characterized by three GAGC repeats, and is followed 
by a terminal resolution site (TRS) (109) (Fig. 3.2 A). The hairpin structure at the 3’ end of 
the ssDNA genome creates a primer for Rep-mediated DNA replication and is essential to 
convert the single-stranded viral DNA into a double-stranded template for transcription and 
replication. The two sequence elements RBS and TRS act as a minimal origin of DNA 
replication and are equally essential for AAV2 DNA replication (143, 146). Second strand 
synthesis follows a unique leading-strand synthesis mechanism and is supported by either 
the cellular or the helper virus replication machinery (36, 58, 93, 98, 99, 149). After second-
strand synthesis, binding of the major Rep proteins at the RBS induces a site specific nick at 
the TRS, allowing the 3’ ITR to unfold in order to complete the replication process (93). The 
resulting complete dsDNA template is termed monomer extended form (mE). The following 
process, termed re-initiation, where either of the DNA ends can fold into new hairpins, leads 
to leading-strand displacement and creates a new primer for the next round of replication. 
This newly synthesized ssDNA template for replication is termed monomer turnaround form 
(mT). The simultaneously generated single-stranded genome is readily used for packaging. 
However, if re-initiation occurs before the hairpin structure of the mT form is resolved by 
terminal resolution the continuing DNA synthesis generates a double-stranded dimer in 
which two genomes are covalently linked by a single ITR. These structures can occur in two 
conformations: head-to-head or tail-to-tail and are termed dimer turnaround (dT) or dimer 
extended (dE) form (54, 144). The complete AAV2 DNA replication process is summarized in 
Figure 3.2 B. 
This unique system of DNA replication is often called “the rolling hairpin model” in analogy to 
the rolling-circle model, which other DNA viruses such as HSV-1 utilizes (132). 
The AAV2 Rep proteins: structure and function 
The AAV2 Rep ORF is under control of two different promoters p5 and p19. Together with a 
common splicing site, it is encoding four different Rep proteins, which differ in their size and 
therefore also in their composition of structural and functional domains (Fig 3.3). The 
complete Rep ORF is consisting of a set of distinct elements of which the most important are 
discussed below and summarized in Figure 3.3.  
At the very N-terminal region, the combined DNA-binding and endonuclease domains are 
located (27, 51, 52). The DNA-binding domain (map position 1-200) is responsible for 
binding to dsDNA templates at specific RBS motifs. The minimal RBS motif is the consensus 
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sequence GAGYGAGC (26). Within the DNA-binding domain lie two rolling circle replication 
(RCR) motifs termed RCR2 and RCR3 (51, 120). These two motifs are essential for the 
terminal resolution process during DNA replication (120) and for genome integration (137). 
Only the major Rep proteins Rep68 and Rep78 contain a DNA-binding and endonuclease 
domain, because the p19 promoter responsible for the expression of Rep40 and Rep52 is 
located right after the DNA-binding motif at map position 225. The helicase domain, which 
claims 40% of the whole ORF (map position 225-490), is located right after the DNA-binding 
and endonuclease domain. The AAV2 Rep helicase belongs to the superfamily 3 (SF3) 
helicases, which are encoded mainly by small DNA viruses (57). The complete helicase 
domain can be subdivided into two main components and several subcomponents. First, 
from map position 225 to 278 an α-helix domain responsible for hexamerization is located. 
The rest of the domain is consisting of a typical AAA+ domain (50, 80). This section can be 
subdivided into different components. The ATPase domain (map position 329-490) (80) is 
consisting of the typical Walker motifs (50). In SF3 helicases the Walker motifs A, B and B’ 
are separated by short uniform sequences, but unlike other superfamily helicases, the SF3 
helicase consists of a third Walker motif C, which is located between the Walker motif B and 
the rest of the C-terminal protein domain (45). Typically, SF3 helicases form hexameric rings 
and rely on a DNA-binding domain in order to bind to DNA templates. The Rep helicases 
have been shown to bind either RBS motifs via the N-terminal DNA-binding domain, or non-
specifically via the helicase domain (160–162). At the C-terminal end of the protein, the PKA 
binding site is located, which is consisting of a Zn-finger motif (55, 116) and a PKI like motif 
(29). While the Zn-finger motif is responsible for inhibition of the cell cycle, the PKI like motif 
is responsible for inhibition of Ad DNA replication. 
All these functional domains are required for the vital processes during the AAV2 life-cycle 
and are regulated in a very tight fashion in order to keep the sensitive balance of self-
replication and inhibiting helper virus replication while maintaining the cellular homeostasis. 
In addition, the capability of mediating site-specific integration makes the Rep proteins a 
complete survival kit, which is one of the prominent characteristics of this multifunctional 
protein. Here, we discuss a selection of vital functions the Rep proteins are performing 
during the AAV2 life-cycle: 
Replication  
As described above, the Rep proteins play an essential role during the DNA replication 
process by introducing site-specific nicks at the TRS and providing helicase activity to 
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unwind the hairpin termini during resolution (59, 100). The terminal resolution process can 
be conducted exclusively by the AAV2 Rep proteins and no other cellular or helper virus 
derived factor is capable of replacing or mimicking this unique Rep activity. During terminal 
resolution, the large Rep proteins (68 and 78) bind to the DNA-binding motif consisting of 
three GAGC tetra-nucleotide repeats (GAGCGAGCGAGC) located at nucleotide position 15 
on the 5’ ITR (84, 85). The subsequent nicking activity is performed at the TRS by the Rep 
endonuclease activity, which results in a gap on the original parental strand. Rep covalently 
binds to the 5`-terminus of this gap and the newly created 3`-terminus serves as the primer 
for repair synthesis of the remaining ITR sequence (13). Thereby, the ATP-dependent Rep 
helicase activity is unwinding the hairpin structure of the ITR, allowing the cellular or helper 
viral DNA polymerase to complete replication (35). Of note, Rep proteins are multimeric 
enzymes, which can form typical pentameric or hexameric rings, although the true oligomeric 
nature is unclear (162). 
Integration  
AAV2 latency is accomplished by either episomal maintenance of the genome in the 
nucleus, or by site-specific integration at the AAVS1 locus within chromosome 19 (32, 148). 
The integration process is mediated by the two major Rep proteins Rep68 and Rep78. Both 
can function as a bridge to link the AAV2 genome to the pre-initiation site at the AAVS1 by 
binding either RBS elements. The resulting close proximity of the two DNA strands is 
believed to facilitate a non-homologous deletion-insertion recombination event leading to the 
integration of the complete AAV2 genome (40, 76, 77, 138, 152, 158, 159). The AAV2 
integration site AAVS1 on the human chromosome 19 is closely linked to the genes TNNT1 
and TNNT3, which both encode muscular troponin T isoforms (33). Because the integration 
process leads to chromosomal rearrangements at that site, it would be conceivable that the 
expression patterns of these two genes are affected. However, none of those two genes 
show altered expression, which is due to a partial duplication process occurring during Rep-
mediated integration (49). In addition, chromosomal rearrangements would not affect the 
multi-nuclei muscle cells to the same extend as cells with only a single nucleus, since 
unaffected alleles within the same cell could compensate for the affected allele. However, 
the complete mechanism how AAV2 integration occurs exactly is still unclear. 
Transcription 
The p5 promoter contains a Rep-binding site (RBS) consisting of two GAGC repeats, which 
allows direct binding of Rep proteins via their DNA-binding domain (100), however with a 
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slightly reduced binding affinity compared to the RBS located on the ITR (41). Together with 
the RBS located on the ITR, they are involved in the Rep-mediated regulation of transcription 
from all AAV2 ORFs (56, 70, 101). For instance, in presence of a helper virus, the two large 
Rep proteins 68 and 78 are repressing the p5 promoter, while the two small Rep proteins 40 
and 52 are capable of de-repressing the promoter, most probably by interaction with the 
large Rep proteins (69, 71, 101). This mechanism allows the virus to tightly control the ratio 
of DNA replication, gene expression and DNA packaging during the lytic life cycle. 
Packaging 
AAV2 capsid assembly and DNA packaging occur in the nucleolus of infected cells (155). 
The two small Rep proteins Rep 40 and Rep 52 are required for the helicase-mediated 
packaging of ssDNA genomes into preformed AAV2 capsids. J.A. King proposed a model, 
where capsid immobilized Rep proteins function as a molecular motor pump to translocate 
the DNA molecules directly into the capsids (63, 119). They could demonstrate that the site-
directed translocation process occurs from the 3’-end of the genome, which is in correlation 
with the 3’-5’ processivity determined for the Rep40/52 helicases (50).  
Inhibition of helper viruses  
Inhibition of helper virus replication in the co-infected cell is of great interest for AAV2, since 
an additional replicating virus in the cell most probably would compete for cellular resources 
and could affect the cell-cycle in disadvantage for AAV2 replication. Therefore, AAV2 has 
evolved distinct pathways to inhibit helper virus replication. The intriguing part of this 
achievement is the strategies AAV2 has developed, where indeed helper virus replication is 
inhibited, but at the same time helper factor supply from these viruses is not affected. AAV2-
mediated inhibition of Ad replication has been among the best studied examples, whereas 
inhibition of other helper viruses, such as herpes viruses or papillomaviruses is less well 
understood. Interestingly, as different the life-cycle and cell tropism of the helper viruses, as 
versatile are the strategies which AAV2 has developed for inhibition. However, one factor all 
strategies have in common: they all are driven and mediated by the AAV2 Rep proteins. 
It has been shown that the AAV2 Rep proteins are capable of binding to the Ad E2A 
promoter directly, independently of a consensus RBS located at this site (19). Also, Rep is 
known to bind to a 55-bp DNA fragment within the Ad major late transcription promoter 
(MLP) via interaction with the cellular TATA box-binding protein (TBP) (96). These 
interactions of Rep with the Ad genome are mediating inhibition of transcription and therefore 
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might directly affect Ad replication. However, although the inhibition of these two promoters 
leads to decreased levels of E2A and E4 expression, the reduced levels of those proteins 
seemed not to be solely responsible for inhibition of Ad DNA replication. Rather, the AAV2 
Rep proteins might inhibit Ad DNA replication directly (134). In addition, AAV2 also is 
restricting Ad replication via the inhibition of the cAMP-dependent protein kinase A (PKA) 
(29). Ad utilizes the PKA/CREB pathway to induce the switch from the early to the late 
replication stage by inducing DNA replication and late gene expression. The PKI like motif on 
the C-terminal region of Rep however is inhibiting PKA activity in the co-infected cell, thereby 
indirectly inhibiting Ad DNA replication. 
In the case of herpes virus as the helper virus, the mechanism how the AAV2 Rep protein is 
inhibiting replication is not so clear. So far, it has been shown that AAV2 inhibits HSV-1 DNA 
replication in simian virus 40 (SV40)-transformed hamster cells (4). Also, the same group 
determined in a follow up study that expression of the AAV2 Rep gene only was responsible 
for the inhibition of DNA replication initiated by the HSV-1 oriS (47). Another study by 
Kleinschmidt et.al determined the sequence elements of Rep required for inhibition of HSV-1 
induced DNA replication. They showed that specific sequence elements at the N-terminus of 
Rep are responsible for this inhibition and that Rep proteins consisting of 60% of their 
internal regions are still capable of inhibiting HSV-1 replication (64). These observations are 
in agreement with other studies, which were assessing HSV/AAV hybrid vectors and their 
capability for site-specific integration (48, 142). They observed that hybrid-amplicon vector 
titers were significantly reduced when the rep gene is provided either in cis within the same 
vector or in trans by co-transfecting a Rep expressing plasmid (48). A more recent study by 
Glauser et al, which investigated competing AAV2 and HSV-1 DNA replication in the same 
cell, demonstrated that wtAAV2, but not rep-deficient rAAV2, is inhibiting formation of HSV-1 
replication compartments. Moreover, that study showed that Rep-mediated inhibition of HSV-
1 DNA replication is dose dependent and leads to strongly reduced expression levels of the 
HSV-1 late genes including VP16 and glycoprotein C (gC) (43). The latter observation 
provides further evidence that Rep-mediated inhibition of HSV-1 replication occurs at the 
stage of HSV-1 DNA replication. 
However, the exact mechanism how the AAV2 Rep proteins are inhibiting HSV-1 DNA 
replication still is not clear and needs to be elucidated. 
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3.3. Herpes Simplex Virus Type-1 (HSV-1) 
 
HSV-1 classification and biology 
Herpes viruses belong to the family of the Herpesviridae, which can be divided into three 
subfamilies according to their host range and their life-cycle: the Alphaherpesvirinae, the 
Betaherpesvirinae and the Gammaherpesvirinae (8). All herpes viruses share the ability to 
follow either a lytic or a latent infection. To date, there are eight human herpes viruses 
identified. The most common human herpes virus is HSV-1, which belongs to the subfamily 
of the Alphaherpesvirinae. HSV-1 is causing mucosal eruptions at the site of infections, 
which can reoccur at the same site upon reactivation from latency, because latency usually 
is established in sensory neurons of the trigeminal ganglia, which are innervating the 
mucosal tissue (24, 107, 126). Typically, HSV-1 is infecting the mucosal tissue in and around 
the oral region and causing characteristic vesicular blisters, which can disrupt and therefore 
mediate shedding of newly synthesized virus. Seroprevalence in the human population is 
relatively high at around 60 to 90% (22). 
HSV-1 structure and genome organization 
The HSV-1 virion is built up by three structural components which are the capsid, the 
tegument and the surrounding envelope (35) (Fig. 3.4). The capsid is enclosing a 152 kb 
dsDNA genome, which encodes approximately 85 genes. The surrounding tegument layer 
comprises a distinct set of tegument proteins, which are involved in e.g. viral capsid 
trafficking from the cell membrane to the nucleus (30, 83, 121), modulation of host cell gene 
expression (79) and onset of viral gene expression (62). The most outer envelope layer is 
derived from the host cell and consists of viral glycoproteins required for receptor binding, 
cell to cell spread, and entry (2, 3, 14, 103). 
The viral genome is a linear double stranded DNA molecule and has a unique structure. It is 
divided into two covalently joined segments, unique long (UL) and unique short (US), which 
are flanked by inverted repeat regions (TRL, IRL, IRS and TRS), where the IR sequences are 
linking the two unique segments (Fig. 3.5). The genome contains three origins of DNA 
replication (ori), which are located within the UL (oriL) and within the TRS (oriS), respectively 
(127). DNA packaging/cleavage signals (pac) are located at each end of the genome and 
within each IR sequence (28).  
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HSV-1 life cycle and DNA replication 
After binding and stabilization of the HSV-1 virion at the cell membrane mediated by the viral 
glycoproteins, the capsid is released into the cell (105, 118). The main HSV-1 receptors on 
the cell surface are heparan sulfate proteoglycans (118), but attachment and entry is 
supported by several co-receptors, the so called herpes virus entry mediator protein 
receptors (Hve) (102, 105). After entry of the capsids into the cytoplasm, they migrate along 
microtubules to the cell nucleus (121), where the genome is released directly into the host 
cell chromatin and circularizes. After VP16-mediated transactivation of specific viral genes, 
which are encoding for transcription factors, the lytic replication cycle of HSV-1 is initiated. 
Gene expression occurs in a temporally regulated cascade; immediate early (IE), early (E) 
and late (L) (35, 108). IE proteins mainly have regulatory functions and initiate expression of 
the E genes. The E proteins comprise enzymes necessary for viral DNA replication, 
including the viral polymerase (UL30), and are therefore required for the expression of the L 
genes, as these genes are relying on the onset of DNA replication. Most of the late genes 
are encoding structural components, which consist of the capsid proteins and the envelope 
glycoproteins.  
HSV-1 DNA replication follows a yet not fully understood rolling-circle replication mechanism. 
Replication is initiated at either oriL or oriS and is mainly mediated by the viral replication 
complex formed by the helicase-primase complex (UL5, UL8 and UL52) and the viral 
polymerase (UL30 and UL42). The ssDNA binding protein ICP8 (UL29) and the origin 
binding protein (UL9) stabilize the replication machinery and are essential replication factors 
(78, 81). All viral replication events are located in the nucleus within distinct areas termed 
replication compartments (RCs) (123). Those structures arise at 1-2 hours after infection and 
start as punctuate patterns associated with ND10 bodies, which constantly grow during the 
course of DNA replication until they engage the complete nucleus (17, 82). 
 
3.4. Interaction between HSV-1 and AAV2 
 
When it was discovered that herpes viruses provide helper factors for AAV2 replication, it 
was not clear, which proteins are involved and to what extend helper factors are supporting 
AAV2 replication. It was believed that herpes viruses are only partial helper viruses (12). A 
study by Buller and coworkers then demonstrated that HSV-1 and HSV-2 are complete 
helper viruses for AAV2 replication (16). Interestingly, not only alphaherpesviruses can 
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provide helper functions, but also herpes viruses of the subfamily of the betaherpesviruses, 
such as the human cytomegalovirus (HCMV) (87) and human herpes virus 6 (HHV6) can 
provide full helper functions for AAV2 replication (133). The best characterized herpes virus 
as a helper virus for AAV2 however is HSV-1. 
Helper factors provided by HSV-1 for AAV2 replication 
The first study, which was determining the minimal set of helper factors from HSV-1, was 
published by Mishra and Rose, who found that at least five of seven HSV-1 genes necessary 
for HSV-1 DNA replication (UL5, UL8, UL9, UL29 and UL30) are necessary to support AAV2 
DNA replication (88). They stated that none of these helper factors are strictly required for 
AAV2 replication; however, they demonstrated that the transcriptional regulatory protein 
ICP4 was required, most probably to trans-activate HSV-1 helper genes. A second study by 
Weindler and Heilbronn suggested that only four factors are required for AAV2 DNA 
replication, in particular UL5, UL8 and UL52 encoding the helicase-primase complex and the 
ssDNA-binding protein UL29 (ICP8) (149). However, it has also been shown later that even 
a mutant helicase-primase complex could still provide helper functions, which was somehow 
unexpected (128). All these observations together suggest that the UL29 (ICP8) gene is the 
key helper factor for AAV2 DNA replication. This notion is further confirmed by the fact that 
ICP8 is strongly co-localizing with AAV2 Rep proteins in AAV2 RCs, whereas ICP4 is not 
(43, 128). These data confirm that ICP4 is not a required helper factor for AAV2 DNA 
replication. In addition, the role of the HSV-1 ICP0 protein for AAV2 replication was 
investigated (88). It turned out, that ICP0 was not directly involved in DNA replication, rather 
it transactivates the p5 promoter resulting in the onset of Rep expression from latent AAV2 
genomes (38, 39). A more recent study by Nicholas et al. revealed another factor, UL12 that 
enhanced AAV2 replication (97). The UL12 protein was co-localizing with AAV2 RCs, but the 
function of UL12 during AAV2 replication remains unclear. 
Overall, the nature of helper functions provided by HSV-1 differs completely from the helper 
functions provided by Ad. While Ad is contributing on the level of cell cycle manipulation and 
transactivation of gene expression, HSV-1 is rather supporting AAV2 DNA replication 
directly. However, recently it became clear that the cell cycle also seems to be an important 
factor for Rep-expression and AAV2 replication (1, 139, 140). 
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Interaction between HSV-1, AAV2 and the cell 
A recent study by Vogel and colleagues has demonstrated that AAV2 modulates the host 
DNA damage response (DDR) induced by HSV-1 in the co-infected cell and therefore may 
modulate the fate of the cell cycle (140). Generally, HSV-1 is inducing a DDR in infected 
cells characterized by the activation of the MRN complex, the phosphatidylinositol-3-kinase-
like kinase (PIKK)  ataxia-telangiectasia mutated (ATM), p53 and Rad51 (34, 74, 117, 153), 
but not the ATM- and Rad3-related kinase (ATR) (89, 90, 154). However, it has become 
clear that HSV-1 / AAV2 co-infection leads to phosphorylation of ATR, but the ATR- pathway 
appeared not to be activated, as downstream targets such as the checkpoint kinase 1 (Chk1) 
were not phosphorylated (140). A second observation revealed that the HSV-1 ICP0-
mediated degradation of DNA-PKCS is significantly delayed during co-infection, which is 
leading to the activation of downstream targets such as p53, replication protein A (RPA) and 
the checkpoint kinase 2 (Chk2) (140). The DNA-PK dependent activation of p53 and Chk2 in 
co-infected cells, which are naturally phosphorylated by ATM, was confirmed in ATM-
deficient cells, where p53 and Chk2 were still activated most probably by DNA-PKCS (140).  
However, whether these changes in DNA damage signaling are indeed promoting the cell 
cycle in favor of AAV2 DNA replication and what factors from AAV2 are required still needs 
to be elucidated.  
A more global approach was performed by two studies which identified cellular components 
contributing to AAV2 replication in HSV-1 co-infected cells (94, 97). They identified a large 
set of cellular and viral proteins associated with either the AAV2 Rep or RCs or both. A 
summary of the results from these studies are reviewed in (139). 
Interaction between HSV-1 and AAV2 Rep 
Specific interactions between the AAV2 Rep proteins and HSV-1 replication are poorly 
investigated. As summarized in section 3.2 (Inhibition of helper viruses), it is known that the 
AAV2 Rep proteins are responsible for the inhibition of HSV-1 DNA replication, but the exact 
mechanism is not known. The discovery of this process would be of great interest, as it 
would provide critical knowledge that helps to understand the complex interactions of those 
two viruses in the co-infected cell. An interaction model of two different viruses infecting the 
same cell forms the basis for understanding even more complex interaction models in which 
more than two pathogens co-exist in an organism, a tissue or a cell, which is a normal state 
in higher organisms. 
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3.5. HSV/AAV Hybrid Vectors 
 
The potential of AAV as a gene therapy vector has been discovered almost thirty years ago. 
Since then, AAV has been employed successfully to develop gene therapy vectors such as 
the recently emerged gene therapy product Glybera (15, 18, 157). The success of AAV 
vectors is based on various advantages of this virus (44): (i) until now, AAV has not been 
associated with any human or animal disease; (ii) without a helper virus, wtAAV can 
integrate its genome at a specific site on the human chromosome 19 (AAVS1) and therefore 
has the potential to deliver transgenes directly to the host genome assuring long-term 
transgene expression on a physiological level; (iii) AAV can infect many different dividing and 
non-dividing cell types; (iv) the AAV genome is organized rather simple and is therefore easy 
to clone and manipulate. However, a number of drawbacks limit the use of AAV as a gene 
therapy vector dramatically. The relatively small transgene capacity of about 4.7kb and the 
fact that the toxic Rep proteins are required for integration are two of the most important 
limitations AAV vectors have. 
HSV-1 derived gene therapy vectors are particularly promising for treating disorders of the 
nervous system. Several features make HSV-1 suitable as a gene delivery vector: (i) more 
than 20% of the HSV-1 genes are non-essential for replication in cell culture and can be 
replaced with transgenes of interest; (ii) similar to AAV, HSV-1 can infect both dividing and 
non-dividing cells; (iii) the episomal HSV-1 genome can enter a state of latency in neurons, 
however with reduced transcriptional activity. Two fundamentally different HSV-1 vector 
types have been developed so far; the recombinant HSV-1 (rHSV) and the HSV-1 
amplicons. rHSV vectors are generated by replacing one or more virus genes with transgene 
cassettes of interest. HSV-1 amplicon vectors on the other hand contain only two cis-
elements from the HSV-1 genome: (i) an origin of DNA replication (e.g. oriS) and (ii) a DNA 
cleavage/packaging signal (pac) (Fig. 3.6 A). A plasmid harboring these two genetic 
elements from HSV-1 is termed amplicon. Such amplicons containing the transgenes of 
interest are packaged into fully functional HSV-1 virions in cells super-infected with wtHSV-1 
(124). One drawback of this method is the massive contamination of vector stocks with 
wtHSV-1 particles. The generation of a replication and packaging deficient, BAC-cloned 
HSV-1 genome providing all genes necessary to package amplicons reduced the 
contamination of amplicon stocks with wtHSV-1 and therefore reduced immunogenicity and 
toxicity of HSV-1 amplicon stocks (37, 110, 111, 125). Besides the advantages of HSV-1 
vectors in general, several HSV-1 amplicon-specific advantages make this vector type a 
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promising candidate for gene therapy trials: (i) the very large transgene capacity of HSV-
based vectors is maintained; (ii) the production of amplicon stocks which are almost 100% 
free of contaminating wtHSV-1 particles and (iii) the capability to infect most cell types in 
mammals. However, one major drawback still remains: transgene expression of any HSV-1 
based vector type is transient. 
To overcome the disadvantages of AAV and HSV-1 based vectors, HSV/AAV hybrid vectors 
were constructed (48, 60, 142). This vector type is based on the HSV-1 amplicon system 
vector and therefore conserves all the HSV-1 elements and properties of standard HSV-1 
amplicons. But at the same time these hybrid vectors harbor the AAV2 rep gene and the 
AAV2 ITRs flanking the transgene cassette (Fig. 3.6 B). The presence of the AAV2 elements 
allows the vector to integrate the ITR-flanked transgene cassette into the host genome in a 
Rep-dependent fashion. This feature circumvents the poor transgene maintenance of 
transiently expressing HSV-1 amplicon vectors. At the same time HSV/AAV hybrid vectors 
overcome the small transgene capacity of rAAV vectors. In addition, the presence of the rep 
gene on the same vector but outside of the ITR-cassette assures that rep is not integrated 
and therefore circumvents Rep-mediated toxicity and eventually the rescue of the ITR-
cassette from the integrated state. However, some elements of the two hybrid vector 
partners may interfere with each other and thereby reduce the performance of this vector. In 
particular, the two origins of DNA replication, e.g. the HSV-1 oriS, the AAV2 ITRs and the 
AAV2 p5 promoter which also functions as an origin of DNA replication (41) may compete for 
the HSV-1 helper factors and therefore interfere with the HSV-1 mediated replication of the 
amplicon plasmid, resulting in low packaging efficiency. Moreover, the inevitable expression 
of the toxic Rep proteins during packaging may have a direct inhibitory effect on HSV-1 
replication and therefore contribute to low hybrid-vector titers (41, 42, 48). 
The identification of mechanisms how Rep can inhibit HSV-1 replication may contribute to 
the generation of improved HSV/AAV hybrid vectors. 
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3.6. Figure Legends & Figures 
 
Figure 3.1. The AAV2 genome organization. Schematic representation of the complete 
AAV2 genome. On top, the ssDNA is shown in blue. The two ORFs rep and cap are flanked 
by two terminal repeats (TR). Two promoters (p5 and p19) are controlling expression of the 
rep ORF, and together with a common splicing site, they are responsible for the expression 
of the four Rep proteins (Rep78, Rep68, Rep 52 and Rep40). The cap gene is transcribed 
from the p40 promoter and due to alternative start codons leads to the expression of the 
three capsid proteins (VP1, VP2 and VP3). A non-conventional start codon within the cap 
ORF gives rise to the AAP protein. The transcripts of all proteins are depicted in green and 
their size is indicated at the right site. 
Figure 3.2. Structure of the AAV2 ITR and model of the rolling hairpin mechanism. (A) 
The structure and the sequence of the AAV2 3’-ITR is represented. The palindromic 
sequence of the ITR is folded into a hairpin shaped structure. The Rep-binding site, or Rep-
binding element (RBE), consists of three perfect GAGC tetranucleotide repeats (open box). 
The arrow points to the site where Rep cleaves the DNA within the terminal resolution site 
(trs). The duplexed 3’-end of the genome constitutes the primer for DNA replication, a 
process called self-priming. (B) The diagram represents the model of AAV2 DNA replication. 
The different steps and structures of the AAV2 genome during DNA replication are indicated. 
The left half of the model highlights the replication cycle which leads to monomer-length 
single-stranded progeny genomes. The right half of the model highlights the synthesis of 
dimer molecules, which are generated when re-initiation occurs before terminal resolution. 
DNA pol., DNA polymerase; mT, monomer turnaround form; TRS, terminal resolution site; 
mE, monomer extended form; ss, single-stranded DNA; dT dimer turnaround form; dE, dimer 
extended form.  
Figure 3.3. Schematic representation of AAV2 Rep functional domains. The complete 
rep ORF and the four different Rep proteins (Rep40, Rep 52, Rep68 and Rep78) are shown 
on the top of the scheme (grey boxes). The relative location and size of the functional 
domains are represented below (red boxes) and are discussed in the text. They consist of 
the DNA-binding domain, the endonuclease domain harbouring the two rolling-circle 
replication motifs 2 and 3 (RCR2 and RCR3) (yellow boxes), the helicase domain containing 
the AAA+ domain and the Walker motifs A, B, B’ and C (red boxes), as well as the C-
terminal PKA binding site containing the PKI like motif (blue boxes).  
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Figure 3.4. Architecture of the HSV-1 virion particle. The HSV-1 virion is composed of 
three structural elements: (i) the capsid enclosing the dsDNA genome, (ii) the tegument 
harbouring a distinct set of viral proteins and (iii) the envelope consisting of a bi-layerd lipid 
membrane, which is decorated with viral glycoproteins. The diameter of the whole particle 
varies between 200 and 300 nm. The electronmicrograph is courtesy of E.Schraner, Institute 
of Virology, University of Zurich. The cryoelectronmicrograph is courtesy of the Max-Planck-
Institute of Biochemistry. 
Figure 3.5. The HSV-1 genome structure. The HSV-1 genome is a linear double-stranded 
DNA molecule of approximately 152 kb. It is divided into two distinct segments, unique long 
(UL) and unique short (US), which are covalently linked via the internal repeats (IRL and IRS). 
The genome contains terminal repeats (TR) at both ends. The origins of DNA replication 
(oriL and oriS) as well as the DNA packaging/cleavage signals (pac), which are the only cis-
acting elements required for replication and packaging, are indicated (green and red boxes, 
respectively). 
Figure 3.6. The HSV-1 amplicon and hybrid vector systems. (A) Vero 2-2 cells are co-
transfected with the HSV-1 amplicon vector pHSVGFP harboring a transgene cassette 
encoding for the enhanced green fluorescent protein (EGFP) and replication-competent, but 
packaging-defective HSV-1 helper DNA (fHSVΔpacΔ27). This helper DNA provides all the 
functions necessary for replication and packaging of the HSV-amplicon DNA, but due to the 
lack of the pac signal is packaging-defective. The resulting HSV-1 amplicon vector stock is 
consisting of fully functional HSV-1 virions containing head-to-tail concatemers of the 
amplicon DNA harboring the transgene cassette. (B) The HSV/AAV hybrid vector is based 
on the HSV-1 amplicon vector as described in panel A. In addition, the HSV/AAV hybrid 
vector pHyRaNGFPa contains two additional AAV2-specific elements; (i) the AAV2 ITRs 
which flank the transgene cassette (EGFP) and (ii) the complete rep ORF. Vector production 
follows the same procedure as for the HSV-1 amplicon vector system. The resulting 
HSV/AAV hybrid vector stocks consist of the same HSV-1 virions as the HSV-1 amplicon 
stocks, but contain head-to-tail concatemers of the HSV/AAV hybrid vector harboring the 
additional AAV2 elements to mediate site-specific integration of the transgene cassette. 
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}
HSV-1 ori-S
HSV-1 ori-L
}
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4. Specific Aims 
 
1. The first aim was to characterize AAV2 Rep-mediated inhibition of HSV-1 replication, 
specifically to find out whether Rep is reducing HSV-1 gene expression and at what 
stage of the HSV-1 life-cycle the inhibition occurs. 
 
2. The second aim was to identify the functional domains of Rep that are required and 
sufficient for inhibition of HSV-1 DNA replication. 
 
3. The third aim was to discover the mechanism of Rep-mediated inhibition of HSV-1 
replication. Two specific pathways were assessed: (i) the Rep-mediated induction of 
apoptosis and (ii) the Rep-induced activation of a DNA-damage response. 
 
4. Aim four was to assess the role of the Rep-helicase activity in the inhibition of HSV-1 
replication.  
 
5. The fifth aim was to test whether the AAV2 Rep proteins are capable of binding to the 
HSV-1 dsDNA, thereby directing the inhibitory Rep-helicase activity towards the HSV-1 
DNA and inhibiting the replication process. 
 
6. The last aim was to characterize the phenotype of a novel Rep mutant RepD371Y. 
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5. Characterization of the AAV2 Rep-mediated Inhibition of HSV-1 
DNA Replication 
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Adeno-associated virus (AAV) has previously been shown to inhibit the replication of its helper virus herpes
simplex virus type 1 (HSV-1), and the inhibitory activity has been attributed to the expression of the AAV Rep
proteins. In the present study, we assessed the Rep activities required for inhibition of HSV-1 replication using
a panel of wild-type and mutant Rep proteins lacking defined domains and activities. We found that the
inhibition of HSV-1 replication required Rep DNA-binding and ATPase/helicase activities but not endonucle-
ase activity. The Rep activities required for inhibition of HSV-1 replication precisely coincided with the
activities that were responsible for induction of cellular DNA damage and apoptosis, suggesting that these
three processes are closely linked. Notably, the presence of Rep induced the hyperphosphorylation of a DNA
damage marker, replication protein A (RPA), which has been reported not to be normally hyperphosphorylated
during HSV-1 infection and to be sequestered away from HSV-1 replication compartments during infection.
Finally, we demonstrate that the execution of apoptosis is not required for inhibition of HSV-1 replication and
that the hyperphosphorylation of RPA per se is not inhibitory for HSV-1 replication, suggesting that these two
processes are not directly responsible for the inhibition of HSV-1 replication by Rep.
Adeno-associated virus (AAV) is a widespread, nonpatho-
genic human parvovirus with a unique biphasic life cycle. In the
absence of a helper virus, AAV establishes a latent infection in
the host cell mediated either by site-specific integration of the
viral genome into human chromosome 19 or by episomal per-
sistence of circularized virus genomes (reviewed in reference
53). In the presence of helper viruses such as a herpesvirus,
adenovirus (Ad), or papillomavirus, AAV is rescued from la-
tency and undergoes lytic replication. The AAV genome is a
single-stranded DNA (ssDNA) of 4,680 nucleotides, which is
packaged into an icosahedral capsid with a diameter of 20 nm.
The AAV genome harbors two open reading frames (ORFs),
rep and cap, which are flanked by two inverted terminal repeats
(ITRs) containing viral origins of DNA replication. The cap
ORF is transcribed from the p40 promoter and encodes the
capsid proteins VP1, VP2, and VP3, which differ in their N
termini due to alternative start codons. The rep ORF encodes
the Rep proteins, which are expressed in four different forms
due to transcription from two different promoters, p5 and p19,
and alternative splicing at an intron at the C-terminal end. The
different Rep proteins are termed Rep40, Rep52, Rep68, and
Rep78 according to their apparent molecular weight. The Rep
proteins are involved in diverse processes in the viral life cycle,
such as DNA replication, regulation of gene expression, ge-
nome packaging, and site-specific integration (reviewed in ref-
erence 56). The biochemical activities of Rep required for
AAV DNA metabolism include site-specific DNA-binding and
endonuclease activities, as well as non-site-specific ATPase/
helicase activity. While the ATPase/helicase activity is in all
four Rep proteins, the site-specific DNA-binding and endonu-
clease activities are present only in the large Rep proteins
Rep68 and Rep78 (Fig. 1A) (18, 74, 88, 91). It has recently
become clear that the Rep proteins also have a variety of
effects on the host cell, the overall purpose of which likely is
the creation of a cellular environment favorable for AAV rep-
lication. These effects of the Rep proteins on the cell include
DNA damage, cell cycle arrest, apoptosis, and inhibition of
signal transduction by the protein kinases PKA and PRKX.
Rep78 can induce a complete S-phase arrest, which is medi-
ated by the protein’s ability to induce cellular DNA damage
combined with its ability to bind to Cdc25A (5). The induction
of DNA damage was postulated to require Rep endonuclease
activity, while the interaction with Cdc25A was shown to be
dependent on the zinc finger motifs in the C-terminal domain
present in Rep52 and Rep78 (5) (Fig. 1A). The binding of Rep
to Cdc25A prevents the latter from activating its substrates
Cdk1 and Cdk2, resulting in the accumulation of hypophos-
phorylated (i.e., active) pRb, which in turn limits the cell’s
progression through S phase (5, 65). In addition and probably
related to its ability to arrest the cell cycle, Rep has been shown
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to induce p53-independent apoptosis via its DNA-binding and
ATPase/helicase activities (66). Finally, the ability of Rep to
inhibit the protein kinases PKA and PRKX, both members of
the cyclic AMP (cAMP) signal transduction pathway, results in
decreased expression of cAMP-responsive genes and contrib-
utes to Rep-mediated inhibition of Ad replication (16, 22, 23).
Inhibition of PKA and PrKX was shown to depend on a PKI-
like motif in the C-terminal domain present in Rep52 and
Rep78 (Fig. 1A) (67).
Herpes simplex virus type 1 (HSV-1) is a complete helper
virus for productive AAV replication (9). HSV-1 is a wide-
spread human pathogen whose biphasic life cycle is character-
ized by lytic infection in epithelial cells of the mucosa and
latent infection in the innervating sensory neurons. The HSV-1
genome is a 152-kb double-stranded DNA (dsDNA) and en-
codes approximately 80 gene products, which are expressed in
a temporally regulated cascade comprising immediate-early
(IE), early, and late phases (reviewed in reference 76). The
HSV-1 helper factors for AAV replication act at two stages of
the AAV life cycle, i.e., rep gene expression and DNA repli-
cation. The HSV-1 IE proteins ICP0, ICP4, and ICP22 syner-
gistically transactivate rep expression, an effect which was
shown to be particularly important for rescue of latent AAV
(3, 28). The HSV-1 IE protein ICP27, in contrast, is inhibitory
for AAV replication but essential for HSV-1 replication (3,
63). The HSV-1 helicase-primase complex (UL5/UL8/UL52),
the ssDNA-binding protein ICP8 (UL29), and theDNA polymer-
ase complex (UL30/UL42) are thought to become part of the
AAV DNA replication complex, possibly through a direct inter-
action between ICP8 and Rep (3, 33, 71, 75, 80, 82). Although the
helicase-primase complex and ICP8 are sufficient to support min-
imal levels of AAVDNA replication (82), the entire set of helper
factors is required for the full helper activity (3).
The requirement of AAV for coinfection with a helper virus
for productive replication inevitably leads to competition for
cellular resources as well as for the helper factors themselves,
which often are essential for both AAV and the helper virus.
The fact that AAV inhibits the replication of its helper viruses
Ad (10–12) and HSV (4, 31) suggests that it has developed
strategies to influence this competition for its own advantage.
In order to be successful, such strategies must limit the repli-
cation of the helper virus without affecting the synthesis of the
helper factors required for AAV replication. In the case of
HSV-1 as the helper virus, the helper factors are all expressed
with IE or early kinetics preceding viral DNA replication (3,
81, 82). As expected for a successful strategy of helper virus
inhibition, AAV limits mainly HSV-1 DNA replication and
late gene expression, while IE and early gene expression is only
marginally reduced (31). Similar observations were also made
with Ad as the helper virus (77). Previous research from our
laboratory has shown that AAV and HSV-1 replication pro-
ceeds in spatially separate replication compartments (RCs),
FIG. 1. (A) Rep proteins analyzed in this study. The open bar at the top represents the full-length AAV repORF, including the translation start
sites of Rep68/78 and Rep40/52 (arrowheads) and the translation termination signals of Rep52/78 and Rep40/68 (circles). The gray boxes in the
open bar at the bottom indicate regions of interest for this study, including the DNA-binding domain, the rolling-circle replication motifs 2 and
3 (RCR2 and RCR3) involved in the endonuclease activity, the ATPase/helicase domain, the PKI-like motif (PKI), and the zinc finger motifs (Zn).
The gray bars in the middle show the Rep proteins expressed in this study, with mutations being indicated by black lines. Rep78 is the full-length
Rep protein, while Rep52 lacks the N-terminal domain and thus DNA-binding and endonuclease activities, Rep68 lacks the C-terminal domain
containing the PKI-like motif and the zinc finger motifs, Rep78(Y156F) contains a mutation in the RCR3 motif abolishing endonuclease activity,
and Rep78(K340H) contains a mutation in the ATPase/helicase domain abolishing NTP-binding and thus helicase activity. (B) Rep expression
levels. Vero cells were transfected with the pcDNA.Rep constructs or empty pcDNA vector together with pEGFP-N3, harvested 24 h later, and
processed for Western blotting with a Rep-specific antibody. Detection of EGFP served as a transfection and loading control. (C) Evaluation of
wild-type and mutant Rep proteins for their ability to replicate AAV DNA. Vero cells were transfected with pAAVlacO, pSV2-EYFP/lacI, and
0.1 g of the pcDNA.Rep constructs or empty pcDNA vector. On the following day, the cells were infected with HSV-1 at an MOI of 10 PFU.
At 14 h p.i., the cells were fixed and stained with an HSV-1 ICP8-specific MAb (red) and DAPI (4,6-diamidino-2-phenylindole) (blue). EYFP
fluorescence is shown in green. Images were recorded by CLSM and show single z stacks of representative cells.
VOL. 84, 2010 INHIBITION OF HSV-1 REPLICATION BY AAV Rep PROTEINS 3809
 on A
pril 8, 2014 by U
ZH
 H
auptbibliothek / Zentralbibliothek Zuerich
http://jvi.asm
.org/
D
ow
nloaded from
 
46
which recruit distinct sets of viral and cellular proteins. ICP8
was found in both HSV-1 and AAV RCs, although with dif-
ferential staining patterns (31). It is therefore conceivable that
the competition between HSV-1 and AAV RCs for ICP8 and
possibly other HSV-1 replication factors contributes to inhibi-
tion of HSV-1 replication in coinfected cells. However, we and
others have shown that the mere presence of AAV Rep pro-
tein in the absence of replicating AAV DNA is sufficient for
inhibition of HSV-1 RC formation and HSV-1 oriS plasmid
replication (31, 32). Similar observations were made for Ad in
that Rep was shown to inhibit the maturation of Ad RCs (83).
Rep-mediated inhibition of HSV-1 has also been observed
during the production of chimeric AAV/HSV gene delivery
vectors. Such vectors are based on helper virus-free HSV-1
amplicon vectors that incorporate the AAV ITRs flanking the
transgene, as well as the AAV rep gene. HSV/AAV hybrid
vectors combine the large transgene capacity of HSV-1 with
the site-specific integration machinery of AAV and therefore
support stable, long-term transgene expression (reviewed in
reference 29). The presence of the rep gene on the hybrid
vector genome, however, negatively affects vector replication,
resulting in significantly reduced titers of vector stocks, and
thus hampers efficient hybrid vector production (35).
To date, the molecular mechanisms underlying the inhibi-
tion of HSV-1 replication by AAV Rep protein remain poorly
understood. We therefore further characterized Rep-mediated
inhibition of HSV-1 replication in the present study. To this
end, we investigated the effects of Rep on HSV-1 gene expres-
sion and DNA replication and assessed the Rep activities re-
quired for inhibition of HSV-1 replication using a panel of
wild-type and mutant Rep proteins lacking defined domains
and activities. Our data show that Rep mainly affects HSV-1
DNA replication and that the inhibitory effect of Rep depends
on its DNA-binding and ATPase/helicase activities but not on
its endonuclease activity. The Rep activities required for inhi-
bition of HSV-1 replication precisely coincide with those re-
quired for the induction of cellular DNA damage and apop-
tosis, suggesting that these three processes are closely linked.
Notably, the presence of Rep induced the hyperphosphoryla-
tion of a DNA damage marker, replication protein A (RPA),
which has been reported not to be normally hyperphosphory-
lated during HSV-1 infection and to be sequestered away from
HSV-1 replication compartments during infection. (84–86).
Finally, we demonstrate that the execution of apoptosis is not
required for inhibition of HSV-1 replication and that the hy-
perphosphorylation of RPA per se is not inhibitory for HSV-1
replication, suggesting that these two processes are not directly
responsible for the inhibition of HSV-1 replication by Rep.
MATERIALS AND METHODS
Cell culture and viruses. Vero and Vero 2-2 cells (72) were maintained in
Dulbecco’s modified Eagle medium supplemented with 10% fetal bovine serum,
100 units/ml penicillin G, 100 g/ml streptomycin, and 0.25 g/ml amphotericin
B. For culturing Vero 2-2 cells, 500 g/ml G418 was included in addition.
HSV-1 strain F was grown and titers were determined in Vero cells. Briefly,
confluent monolayers of Vero cells were infected with HSV-1 at a multiplicity of
infection (MOI) of 0.1 PFU and incubated until the cytopathic effect (CPE)
reached 100%. The cells were then lysed by three cycles of freeze and thawing
and cellular debris removed by centrifugation for 10 min at 1,900  g. The
cleared lysate was titrated on Vero cells using the Spearman-Karber method.
AAV type 2 (AAV2) was grown and titrated as described previously (46). UV
inactivation of AAV2 with 254-nm UV light at a dose of 960 mJ/cm2 was carried
out in a UVC 500 UV cross-linker (Hoefer Pharmacia Biotech). The virus
suspension was placed onto the lid of a 96-well tissue culture plate in order to
form a layer of about 1 to 2 mm and kept on ice during the inactivation
procedure. HSV-1 C12 is a recombinant HSV-1 strain SC16 containing a
human cytomegalovirus (HCMV) IE1 enhancer/promoter-driven enhanced
green fluorescent protein (EGFP) expression cassette in the US5 (gJ) locus
and was kindly provided by S. Efstathiou (University of Cambridge, Cam-
bridge, United Kingdom).
Plasmids. pcDNA3.1 was purchased from Invitrogen and pEGFP-N3 from
Clontech. pHSVGFP, an HSV-1 amplicon vector containing the EGFP-coding
sequence under the control of the HSV-1 IE 4/5 promoter, was described pre-
viously (1). pAV2GFP, a recombinant AAV (rAAV) plasmid containing the
EGFP-coding sequence under the control of the HCMV IE1 enhancer/promoter
flanked by the AAV2 ITRs, was described previously (35). fHSVpac27kn
and pEBHICP27 together represent a replication-competent, packaging-defec-
tive HSV-1 genome and were described previously (64). Plasmids pCM-UL5,
-UL8, -UL9, -UL29, -UL30, and -UL42, expressing the corresponding HSV-1
replication factors from the HCMV IE1 enhancer/promoter (34), were kindly
provided by R. Heilbronn (Free University of Berlin, Berlin, Germany). Plasmid
pD-UL52, expressing HSV-1 UL52 from the short eukaryotic initiation factor 1
 subunit (sEIF) promoter, was described previously (3). pAAVlacO, an rAAV
plasmid containing 40 lac operator (lacO) repeats flanked by the AAV2 ITRs,
was described previously (25). Plasmid pRep, containing the AAV2 rep ORF
under control of its native p5 and p19 promoters, was described previously (35).
Plasmid pSV2-EYFP/lacI, expressing enhanced yellow fluorescent protein
(EYFP) linked to lac repressor protein (LacI) (79), was kindly provided by D. L.
Spector (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). For the
construction of plasmids pcDNA.Rep52, pcDNA.Rep68, pcDNARep78, and
pcDNA.Rep78(K340H), the corresponding AAV2 rep ORFs were PCR ampli-
fied from plasmids pBP52, pBP68, pBP78, and pBP78K340H (5, 65) (kindly
provided by C. Berthet and P. Beard, ISREC, Lausanne, Switzerland) with
primers containing BglII and XbaI restriction sites and inserted between the
BamHI and XbaI restriction sites of pcDNA3.1. For construction of
pcDNA.Rep78(Y156F), the 359-bp SacII-BamHI rep fragment from plasmid
pCL-HisRep68Y156F (27) containing the Y156F mutation was transferred into
the rep ORF in plasmid pcDNA.Rep78. For construction of pcDNA.EGFP, the
EcoRI-NotI fragment from pEGFP-N3 containing the ORF encoding enhanced
green fluorescent protein (EGFP) was introduced between the EcoRI and NotI
sites of pcDNA3.1.
Antibodies. (i) Primary antibodies. The mouse anti-HSV-1 ICP8 monoclonal
antibody (MAb) 7381 and the mouse anti-HSV-1 UL42 MAb Z1F11 were kindly
provided by R. D. Everett (MRC Virology Unit, Glasgow, United Kingdom), the
rabbit anti-HSV-1 ICP8 polyclonal antibody (PAb) 4-83 (41) by D. M. Knipe
(Harvard Medical School, Boston, MA), the mouse anti-HSV-1 VP16 MAb LP1
(54) by A. Minson and H. Browne (University of Cambridge, Cambridge, United
Kingdom), the rabbit anti-HSV-1 gC PAb R47 (17) by G. H. Cohen and R. J.
Eisenberg (University of Pennsylvania, Philadelphia, PA), the rabbit anti-HSV-1
VP22 PAb AGV031 by G. Elliott (Imperial College London, London, United
Kingdom), and the rabbit anti-AAV Rep PAb (78) by J. P. Trempe (Medical
University of Ohio, Toledo, OH). The mouse anti-HSV-1 UL5 MAb 376, the
mouse anti-HSV-1 UL8 MAb 817 (49, 55), the mouse anti-HSV-1 UL9 MAb
13924 (55), the mouse anti-HSV-1 UL30 MAb 13429 (48), and the mouse
anti-HSV-1 UL52 MAb 14462 (48) were kindly provided by N. D. Stow (MRC
Virology Unit, Glasgow, United Kingdom). The mouse anti-HSV-1 ICP4 MAb
was purchased from Advanced Biotechnologies, the mouse anti-HSV-1 ICP8
MAb 10A3 from Abcam, the mouse anti-AAV Rep MAb clone 303.9 from
Fitzgerald Industries International, the mouse anti-GFP MAb JL-8 from Clon-
tech, the mouse antiactin MAb clone AC-47 from Sigma, the mouse anti-phos-
pho-ATM S1981 MAb clone 10H11.E12 from Rockland Immunochemicals, the
rabbit anti-phospho-RPA32 S4/S8 PAb BL647 from Bethyl Laboratories, and the
mouse anti-phospho-H2AX S139 MAb clone JBW301 from Upstate (Millipore).
(ii) Secondary antibodies. Goat anti-mouse IgG(HL)-Alexa Fluor 488
(AF488), goat anti-mouse IgG(HL)-AF568, goat anti-mouse IgG(HL)-
AF594, goat anti-rabbit IgG(HL)-AF488, goat anti-rabbit IgG(HL)-AF568,
and F(ab)2 fragment of goat anti-rabbit IgG(HL)-AF594 were purchased from
Molecular Probes (Invitrogen), rabbit anti-mouse IgG(whole molecule)-peroxi-
dase from Sigma, and goat anti-rabbit IgG(HL)-horseradish peroxidase (HRP)
from Southern Biotech.
Transfection. Cells seeded on the previous day were transfected with Lipo-
fectamine and Plus reagents (Invitrogen) according to the manufacturer’s pro-
tocol, except for the data presented in Fig. 5, for which Lipofectamine2000
(Invitrogen) was used. Transfections were carried out in three different plate
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formats: 6-cm plates (Southern blot analysis), 12-well plates (Western blot anal-
ysis), and 24-well plates (pHSVGFP packaging, HSV-1 C12 replication, and
annexin V and immunofluorescence staining). The relative amounts of DNA
used for transfection of different plate formats were as follows: 6-cm plate, 100%;
12-well plate, 20%; and 24-well plate, 10%. For easier comparability of DNA
amounts between the different assays, the DNA amounts indicated throughout
correspond to values normalized to the 6-cm format.
Western blot analysis. For the results shown in Fig. 1B, Vero cells were
transfected with 0.5 g of the individual pcDNA.Rep plasmids or empty pcDNA
vector together with 0.5 g pEGFP-N3. For the results presented in Fig. 2D,
Vero 2-2 cells were transfected with 0.5 g pHSVGFP, 2 g fHSVpac27kn,
and 0.2 g pEBHICP27 together with the indicated amounts of pcDNA.Rep
plasmids or empty pcDNA vector. For the results presented in Fig. 3A, Vero cells
were transfected with 0.5 g pHSVGFP, 0.2 g each of pCM-UL5/8/9/29/30/42
plasmids, and 0.4 g of pD-UL52 together with the indicated amounts of
pcDNA.Rep plasmids or empty pcDNA vector. At 48 h after transfection, the
cells were lysed and processed for Western blot analysis as described previously
(31). Primary antibodies were used at the following dilutions: mouse anti-AAV
Rep MAb clone 303.9, 1:200; mouse anti-GFP MAb JL-8, 1:8,000; mouse anti-
HSV-1 ICP4 MAb, 1:10,000; rabbit anti-HSV-1 ICP8 PAb 4-83, 1:5,000; mouse
anti-HSV-1 ICP8 MAb 10A3, 1:1,000; mouse anti-HSV-1 UL5 MAb 376,
1:1,000; mouse anti-HSV-1 UL8 MAb 817, 1:500; mouse anti-HSV-1 UL9 MAb
13924, 1:500; mouse anti-HSV-1 UL30 MAb 13429, 1:500; mouse anti-HSV-1
UL52 MAb 14462, 1:200; mouse anti-HSV-1 UL42 MAb Z1F11, 1:1,000; mouse
anti-HSV-1 VP16 MAb LP1, 1:5,000; rabbit anti-HSV-1 VP22 AGV031,
1:10,000; rabbit anti-HSV-1 gC PAb R47, 1:10,000; and mouse antiactin MAb
clone AC-47, 1:10,000. Secondary antibodies were used at the following dilu-
tions: rabbit anti-mouse IgG(whole molecule)-peroxidase, 1:10,000; goat anti-
rabbit IgG(HL)-HRP, 1:10,000.
Live visualization assay for AAV DNA replication. The live visualization assay
for AAV DNA replication has been described previously (25). Briefly, Vero cells
grown on coverslips were transfected with 0.5 g of the pAAVlacO replicon, 0.1
g of the EYFP-LacI-expressing plasmid pSV2-EYFP/lacI, and 0.1 g of the
pcDNA.Rep plasmids or the empty pcDNA vector. On the following day, the
cells were infected with HSV-1 at an MOI of 10 PFU to provide helper functions
for AAV replication. The cells were fixed at 14 h postinfection (p.i.) and pro-
cessed for immunofluorescence staining.
Immunofluorescence. Immunofluorescence staining was performed as de-
scribed previously (31). The primary antibodies were used at the following
dilutions: mouse anti-HSV-1 ICP8 MAb 7381, 1:1,000; mouse anti-AAV Rep
MAb, 1:10; rabbit anti-AAV Rep PAb, 1:400; rabbit anti-phospho-RPA32 S4/S8
PAb, 1:100; mouse anti-phospho-ATM S1981 MAb, 1:100; and mouse anti-
phospho-H2AX S139 MAb, 1:100. Alexa Fluor-conjugated secondary antibodies
were diluted 1:200 to 1:1,000. Confocal laser scanning microscopy (CLSM) was
performed as described previously (21).
Packaging of HSV-1 amplicons. Packaging of the HSV-1 amplicon pHSVGFP
was done essentially as described previously (64). Briefly, Vero 2-2 cells were
transfected with 0.5 g of pHSVGFP, 2 g of fHSVpac27kn, and 0.2 g of
pEBHICP27 together with the indicated amounts of pcDNA.Rep plasmids or
empty pcDNA vector. Three days later, cells were harvested and HSV-1 ampli-
con particles released from cells by three cycles of freezing and thawing. Cellular
debris was removed by centrifugation at 1,900  g for 5 min. The cleared
supernatant was titrated by infection of Vero cells and enumeration of EGFP
cells 48 h p.i. by flow cytometry on a FACSCalibur (BD Biosciences).
Southern blot analysis. For the results presented in Fig. 2E and F, Vero 2-2
cells were transfected with 0.5 g of pHSVGFP or pAV2GFP, 2 g of
fHSVpac27kn, and 0.2 g of pEBHICP27 together with the indicated
amounts of pcDNA.Rep78 or empty pcDNA vector. For the results presented in
Fig. 3B, Vero 2-2 cells were transfected with 0.5 g of pHSVGFP, 1 g of
fHSVpac27kn, 0.1 g of pEBHICP27, and 0.2 g each of pCM-UL5/8/9/
29/30/42 and pD-UL52 plasmids together with the indicated amounts of
pcDNA.Rep78 or empty pcDNA vector. For the results presented in Fig. 3C,
Vero 2-2 cells were transfected with 0.5 g of pHSVGFP, 0.1 g of pEBHICP27,
and 0.4 g each of pCM-UL5/8/9/29/30/42 and pD-UL52 plasmids together with
the indicated amounts of pcDNA.Rep78 or empty pcDNA vector. Three days
later, the cells were harvested and extrachromosomal DNA extracted by the
procedure described by Hirt (36). The DNA was digested as indicated in the
text, separated on 1% agarose gels, and transferred to positively charged
nylon membranes (Hybond N; Amersham). Hybridization with a digoxi-
genin (DIG)-labeled probe specific for the EGFP-coding sequence and im-
munological detection using an alkaline phosphatase-conjugated anti-DIG
antibody and chemiluminescence substrate (CDP Star) were performed as
described by the supplier (Roche). The DIG-labeled probe was produced by
PCR amplification of the ORF encoding EGFP from plasmid pEGFP-N3
using the PCR DIG probe synthesis kit (Roche). The PCR product was
purified with the QIAquick PCR purification kit (Qiagen) before being used
for hybridization.
Treatment with HU, CPT, and UV-AAV.Hydroxyurea (HU) and camptothecin
(CPT) were purchased from Sigma and stock solutions prepared in H2O and
dimethyl sulfoxide (DMSO), respectively. Vero cells were treated for the indi-
cated times with 2.5 mMHU, 1 MCPT (or DMSO as a control), and 104 or 5
104 genome-containing particles (gcp) of UV-inactivated AAV (UV-AAV). The
cells were then either processed for immunofluorescence staining (see Fig. 6A to
C) or washed three times with phosphate-buffered saline (PBS) followed by
infection with HSV-1 C12 at an MOI of 5 PFU (see Fig. 6E). When the CPE
reached 100% (30 h p.i.), cells were harvested and virus particles released from
cells by three cycles of freezing and thawing. Cellular debris was removed by
centrifugation at 1,900  g for 5 min. The cleared supernatant was titrated by
infection of Vero cells in the presence of 100 g/ml phosphonoacetic acid
(PAA) and enumeration of EGFP cells at 24 h p.i. by flow cytometry on a
FACSCalibur (BD Biosciences).
Treatment with caspase inhibitors. The broad-spectrum caspase inhibitors
Z-VAD(OMe)-FMK (caspase inhibitor I) and Boc-D-FMK (caspase inhibitor
III) were purchased from Calbiochem (Merck). Stock solutions were prepared in
DMSO and added to cell culture media at final concentrations of 100 M.
Control cells were treated with the solvent DMSO alone. Every 24 h, half of the
cell culture medium was removed and replaced by medium containing fresh
caspase inhibitors or DMSO.
Annexin V staining. Vero cells were transfected with 0.25 g pEGFP-N3
together with 0.5 or 1 g pcDNA.Rep plasmids or empty pcDNA vector as
indicated in Results. Annexin V staining was performed using the annexin V-Cy5
Apoptosis Detection Kit from Abcam according to the manufacturer’s manual.
The cells were analyzed by flow cytometry on a FACSCalibur (BD Biosciences)
with filters specific for EGFP (transfected cells) and Cy5 (annexin V cells).
RESULTS
Expression of wild-type and mutant AAV Rep proteins. For
high-level, constitutive expression of Rep proteins, the corre-
sponding ORFs were placed under control of the HCMV IE1
enhancer/promoter in the pcDNA3.1 expression vector. A
map of the Rep proteins used in this study is shown in Fig. 1A,
and their activities are summarized in Table 1. Briefly, we
compared the full-length Rep78 protein with (i) Rep52, which
lacks the N-terminal site-specific DNA-binding and endonu-
clease activities (60); (ii) Rep68, which lacks the C-terminal
PKI-like and zinc finger motifs (22, 37); (iii) Rep78(Y156F),
TABLE 1. Summary of Rep constructs and their activities
Rep protein DNA binding
Endonuclease on:
ATPase/helicase C-terminaldomain
Replication
of AAV
Inhibition of
HSV-1 Apoptosis DNA damagessDNA dsDNA
Rep52         
Rep68         
Rep78         
Rep78(Y156F)         
Rep78(K340H)        / 
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which contains a mutation in rolling-circle replication motif 3
(RCR3), thereby abolishing site-specific endonuclease activity
(20, 73); and (iv) Rep78(K340H), which contains a mutation in
the consensus nucleoside triphosphate (NTP)-binding site,
thereby abolishing ATPase/helicase activity (13, 43). The loss
of ATPase/helicase activity in the K340H mutant results in a
loss of endonuclease activity on dsDNA substrates, because
endonuclease activity on dsDNA requires prior unwinding via
the helicase activity (50, 60). Of note also is that the K340H
mutant still retains endonuclease activity on ssDNA substrates,
while the Y156F mutant lacks endonuclease activity on both
ssDNA and dsDNA substrates (20, 73) (Table 1).
To assess the expression levels from the different constructs,
Vero cells were transfected with the Rep-encoding plasmids
together with a plasmid expressing EGFP, which served as
transfection and loading control. Western blotting with Rep-
and EGFP-specific antibodies showed that all Rep proteins
had the expected sizes and were expressed at comparable lev-
els (Fig. 1B). To ascertain the functionality of the expressed
Rep proteins, we tested their ability to support AAV DNA
replication. To this end, we employed a previously described
live cell visualization assay for AAV replication, in which AAV
RCs are visualized by the binding of an EYFP-LacI fusion
protein to lacO repeats present in a recombinant AAV
(rAAV) genome (25). The rAAV genome and the plasmid
encoding the EYFP-LacI fusion protein were transfected to-
gether with the individual Rep-encoding plasmids, while the
helper factors for AAV replication were provided by infection
with HSV-1. Transfected cells were identified by EYFP-LacI
expression, while HSV-1-infected cells were identified by stain-
ing for HSV-1 ICP8, which localizes to HSV-1 and AAV RCs.
AAV DNA replication is known to require Rep DNA-binding,
endonuclease, and ATPase/helicase activities (7, 8, 38, 39, 50).
In line with this, AAV RCs were observed only in cells trans-
fected with the Rep68 and Rep78 constructs, while Rep52,
Rep78(Y156F), and Rep78(K340H), as well as the empty vec-
tor, did not support AAV DNA replication (Fig. 1C).
Taken together, these results demonstrate that the different
Rep constructs used in this study are expressed at comparable
levels and meet the expected profile regarding their ability to
replicate AAV DNA (summarized in Table 1).
AAV Rep inhibits HSV-1 gene expression and DNA replica-
tion. Although Rep-mediated inhibition of HSV-1 replication
has previously been reported (31, 32, 35), the molecular mech-
anisms underlying theses observations remain unclear. We
therefore set out to further characterize the effect of Rep on
the replication of HSV-1. As a global measure of HSV-1 rep-
lication efficiency, we employed a previously described HSV-1
amplicon packaging assay (1, 59, 64). Briefly, Vero 2-2 cells,
which express HSV-1 ICP27 from its native promoter (72),
were transfected with an HSV-1 amplicon plasmid encoding
EGFP, pHSVGFP, together with an HSV-1 helper bacterial
artificial chromosome (BAC), fHSVpac27kn, and an
ICP27 expressing plasmid, pEBHICP27. The HSV-1 amplicon
plasmid pHSVGFP contains the HSV-1 oriS, the HSV-1 cleav-
age/packaging signal (pac), and an EGFP expression cassette.
It is replicated and packaged into HSV-1 particles in the pres-
ence of HSV-1 helper functions, and titers of vectors stocks can
readily be determined with help of the EGFP reporter trans-
gene (1, 59). The HSV-1 helper BAC fHSVpac27kn con-
sists of an HSV-1 genome with the ICP27 gene and pac deleted
(the nonessential 134.5 gene is also deleted due to deletion of
pac). In the presence of trans-expressed ICP27, the HSV-1
helper BAC represents a replication-competent, packaging-
defective HSV-1 genome providing helper functions for repli-
cation and packaging of HSV-1 amplicon plasmids (59, 64).
Although Vero 2-2 cells express ICP27, the cotransfection of
an ICP27-expressing plasmid is required for high titers of
HSV-1 amplicon vector stocks (64). Packaged HSV-1 amplicon
stocks were harvested at 72 h after transfection and the titers
determined by enumerating EGFP cells upon infection of
Vero cells. By providing the helper functions from a packag-
ing-defective HSV-1 genome, we ensured that replication of
the HSV-1 amplicon could occur only in transfected cells and
that HSV-1 infection could not spread to neighboring, untrans-
fected cells. The effects of Rep on HSV-1 replication could
therefore readily be assessed by cotransfection of Rep encod-
ing plasmids together with the HSV-1 amplicon and HSV-1
helper DNA. As shown in Fig. 2A, the cotransfection of in-
creasing amounts of the construct encoding the full-length Rep
protein, Rep78, led to a pronounced, dose-dependent inhibi-
tion of HSV-1 replication, demonstrating that the HSV-1 am-
plicon packaging assay provides a sensitive means to assess the
effects of Rep on HSV-1 replication efficiency.
We have previously demonstrated that AAV-mediated inhi-
bition of HSV-1 replication in the context of AAV/HSV-1
coinfection occurs mainly at the stage of DNA replication (31).
In order to find out if this also holds true for inhibition of
HSV-1 by expression of Rep78, we assessed the amounts of
replicated HSV-1 amplicon DNA by Southern blotting. Cells
transfected with increasing amounts of the Rep78 construct
together with HSV-1 amplicon DNA (pHSVGFP) and HSV-1
helper DNA were harvested 72 h later for extraction of extra-
chromosomal DNA. To distinguish between transfected and
newly synthesized HSV-1 amplicon DNA, the DNA was di-
gested with DpnI, which selectively cleaves the transfected
DNA of bacterial origin (i.e., Dam-methylated DNA). The
DNA was also cleaved with HindIII, which cuts once on
pHSVGFP and therefore reduces the concatemeric replication
products into linear monomers. HSV-1 amplicon DNA was
detected with a probe specific for the EGFP-coding sequence.
Figure 2E shows that transfection of the Rep78 plasmid led to
a dose-dependent reduction of the DpnI-resistant HSV-1 am-
plicon replication products, demonstrating that Rep inhibits
HSV-1 DNA replication.
Inhibited HSV-1 DNA replication can theoretically result
either from blocks at the stages of IE or early gene expression
or from a block of DNA replication itself. To determine which
of the above possibilities holds true for our experimental sys-
tem, we analyzed HSV-1 gene expression in the presence of
Rep78. Cells transfected with increasing amounts of the Rep78
construct together with HSV-1 amplicon DNA (pHSVGFP)
and HSV-1 helper DNA were harvested 48 h later and sub-
jected to Western analysis with antibodies specific for HSV-1
proteins of all kinetic classes. As shown in Fig. 2D, expression
of Rep78 resulted in a dose-dependent inhibition of the levels
of the IE protein ICP4; the early proteins UL9, ICP8, UL5,
and UL42; and the late proteins VP16, VP22, and glycoprotein
C (gC). Of note, the inhibitory effect on the late proteins was
more pronounced than that on the IE and early proteins. (We
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FIG. 2. (A) Effects of Rep78 on HSV-1 productivity. Vero 2-2 cells were transfected with pHSVGFP, fHSVpac27kn, pEBHICP27, and the
indicated amounts (in g) of pcDNA.Rep78 or empty pcDNA vector. The pHSVGFP amplicon vectors were harvested 72 h later and titrated on
Vero cells. (B) Screening of Rep proteins for inhibitory activity on HSV-1 replication. Vero 2-2 cells were transfected with pHSVGFP,
fHSVpac27kn, pEBHICP27, and 0.5 g each of the pcDNA.Rep constructs or empty pcDNA vector. The pHSVGFP amplicon vectors were
harvested 72 h later and titrated on Vero cells. (C) trans-complementation of Rep DNA-binding and ATPase/helicase activities. Vero 2-2 cells were
transfected with pHSVGFP, fHSVpac27kn, pEBHICP27, and the indicated amounts (in g) of the pcDNA.Rep constructs or empty pcDNA
vector. The pHSVGFP amplicon vectors were harvested 72 h later and titrated on Vero cells. The data in panels A to C are shown as means 	
standard deviations (SD) from triplicate experiments. (D) Effects of Rep on HSV-1 protein levels. Vero 2-2 cells were transfected with pHSVGFP,
fHSVpac27kn, pEBHICP27, and the indicated amounts (in g) of pcDNA.Rep78 or empty pcDNA vector. At 48 h after transfection, the cells
were lysed and analyzed by Western blotting with antibodies specific for AAV Rep and HSV-1 ICP4, UL9, ICP8, UL5, UL42, VP16, VP22, and
gC. Detection of actin served as a loading control. The asterisk indicates an unspecific band. (E) Effects of Rep78 on HSV-1 DNA replication. Vero
2-2 cells were transfected as described for panel D. At 72 h after transfection, extrachromosomal DNA was extracted, digested with DpnI and
HindIII, and analyzed by Southern blotting with a DIG-labeled probe specific for the EGFP-coding sequence on pHSVGFP. The linearized
pHSVGFP replication products (DpnI resistant) and the DpnI fragments of the transfected pHSVGFP plasmid (DpnI sensitive) are indicated.
One or 10 ng of linearized pHSVGFP plasmid was loaded as a positive control and size marker (M). (F) Effects of Rep on AAV DNA replication.
Vero 2-2 cells were transfected with pAV2GFP, fHSVpac27kn, pEBHICP27, and the indicated amounts (in g) of pRep, pcDNA.Rep78, or
empty pcDNA vector. At 72 h after transfection, extrachromosomal DNA was extracted, digested with DpnI, and analyzed by Southern blotting
with a DIG-labeled probe specific for the EGFP-coding sequence on rAV2GFP. Rescued monomeric (ITRm) and dimeric (ITRd) rAV2GFP
replication intermediates (DpnI resistant) and the DpnI fragments of the transfected pAV2GFP plasmid (DpnI sensitive) are indicated. One
nanogram of the BglII-excised ITR cassette from pAV2GFP was loaded as a positive control and size marker (M).
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also attempted to detect UL8, UL52, and UL30, but the levels
expressed in HSV-1 helper BAC-transfected cells were too low
for detection by Western blotting.)
To assess if the observed inhibition of HSV-1 gene expres-
sion and DNA replication is specific for HSV-1 and not due to
general cytotoxicity of Rep, we assessed whether the amounts
of Rep78 plasmid used were compatible with AAV DNA rep-
lication. General cytotoxic effects of Rep would be expected to
inhibit both HSV-1 and AAV DNA replication. To this end,
we performed an replication assay equivalent to that shown in
Fig. 2E, except that an rAAV plasmid (pAV2GFP) was used
instead of the HSV-1 amplicon. AAV DNA replication from
pAV2GFP results in the rescue of DpnI-resistant mono- and
multimeric ITR cassettes (i.e., rAAV replication intermedi-
ates). rAAV DNA was detected with a probe specific for the
EGFP-coding sequence. Transfection of a plasmid encoding all
four Rep proteins under control of the native p5 and p19
promoters, pRep, served as a control for physiological Rep
levels. The blot in Fig. 2F shows that all the amounts of Rep78
plasmid used supported AAV DNA replication, while no AAV
DNA replication was observed in the absence of Rep. Spe-
cifically, the levels of the AAV replication intermediates
were comparable between pRep and 0.1 to 0.5 g of
pcDNA.Rep78, while the levels were slightly reduced with 1
g of pcDNA.Rep78, indicating that very high Rep levels are
inhibitory to AAV replication (Fig. 2F).
The seven essential HSV-1 replication factors, UL9, ICP8,
UL5/8/52, and UL30/42, are all expressed with early kinetics
(81). We therefore aimed to find out if the observed inhibition
of the HSV-1 early gene expression (Fig. 2D), in particular the
expression of the replication factors, was responsible for the
observed inhibition of HSV-1 DNA replication or if, alterna-
tively, Rep rather had a direct inhibitory effect on HSV-1 DNA
replication. If the former was the case, Rep would not be
expected to inhibit HSV-1 DNA replication if abundant levels
of HSV-1 replication factors were provided by overexpression
from constitutive promoters. If, however, Rep acted directly on
HSV-1 DNA replication, inhibition of HSV-1 DNA replication
would be expected even in the presence of overexpressed rep-
lication factors. We first tested the effect of Rep78 on the levels
of the seven HSV-1 replication factors when expressed from
the HCMV IE1 enhancer/promoter (UL9, ICP8, UL5, UL8,
UL30, and UL42) or the short eukaryotic initiation factor 1 
subunit (sEIF) promoter (UL52). As shown in Fig. 3A,
Rep78 had no significant inhibitory effect on the levels of the
HSV-1 replication factors expressed from constitutive promoters.
We next assessed the effect of Rep78 on pHSVGFP amplicon
replication mediated by HSV-1 helper BAC and overexpressed
HSV-1 replication factors (Fig. 3B) or by overexpressed HSV-1
replication factors alone (Fig. 3C). In either situation, Rep78
significantly inhibited the replication of the HSV-1 amplicon,
demonstrating that Rep inhibits HSV-1 DNA replication even in
the presence of abundant HSV-1 replication factors.
Taken together, these findings show that the expression of
Rep78 from the HCMV IE1 enhancer/promoter strongly in-
hibits HSV-1 productivity (Fig. 2A), HSV-1 gene expression
(Fig. 2D), and HSV-1 DNA replication (Fig. 2E). The inhibi-
tory effects of Rep78 on HSV-1 appeared to be specific and not
due to general cytotoxicity, since the Rep levels employed were
compatible with AAV DNA replication (Fig. 2F). Further-
more, the data show that the inhibition of HSV-1 DNA repli-
cation by Rep was not due to the reduction of the expression
of the HSV-1 replication factors but presumably was caused by
a direct inhibitory effect of Rep on HSV-1 DNA replication
(Fig. 3). The finding that Rep levels compatible with efficient
AAV DNA replication are strongly inhibitory for HSV-1 DNA
replication (Fig. 2E and F) further corroborates this notion,
since both AAV and HSV-1 DNA replication depend on the
HSV-1 replication factors (3).
Rep DNA-binding and ATPase/helicase activities are re-
quired for inhibition of HSV-1. We next aimed to identify
which activities of Rep78 were required for the observed inhi-
bition of HSV-1 replication. For this, all Rep constructs pre-
sented in Fig. 1 were screened for their ability to inhibit HSV-1
replication. This time we transfected 0.5 g of the Rep plas-
mids, since this amount was sufficient for considerable inhibi-
tion of HSV-1 replication by Rep78 (Fig. 2A and E). As shown
in Fig. 2B, Rep68, Rep78, and Rep78(Y156F) all inhibited
HSV-1 replication at comparable levels, while almost no inhi-
bition was observed in the presence of Rep52 and Rep78
(K340H). The lack of inhibitory activity of Rep52 and
Rep78(K340H) demonstrates that DNA-binding and ATPase/
helicase activities are essential for inhibition of HSV-1 repli-
cation. The finding that Rep78(Y156F) and Rep68 inhibit
HSV-1 replication allows to conclude that endonuclease activ-
ity and the C-terminal domain containing the PKI-like and the
zinc finger motifs are not required for inhibition of HSV-1.
We then asked if Rep DNA-binding and ATPase/helicase
activities need to be present on the same Rep molecule or if
trans-complementation of DNA-binding and ATPase/helicase
activities would restore the inhibitory effect. Although Rep78
(K340) has a dominant-negative effect on the helicase activity of
wild-type Rep78, it does not have any dominant-negative effect
on Rep52 helicase activity (74). Transfection of cells with
Rep78(K340H), which has site-specific DNA-binding activity
but no ATPase/helicase activity, together with Rep52, which
has ATPase/helicase activity but no site-specific DNA-binding
activity, therefore allows us to assess if Rep DNA-binding and
ATPase/helicase activities act separately or if the ATPase/
helicase activity of Rep needs to be targeted to a dsDNA
substrate via the site-specific DNA-binding domain. As shown
in Fig. 2C, cotransfection of Rep78(K340H) with Rep52 did
not restore the inhibitory effect, suggesting that the two activ-
ities need to be present in cis.
Taken together, these results demonstrate that Rep-medi-
ated inhibition of HSV-1 replication does not depend on the
endonuclease activity or the C-terminal domain but requires
DNA-binding and ATPase/helicase activities on the same Rep
molecule (summarized in Table 1).
The activities of Rep required for inhibition of HSV-1 rep-
lication coincide with those required for induction of apopto-
sis. Rep proteins have previously been described to induce
apoptosis in HL-60 and NT2 cells, which are a p53-null pro-
myeloid cell line and a p53-containing embryonal carcinoma
cell line, respectively (66). The induction of apoptosis has been
shown to be mediated by the DNA-binding and ATPase/heli-
case activities of Rep (66), notably the same activities which
are required for inhibition of HSV-1 replication.
We therefore first wanted to determine if Rep expression is
also able to induce apoptosis in Vero cells. In the following
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experiments, unless otherwise stated, cells were transfected
with 0.5 g of the Rep constructs. In a first experiment, we
assessed the time course of Rep-mediated apoptosis. For this,
Vero cells were transfected with the Rep78 construct or the
empty vector, together with a plasmid expressing EGFP
(pEGFP-N3), and analyzed 24, 48, and 72 h later by staining
with annexin V followed by flow cytometry. Transfected cells
were identified by EGFP fluorescence. The results shown in
Fig. 4A show that Rep78 is able to induce apoptosis in Vero
cells starting from 48 h after transfection. We next assessed if
the observed induction of apoptosis in Vero cells also depends
on the DNA-binding and ATPase/helicase activities of Rep, as
previously reported for HL-60 and NT2 cells (66). This was
indeed the case, as apoptosis was readily induced by Rep68,
FIG. 3. (A) Effects of Rep on levels of HSV-1 replication factors expressed from constitutive promoters. Vero cells were transfected with
pCM-UL5, -UL8, -UL9, -UL29, -UL30, -UL42, pD-UL52, and the indicated amounts (in g) of pcDNA.Rep78 or empty pcDNA vector.
Untransfected cells were loaded as a control (UT). At 48 h after transfection, the cells were lysed and analyzed by Western blotting with antibodies
specific for AAV Rep and HSV-1 UL9, ICP8, UL5, UL8, UL52, UL30, and UL42. Detection of actin served as a loading control. (B) Effects of
Rep on pHSVGFP amplicon replication mediated by HSV-1 helper BAC and overexpressed HSV-1 replication factors. Vero 2-2 cells were
transfected with pHSVGFP, fHSVpac27kn, pEBHICP27, pCM-UL5, -UL8, -UL9, -UL29, -UL30, -UL42, pD-UL52, and the indicated
amounts (in g) of pcDNA.Rep78 or empty pcDNA vector. At 72 h after transfection, extrachromosomal DNA was extracted, digested with DpnI
and HindIII, and analyzed by Southern blotting with a DIG-labeled probe specific for the EGFP-coding sequence on pHSVGFP. The linearized
pHSVGFP replication products (DpnI resistant) and the DpnI fragments of the transfected pHSVGFP plasmid (DpnI sensitive) are indicated.
One nanogram of linearized pHSVGFP plasmid was loaded as a positive control and size marker (M). (C) Effects of Rep on pHSVGFP amplicon
replication mediated by overexpressed HSV-1 replication factors. Vero 2-2 cells were transfected with pHSVGFP, pEBHICP27, pCM-UL5, -UL8,
-UL9, -UL29, -UL30, -UL42, pD-UL52, and the indicated amounts (in g) of pcDNA.Rep78 or empty pcDNA vector. Southern blotting was
performed as described for panel B.
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Rep78, and Rep78(Y156F), while Rep52, Rep78(K340H), and
the empty vector induced only low levels of apoptosis (Fig. 4B).
Analogous to Rep-mediated inhibition of HSV-1 replication,
Rep-mediated apoptosis required DNA-binding and ATPase/
helicase activities to be on the same Rep molecule, since trans-
complementation of DNA-binding and ATPase/helicase activ-
ities did not restore efficient induction of apoptosis (Fig. 4C).
The Rep activities required for induction of apoptosis are
summarized in Table 1.
The finding that the requirements for Rep-mediated apop-
FIG. 4. Role of apoptosis in Rep-mediated inhibition of HSV-1 replication. (A) Vero cells were transfected with 0.5 g of pcDNA.Rep78 or
empty pcDNA vector together with 0.25 g pEGFP-N3. At the indicated time points, the cells were stained with Cy5-conjugated annexin V and
analyzed by flow cytometry with filters specific for EGFP (transfected cells) and Cy5 (annexin V cells). (B) Vero cells were transfected with 0.5
g of pcDNA.Rep constructs or empty pcDNA vector together with 0.25 g pEGFP-N3 and analyzed 72 h later by annexin V staining as described
for panel A. (C) Vero cells were transfected with the indicated amounts of pcDNA.Rep constructs or empty pcDNA vector (in g) together with
0.25 g pEGFP-N3 and analyzed 72 h later by annexin V staining as described for panel A. (D) Vero cells were transfected with 0.5 g of
pcDNA.Rep78 or empty pcDNA vector together with 0.25 g pEGFP-N3 and subsequently infected with HSV-1 at an MOI of 10 PFU. At the
indicated time points, the cells were analyzed by annexin V staining as described for panel A. (E) Vero cells were transfected with the indicated
amounts of pcDNA.Rep78 or empty pcDNA vector (in g) and incubated in the presence of the caspase inhibitor Z-VAD-FMK or Boc-D-FMK
(100 M each) or the solvent DMSO as a control. At 72 h after transfection, the cells were analyzed by annexin V staining as described for panel
A. (F) Vero 2-2 cells were transfected with pHSVGFP, fHSVpac27kn, pEBHICP27, and the indicated amounts of the pcDNA.Rep constructs
or empty pcDNA vector (in g). The cells were then incubated in the presence of the caspase inhibitor Z-VAD-FMK or Boc-D-FMK (100 M
each) or the solvent DMSO as a control. The pHSVGFP amplicon vectors were harvested at 72 h after transfection and titrated on Vero cells.
All the data in this figure are shown as means 	 SD from triplicate experiments.
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tosis perfectly coincide with those for Rep-mediated inhibition
of HSV-1 replication may suggest that the induction of apop-
tosis is part of the mechanism by which Rep inhibits HSV-1
replication. We therefore determined if apoptosis is indeed
induced in Rep-expressing and HSV-1 infected cells and if
pharmacological inhibition of apoptosis could prevent Rep-
mediated inhibition of HSV-1 replication. To first find out if
Rep induces apoptosis during HSV-1 infection, cells were
transfected with either the Rep78 plasmid or the empty vector
and infected immediately after transfection with HSV-1 at a
high MOI (10 PFU). Cells were then harvested every 12 h until
the CPE reached 100% (48 h p.i.) and analyzed by annexin V
staining. As shown in Fig. 4D, annexin V staining remained low
throughout the HSV-1 infection both in Rep78-expressing cells
and in cells transfected with the empty vector, showing that the
presence of Rep78 does not lead to apoptosis in the course of
HSV-1 infection. This result is not unexpected, since HSV-1
has previously been shown to encode antiapoptotic factors
(reviewed in reference 58). To assess the effect of pharmaco-
logical inhibition of caspases on Rep-mediated inhibition of
HSV-1 replication, cells transfected with Rep78 or the empty
vector were treated with two different broad-range caspase
inhibitors, Z-VAD-FMK and Boc-D-FMK. As shown in Fig.
4E, both inhibitors prevented Rep-mediated apoptosis. How-
ever, the presence of caspase inhibitors did not prevent Rep-
mediated inhibition of HSV-1 replication (Fig. 4F).
In summary, these data show that the Rep protein per se
induces apoptosis in Vero cells and that the activities of Rep
required for this effect precisely coincide with those required
for inhibition of HSV-1 (i.e., DNA-binding and ATPase/heli-
case activities on the same Rep molecule). However, Rep does
not induce apoptosis during HSV-1 infection, nor does treat-
ment with caspase inhibitors prevent Rep-mediated inhibition
of HSV-1 replication, suggesting that the execution of apop-
tosis is not part of the mechanism by which Rep inhibits HSV-1
replication.
The activities of Rep required for inhibition of HSV-1 rep-
lication coincide with those required for induction of DNA
damage. Expression of Rep78 has previously been shown to
induce DNA damage in U2OS and HeLa cells (5). The result-
ing DNA damage response has been shown to be mediated by
ataxia telangiectasia-mutated (ATM) and to result in the acti-
vation of the checkpoint effector kinase Chk2 and histone
H2AX. The authors postulated that Rep endonuclease activity
induced nicks in the cellular DNA and that this was respon-
sible for the DNA damage response. To reach that conclu-
sion, Berthet and coworkers (5) used a mutant Rep protein
lacking DNA-binding activity, Rep781–171, as well as the
Rep78(K340H) mutant lacking ATPase/helicase activity (and
consequently endonuclease activity on dsDNA). However, they
did not use the Rep78(Y156F) mutant lacking endonuclease
activity and retaining ATPase/helicase activity. Their data
therefore do not elucidate if endonuclease or, rather, ATPase/
helicase activity is required for the induction of cellular DNA
damage.
We therefore assessed the requirements of Rep for the in-
duction of a DNA damage response using our panel of Rep
mutants. For this, Vero cells were transfected with Rep-encod-
ing plasmids or a plasmid expressing EGFP as a negative
control. Transfected cells were identified by staining with Rep-
specific antibodies or by EGFP fluorescence. As markers of a
DNA damage response, we used antibodies specific for hyper-
phosphorylated (i.e., activated) ATM (p-ATM S1981), RPA
(p-RPA32 S4/S8), and H2AX (H2AX S139). In Rep78-trans-
fected cells, the activation of all three markers was observed as
early as 24 h after transfection (data not shown). Such activa-
tion was also observed in cells treated with broad-spectrum
caspase inhibitors, demonstrating that it was not a conse-
quence of Rep-mediated apoptosis (data not shown). To iden-
tify the Rep activities required for activation of the DNA
damage responses, cells were transfected with our panel of
Rep plasmids and analyzed 48 h later by staining for the DNA
damage markers. Examples of Rep78-transfected cells scored
as positive or EGFP-transfected cells scored as negative are
shown in Fig. 5A. Rep-positive cells showing an activated DNA
damage response also showed a somewhat altered chromatin
structure (Fig. 5A), corroborating the notion that Rep dam-
ages cellular chromatin (5). Activation of ATM, RPA, and
H2AX was observed in approximately 30 to 50% of cells trans-
fected with Rep68, Rep78, and Rep78(Y156F), while transfec-
tion with Rep52 and Rep78(K340), as well as a combination of
the two, did not induce more DNA damage than the negative
control (Fig. 5B).
Taken together, these data demonstrate that Rep induces a
cellular DNA damage response in Vero cells characterized by
hyperphosphorylation of ATM, RPA, and H2AX and that this
requires DNA-binding and ATPase/helicase activities on the
same Rep molecule. As such, they show that the activities of
Rep required for induction of cellular DNA damage precisely
coincide with those required for the inhibition of HSV-1 rep-
lication and induction of apoptosis (summarized in Table 1).
The hyperphosphorylation of RPA per se is not responsible
for the inhibition of HSV-1 replication. It has recently become
clear that differential DNA damage responses are induced
during HSV-1 and AAV replication. Specifically, HSV-1 infec-
tion induces hyperphosphorylation of ATM (44, 70) and
H2AX (84), but not RPA (85, 86). In contrast, productive
AAV infection leads to hyperphosphorylation of ATM, RPA,
and H2AX (68). We therefore hypothesized that components
of the DNA damage response elicited by Rep, specifically the
hyperphosphorylation of RPA, may be involved in the inhibi-
tion of HSV-1 replication. HSV-1 replication does not induce
hyperphosphorylation of RPA unless the HSV-1 DNA poly-
merase is blocked by inhibitors such as PAA or acyclovir (85,
86). In addition, endogenous p-RPA is sequestered into virus-
induced chaperone-enriched (VICE) domains during produc-
tive replication (84), suggesting that p-RPA may be inhibitory
to HSV-1 replication and that HSV-1 may prevent such inhi-
bition by excluding p-RPA from HSV-1 RCs. To assess if
hyperphosphorylation of RPA is mediating the inhibition of
HSV-1 replication, we induced hyperphosphorylation of RPA
by pretreatment of cells with hydroxyurea (HU) (47) or camp-
tothecin (CPT) (69) or infection with UV-inactivated AAV
(UV-AAV) (26, 40) and assessed the effect of these treatments
on HSV-1 replication. While HU and CPT treatments result in
damaging of cellular DNA, infection of cells with UV-AAV
induces a DNA damage response without actually damaging
cellular DNA (26, 40). The DNA damage response to UV-
AAV resembles stalled replication fork signaling and involves
DNA polymerase 
, ATR, TopBP1, RPA, the Rad9/Rad1/
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Hus1 complex, H2AX, and Chk1 but not ATM or NBS1 (26,
40). Although the cellular DNA itself is not damaged, such
DNA damage signaling has profound effects on the cell cycle in
that it results in G2 arrest (40, 61).
We first confirmed the induction of a DNA damage re-
sponse in Vero cells upon treatment with HU (2.5 mM), CPT
(1 M), and UV-AAV (MOI of 104 and 5 105 gcp). All three
treatments induced a strong hyperphosphorylation of RPA
(p-RPA32 S4/S8) and H2AX (H2AX S139) compared to that
in control cells (Fig. 6A to C). ATM was strongly hyperphos-
phorylated (p-ATM S1981) upon HU and CPT treatment but
only weakly hyperphosphorylated upon infection with UV-
AAV (Fig. 6A to C), suggesting that HU and CPT, but not
UV-AAV, induced significant double-strand breaks. We next
confirmed efficient inactivation of AAV by assessing the levels
of Rep proteins by Western blotting. While Rep proteins were
readily expressed in AAV/HSV-1-coinfected Vero cells, no
Rep-specific bands were observed in UV-AAV/HSV-1-coin-
fected cells, confirming that UV inactivation was sufficient
(Fig. 6D). Finally, Vero cells were treated with HU, CPT, and
UV-AAV for the indicated times, washed thoroughly, and then
infected with a recombinant HSV-1 expressing EGFP (HSV-1
C12) at high a MOI (5 PFU). When CPE reached 100%, the
HSV-1 C12 produced was harvested and titrated. As shown in
Fig. 6E, HU treatment significantly inhibited HSV-1 replica-
tion compared to untreated cells, while both UV-AAV and
CPT had no significant effect on HSV-1 productivity.
Taken together, these results demonstrate that although all
three pretreatments, HU, CPT, and UV-AAV, strongly in-
duced the hyperphosphorylation of RPA, only HU led to sig-
nificant inhibition of HSV-1 replication, while CPT and UV-
AAV did not affect HSV-1 productivity. As such, they suggest
that the hyperphosphorylation of RPA per se is not inhibitory
for HSV-1 replication and that HU inhibits HSV-1 replication
FIG. 5. Screening of Rep proteins for induction of cellular DNA damage. (A) Examples of Rep78-transfected cells scored as positive and
EGFP-transfected cells scored as negative for DNA damage markers. Vero cells were transfected with 0.5 g of pcDNA.Rep78 or pcDNA.EGFP.
At 48 h after transfection, the cells were fixed and stained with antibodies specific for p-ATM S1981, p-RPA32 S4/S8, or H2AX S139 (red).
pcDNA.Rep78-transfected cells were identified by staining with Rep-specific antibodies, while pcDNA.EGFP-transfected cells were identified by
EGFP fluorescence (green). Cellular chromatin was stained with DAPI (cyan). Images were recorded by CLSM and show single z stacks of
representative cells. (B) Quantification of cells staining positive for DNA damage markers. Vero cells were transfected with 0.5 g of the indicated
pcDNA.Rep constructs or pcDNA.EGFP and stained as described for panel A. Rep or EGFP cells (n 100) were scored for staining of p-ATM
S1981, p-RPA32 S4/S8, or H2AX S139. The data are shown as means 	 SD from three independent experiments.
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FIG. 6. (A to C) Immunofluorescence staining for DNA damage markers upon HU, CPT, and UV-AAV treatment. Vero cells were treated
for the indicated times with HU (2.5 mM) or left untreated (nil) (A), with CPT (1 M) or its solvent DMSO alone (B), or with UV-AAV (MOI
of 104 or 5  104 gcp) or left untreated (nil) (C). The cells were then fixed and stained for p-ATM S1981, p-RPA32 S4/S8, or H2AX S139 (red).
Chromatin was stained with DAPI (blue; inset). Scale bars, 10 m. Images were recorded by CLSM and show single z stacks of representative cells.
(D) Western blot for Rep proteins upon live AAV or UV-AAV infection. Vero cells were left uninfected or infected with live AAV or UV-AAV
(MOI of 5  104 gcp). Twenty-four hours later, the cells were superinfected with HSV-1 (MOI of 5 PFU) or left uninfected. Twenty-four hours
after HSV-1 infection, the cells were lysed and processed for Western blotting with a Rep-specific MAb. Detection of actin served as a loading
control. (E) HSV-1 replication in cells pretreated with HU, CPT, and UV-AAV. Vero cells were left untreated (nil) or treated with HU (2.5 mM),
UV-AAV (MOI of 104 or 5  104 gcp), and CPT (1 M) or its solvent DMSO alone for the indicated times. After three washes in PBS, the cells
were infected with HSV-1 C12 (expressing EGFP) at an MOI of 5 PFU. At 24 h after HSV-1 C12 infection, virus was harvested and titrated on
Vero cells by enumerating EGFP cells. The data are shown as means 	 SD from triplicate experiments. The asterisks indicate statistically
significant reductions compared to untreated cells (P  0.05).
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by a different mechanism, presumably the depletion of de-
oxynucleoside triphosphate (dNTP) pools by inhibition of ri-
bonucleotide reductase (2).
DISCUSSION
In a first set of experiments, we characterized the inhibitory
effect of Rep on HSV-1 replication. For this purpose, we as-
sessed the levels of infectious HSV-1 particles, the levels of
replicated HSV-1 DNA, and the levels of expressed HSV-1
gene products in the presence of Rep78 expressed from the
HCMV IE1 enhancer/promoter. The presence of Rep78 re-
sulted in a dose-dependent inhibition of HSV-1 productivity,
DNA replication, and gene expression. The inhibitory effect on
the latter was not uniform in that Rep78 had a stronger effect
on the late gene products VP16, VP22, and gC than on the IE
gene product ICP4 and the early gene products UL9, ICP8,
UL5, and UL42 (Fig. 2). These findings are consistent with our
previous observations that in the situation of AAV/HSV-1
coinfection, HSV-1 replication is inhibited mainly at the levels
of DNA replication and late gene expression, while IE and
early gene expression is only marginally reduced (31). It ap-
peared, however, that the expression of Rep78 from the
HCMV IE1 enhancer/promoter had a more pronounced effect
on the levels of HSV-1 IE and early gene products than AAV
coinfection, an observation which may be explained by the
different expression kinetics of rep. Specifically, high-level ex-
pression of the AAV rep gene from its native promoters (p5
and p19) requires transactivation by the HSV-1 IE early gene
products ICP0, ICP4, and ICP22 (3). Consequently, in the
situation of AAV/HSV-1 coinfection, expression of the rep
gene is expected to occur with kinetics similar to that of HSV-1
early genes. In the present study, in contrast, Rep78 was ex-
pressed with IE kinetics, which may explain why the inhibitory
effect on HSV-1 IE and early gene products was more pro-
nounced than in the situation of AAV/HSV-1 coinfection (31).
However, the reduced levels of HSV-1 early gene products, in
particular the HSV-1 replication factors, appeared not to be
responsible for the inhibition of HSV-1 DNA replication, since
Rep inhibited HSV-1 DNA replication even in the presence of
overexpressed HSV-1 replication factors (Fig. 3). In addition,
the Rep levels employed were compatible with AAV DNA
replication, which also depends on the HSV-1 replication ma-
chinery (Fig. 2). These findings suggest that Rep may have a
direct inhibitory effect on HSV-1 DNA replication.
In a second set of experiments, we identified the Rep activ-
ities required for inhibition of HSV-1 replication. The results
demonstrate that the inhibition of HSV-1 replication requires
Rep DNA-binding and ATPase/helicase activities on the same
Rep molecule, while the C terminus of Rep78 and Rep endo-
nuclease activity are not required (Fig. 2 and Table 1). The
finding that Rep DNA-binding and ATPase/helicase activities
are required and that they need to be present on the same Rep
molecule is consistent with a model in which the inhibition of
HSV-1 replication involves the interaction of Rep with DNA
and in which the Rep helicase activity needs to be targeted to
a dsDNA substrate via the DNA-binding domain. Theoreti-
cally, the inhibition of HSV-1 replication could result either
from a direct effect of Rep on HSV-1 DNA or else from an
effect on cellular DNA. Rep is known to have a variety of
effects on the host cell, including the induction of DNA dam-
age, cell cycle arrest, and apoptosis (5, 65, 66, 68). Apoptosis
has been shown to require Rep DNA-binding and ATPase/
helicase activities (66), notably the same activities required for
inhibition of HSV-1 replication. We therefore hypothesized
that Rep-mediated induction of apoptosis may be part of the
mechanism by which Rep inhibits HSV-1 replication. Our data
show that although the activities required for induction of
apoptosis and for inhibition of HSV-1 replication coincide
precisely (Fig. 4 and Table 1), execution of apoptosis is not
part of the inhibitory mechanism. First, apoptosis did not occur
in cells expressing Rep78 and infected with HSV-1, and sec-
ond, treatment with caspase inhibitors did not abolish the
inhibitory activity of Rep on HSV-1 replication (Fig. 4). We
concluded from these data that the ability of Rep to induce
apoptosis must be closely linked to its ability to inhibit HSV-1
replication, possibly by acting in the same pathway. Further-
more, the finding that the execution of apoptosis is not re-
quired for inhibition of HSV-1 replication suggests that Rep-
mediated apoptosis may only be the consequence of an
upstream Rep effect leading to inhibition of HSV-1 replica-
tion. A possible candidate for such an upstream effect is the
ability of Rep to induce cellular DNA damage, an effect which
results in DNA damage signaling, cell cycle arrest, and pre-
sumably apoptosis (5). We therefore assessed which activities
of Rep were required for the induction of DNA damage. In-
triguingly, the Rep activities required for induction of cellular
DNA damage precisely corresponded to those required for
induction of apoptosis and inhibition of HSV-1 replication,
corroborating the notion that these three Rep effects are
linked in a common pathway (Fig. 5 and Table 1). Consistent
with previous findings, expression of Rep78 resulted in the
hyperphosphorylation of ATM (p-ATM S1981) and H2AX
(H2AX S139) (5, 68). The phosphatidylinositol 3-kinase-like
kinase (PIKK) ATM is a master regulator of the cellular re-
sponse to double-strand breaks and activates a variety of sub-
strates involved in cell cycle checkpoints and DNA repair.
ATM protein kinase activity is activated upon DNA damage
stimuli, and this activation has been attributed to intermolec-
ular autophosphorylation on serine 1981 and dissociation of
multimeric ATM to an active, monomeric form (reviewed in
reference 42). ATM has been shown to be essential for Rep78-
induced DNA damage signaling, in that expression of Rep78
did not result in cell cycle arrest and activation of H2AX in
ATM-null cell lines (5). H2AX is a histone protein which can
be hyperphosphorylated at serine 139 by ATM in response to
double-strand breaks or, alternatively, by ATM- and Rad3-
related (ATR) kinase in response to replication stalling and
single-strand breaks and is involved in the assembly and reten-
tion of DNA repair factors at the DNA lesion (reviewed in
reference 24). We also observed the hyperphosphorylation of
RPA (p-RPA32 S4/S8), a heterotrimeric ssDNA-binding pro-
tein consisting of 70-, 32-, and 14-kDa subunits which is in-
volved in diverse processes such as DNA replication, DNA
repair, recombination, and DNA damage checkpoints (re-
viewed in reference 92). RPA hyperphosphorylation occurs
upon DNA damage signaling and can be mediated by the
PIKKs ATM, ATR, and DNA-dependent protein kinase
(DNA-PK), depending on the nature of the DNA lesion (re-
viewed in references 6 and 19). Theoretically, there are two
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different possible explanations for the observation that the
ability of Rep to induce DNA damage correlates with its ability
to inhibit HSV-1 replication. First, the Rep-induced DNA
damage itself, presumably acting on both cellular and HSV-1
DNAs, could be responsible for inhibition of HSV-1 replica-
tion. Second, the cellular response to Rep-induced DNA dam-
age could be responsible for inhibition of HSV-1 replication by
creating a cellular environment unfavorable for HSV-1 repli-
cation. Indeed, AAV and HSV-1 have recently been demon-
strated to induce differential DNA damage signaling and to be
differentially affected by DNA damage and repair proteins.
Specifically, productive AAV infection induces the hyperphos-
phorylation of ATM, RPA, and H2AX (68), while HSV-1
infection leads to hyperphosphorylation of ATM (44, 70) and
H2AX (84) but not RPA (85, 86). To find out if the Rep-
mediated activation of RPA may be responsible for inhibition
of HSV-1 replication, we assessed the replication efficiency of
HSV-1 in cells in which RPA hyperphosphorylation had pre-
viously been induced by treatment with HU or CPT or by
infection with UV-AAV. Although all three agents efficiently
induced hyperphosphorylation of RPA, only HU pretreatment
significantly inhibited HSV-1 replication (Fig. 6). This suggests
that Rep-induced activation of RPA per se is not responsible
for the inhibition of HSV-1 replication and that the observed
inhibition of HSV-1 replication by HU involves mechanisms
other than RPA hyperphosphorylation, presumably the deple-
tion of dNTP pools by inhibition of ribonucleotide reductase
(2). These findings may be interpreted in at least two different
ways. First, they may mean that the hyperphosphorylation of
RPA does not interfere with efficient HSV-1 replication. Sec-
ond, they may mean that HSV-1 can efficiently circumvent a
potential inhibitory effect by sequestering p-RPA away from its
RCs into VICE domains (84).
Although the finding that inhibition of HSV-1 replication
requires Rep DNA-binding and ATPase/helicase activities on
the same Rep molecule is consistent with the idea that the
inhibition of HSV-1 replication involves the interaction of Rep
with target DNA, it is also conceivable that Rep inhibits HSV-1
replication by its interaction with the HSV-1 DNA replication
complex. It is thought that the direct interaction between Rep
and ICP8 (33, 75) leads to the recruitment of the HSV-1 DNA
replication complex to AAV replication origins. Consistent
with this, essential roles of ICP8, the HSV-1 helicase-primase
complex, and the HSV-1 DNA polymerase holoenzyme in
AAV replication have been demonstrated (3, 82). However, it
is also possible that the Rep-ICP8 interaction directs Rep to
DNA replication complexes on HSV-1 replication origins,
where it possibly interferes with efficient HSV-1 DNA replica-
tion. In analogy, the interaction of Rep with RPA (75) might
direct Rep to cellular DNA replication complexes, leading to
inhibition of cellular DNA replication. Direct interactions with
the ssDNA-binding proteins ICP8, RPA, and Ad-DBP have
been demonstrated for Rep68 and Rep78 (33, 75), and these
interactions have been shown to enhance binding of Rep68
and Rep78 to the Rep-binding site (RBS) (75). The enhance-
ment of Rep DNA binding by all three ssDNA-binding pro-
teins was also observed for a mutant Rep protein lacking
ATPase/helicase activity, Rep68(K340H/Y121H), implying
that the mutant Rep protein can still interact with ICP8, RPA,
and Ad-DBP (75). As such, these findings are consistent with
the idea that the inability of the Rep78(K340H) mutant to
inhibit the replication of HSV-1 is not due to a loss of the
direct interaction with ICP8 but rather is due to the loss of the
ATPase/helicase activity itself. We therefore consider it more
likely that the inhibition of HSV-1 replication involves the
interaction of Rep with target DNA rather than that with
ICP8.
How could Rep DNA-binding and ATPase/helicase activi-
ties result in cellular DNA damage and apoptosis, as well as
inhibition of HSV-1 replication? Rep displays sequence-spe-
cific binding to dsDNA, which targets the protein to the RBSs
within the AAV replication origins, as well as to its preinte-
gration site on human chromosome 19 (AAVS1). The se-
quence-specific DNA-binding activity requires the amino-ter-
minal 224 amino acids, which are present in Rep68 and Rep78
but not in Rep40 and Rep52 (60). The sequence recognized by
Rep consists of an array of GAGC tetranucleotide repeats,
with the binding affinity being determined by the number of
perfect GAGC repeats present as well as secondary structures
neighboring the RBSs (14, 15, 30, 51, 52, 62, 87). The AAV
genome, for instance, contains RBSs within the ITR replica-
tion origins (GAGC GAGC GAGC GCGC), as well as within
the p5 promoter (GAGT GAGC ACGC AGGG), with the
binding affinity of Rep being higher for the ITR than for the p5
RBS (30). In addition to the RBS present in the AAVS1 pre-
integration site (CAGC GAGC GAGC GAGC), the human
genome contains 2  105 potential RBSs if they are defined as
GAGY GAGC motifs (90). By applying the same definition,
nine minimal RBSs can be found in the HSV-1 genome. How-
ever, the sequence requirements for low-affinity Rep binding
are less stringent, in that a single GAGC repeat followed by a
run of G bases is sufficient (15), suggesting that the above
numbers of potential RBSs within the cellular and HSV-1
genomes are underestimated. In contrast, appropriately spaced
terminal resolution sites (TRSs), where Rep endonuclease ac-
tivity can induce a site- and strand-specific nick, are present
only in the AAV replication origins and in AAVS1, and there-
fore, only these sites function as Rep-dependent replication
origins. The fact that the cellular RBSs outside AAVS1 lack
functional TRSs is thought to determine the specificity of AAV
integration into AAVS1 (45, 87, 90). In the absence of a helper
virus, Rep concentrations are low and Rep is expected to be
targeted to the rather strong RBSs within the AAV replication
origins and the AAVS1 preintegration site, resulting in site-
specific integration and establishment of latent infection. In
the presence of a helper virus such as HSV-1, Rep concentra-
tions are high and Rep is expected to additionally bind to more
degenerate RBSs present on the cellular and HSV-1 genomes.
Binding of Rep to degenerate RBSs lacking an appropriately
spaced TRS is expected to be followed by unwinding via the
helicase activity but not by nicking. The helicase activity of Rep
has no specific sequence requirement for unwinding of dsDNA
substrates. However, Rep helicase activity requires prior bind-
ing to the DNA substrate. If the substrate is blunt-ended
dsDNA, Rep68/78 helicase activity requires the presence of an
RBS, to which the protein binds via its N-terminal DNA-
binding domain (88, 91). If the DNA substrate does not con-
tain an RBS, Rep68/78 and Rep52 helicase activity require a
single-stranded 3 tail, to which Rep binds and along which it
moves in a 3-to-5 direction while unwinding the stretch of
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dsDNA (74, 88, 91). In contrast, Rep40 not only can bind to 3
single-stranded tails but in addition can initiate helicase activ-
ity on a blunt-ended dsDNA substrate (18). Our finding that
Rep68 and Rep78, but not Rep52, inhibit HSV-1 replication
suggests that the substrate for Rep helicase activity is dsDNA
and that Rep binds to its substrate via its sequence-specific
DNA-binding domain. It is conceivable that Rep DNA binding
followed by unwinding of the DNA double strand interferes
with transcription and replication, since it may block access of
transcription and replication factors. However, the mechanism
by which Rep DNA binding and unwinding induces a cellular
DNA damage response is more difficult to understand. One
straightforward explanation would be that the ssDNA exposed
upon Rep helicase activity is sensed as DNA damage, resulting
in the activation of the corresponding DNA damage signaling.
Accumulation of ssDNA as it occurs upon replication stalling
leads to activation of the ATR/ATRIP signaling cascade, re-
sulting in activation of Chk1 and ultimately G2 arrest (reviewed
in reference 19). However, Rep does not induce activation of
ATR and Chk1 but rather that of ATM, Chk2, H2AX, and
RPA (5) (Fig. 5). Since activation of ATM and its downstream
target Chk2 is generally thought to mark the occurrence of
double-strand breaks, it is currently not clear how exactly Rep
induces DNA damage and how the corresponding damage
signaling is activated. It was previously suggested that Rep
damages cellular DNA by inducing nicks via its endonuclease
activity (5). Our finding that the endonuclease activity of Rep
is not required for induction of cellular DNA damage (Fig. 5),
however, suggests that the mechanism is more complex. It is
possible that the process of Rep DNA binding and unwinding
recruits other cellular factors which then induce the actual
DNA damage. Consistent with such a hypothesis, Rep has
been shown to interact with a variety of cellular proteins in-
volved in DNA replication and repair (57).
Whatever the mechanism, our data show that Rep DNA-
binding and ATPase/helicase activities on the same Rep mol-
ecule are required for induction of DNA damage and apopto-
sis, as well as for inhibition of HSV-1 replication, and as such
they suggest that these three processes are closely linked. Since
execution of apoptosis is not involved in inhibition of HSV-1
replication (Fig. 4), we consider it possible that the ability of
Rep to induce DNA damage is actually responsible for inhibi-
tion of HSV-1. Such Rep-induced DNA damage might occur
not only on cellular DNA but also directly on HSV-1 DNA, the
latter of which would presumably interfere with HSV-1 tran-
scription and DNA replication. On AAVDNA, in contrast, the
process of Rep binding and unwinding is followed by nicking
and is targeted to the AAV replication origins (ITR and p5)
where it fulfills an essential step in the AAV DNA replication
cycle, i.e., the creation of a free 3 end for repair synthesis of
the ITRs. Finally, the inhibition of HSV-1 replication would
confer a competitive advantage to AAV, since it would limit
the competition of HSV-1 for replication factors. Although
such an inhibitory mechanism would not be specific for HSV-1
DNA replication in that it is also expected to affect HSV-1
transcription, it would still allow the largely undisturbed ex-
pression of the HSV-1 helper factors for AAV replication,
since rep expression occurs with early kinetics and therefore is
expected to have only a limited inhibitory effect on HSV-1 IE
and early gene transcription.
At present, such a model certainly remains speculative, since
several aspects still need to be addressed experimentally, in
particular the interaction of Rep with cellular and HSV-1
DNAs and the consequences of this interaction for the tran-
scription and replication of these DNA substrates. Nonethe-
less, it represents an intriguing explanation for the observation
that AAV Rep can inhibit the replication of such diverse DNA
substrates as cellular (5, 65, 89), Ad (77), simian virus 40
(SV40) (89), and HSV-1 (32) DNAs, inasmuch as it would
predict inhibited replication of every DNA substrate on which
Rep binding and unwinding occur at random locations and for
which it is not part of the replicative cycle.
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6. Analysis of the Molecular Interactions between the AAV2 Rep 
Proteins and HSV-1 DNA Replication 
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ABSTRACT 
Adeno-associated virus type 2 (AAV2) has previously been shown to inhibit the replication of its 
helper virus herpes simplex virus type 1 (HSV-1). The inhibitory activity has been linked to the 
expression of the AAV2 Rep proteins, more precisely, the helicase and DNA binding domains of 
Rep68 and Rep78, but the exact mechanism of inhibition is not known. Here, we show that the 
AAV2 Rep68 protein can bind to consensus Rep-binding sites (RBS) on the HSV-1 genome and 
that the helicase activity of Rep68 can prevent the replication of any DNA it binds to. These 
results support our hypothesis that the mechanism of Rep68/78 mediated inhibition of HSV-1 
DNA replication may involve direct binding of Rep proteins to the HSV-1 genome and 
modification of the bound DNA via the helicase activity. 
Keywords:  AAV2; HSV-1; Rep-binding site; Rep helicase. 
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FINDINGS 
Adeno-associated virus type 2 (AAV2) is a nonpathogenic human parvovirus with a unique 
biphasic life cycle. In the absence of a helper virus, AAV2 establishes a latent infection while in 
the presence of a helper virus, such as adenovirus (Ad), herpes simplex virus type 1 (HSV-1) or 
papillomavirus, it undergoes lytic replication (5, 16, 41, 44). The AAV2 genome is a single-
stranded DNA (ssDNA) of 4,680 nucleotides, which is packaged into an icosahedral capsid with 
a diameter of 20 nm (26). The genome harbors two clusters of genes, rep and cap, which are 
both flanked by inverted terminal repeats (ITRs). The ITRs form hairpin structures and contain a 
Rep-binding site (RBS) and a terminal resolution site (TRS), which together act as viral origin of 
DNA replication (17, 38). The cap gene is transcribed from the p40 promoter and encodes the 
capsid proteins VP1, VP2, and VP3, which differ in their N termini due to alternative start codons 
(2, 6). The rep gene encodes the Rep proteins, which are expressed in four different forms due 
to transcription from two different promoters, p5 and p19, and alternative splicing at an intron 
near the C-terminal end (7). The different Rep proteins are termed Rep40, Rep52, Rep68, and 
Rep78 according to their apparent molecular weight. The Rep proteins are involved in diverse 
processes in the viral life cycle, such as DNA replication, regulation of gene expression, genome 
packaging, and site-specific genomic integration (18, 20, 23, 24, 35). 
The minimal set of HSV-1 proteins required for initiating AAV2 replication consists of UL5, UL8, 
and UL52, which together form the HSV-1 helicase/primase complex, as well as the ssDNA 
binding protein ICP8 (UL29) (1, 42, 43). However, the HSV-1 immediate-early proteins ICP4 and 
ICP0, the HSV-1 polymerase (UL42 and UL30) and the US12 gene product, strongly enhance 
AAV2 replication (1). AAV2 has developed strategies to inhibit helper virus replication, likely to 
reduce competition (12, 13, 15, 19, 21, 30, 39). For example, expression of the AAV2 non-
structural proteins Rep68/78 initiates a complete shut-off of HSV-1 DNA replication (12, 13). In a 
previous study we demonstrated that the AAV2 Rep protein domains responsible for the 
inhibition of HSV-1 DNA replication include the DNA-binding and the ATPase/helicase domains 
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in cis, while the endonuclease activity is not required (12). We also showed that Rep-mediated 
inhibition of HSV-1 occurs also in absence of AAV2 DNA and is not due to alterations of HSV-1 
immediate-early (IE) and early (E) gene expression, nor is it due to the Rep-mediated induction 
of toxic stress in the cell, but rather occurs at the stage of HSV-1 DNA replication itself. We 
therefore hypothesized that a possible mechanism of Rep68/78 mediated inhibition of HSV-1 
DNA replication may involve binding of Rep proteins to consensus Rep-binding sites (RBS) on 
the HSV-1 genome and modification of the bound DNA substrate via the Rep helicase activity, in 
particular if there was no TRS in close proximity to the RBS that together would act as an origin 
of DNA replication. To investigate this possibility, we now addressed the following two questions: 
(i) can the AAV2 Rep68/78 helicase activity in absence of the endonuclease activity inhibit 
replication of any DNA when binding is facilitated? (ii) Do consensus RBS exist on the HSV-1 
genome and if so, can AAV2 Rep68/78 bind to these sites? 
To address the first question, we used an assay that we have established previously to 
investigate the replication of HSV-1 and AAV2 DNA both in live and in fixed cells (10, 11, 13). 
Briefly, cells are co-transfected with a plasmid that contains 40 binding sites for the lac repressor 
protein LacI and an HSV-1 origin of DNA replication (pHSV-lacO), and a second plasmid that 
encodes the lac-operon binding motif of LacI fused with an autofluorescent protein, such as 
enhanced yellow fluorescent protein (EYFP-LacI). In presence of HSV-1 helper functions, pHSV-
lacO replicons (and therefore the binding sites for LacI) are amplified (because of the HSV-1 
origin of DNA replication) and recruitment of autofluorescent LacI protein then allows 
visualization of pHSV-lacO DNA replication. We have now modified this assay by transfecting a 
third plasmid encoding the AAV2 Rep52 protein, which contains the helicase domain but not the 
DNA binding or endonuclease domains of Rep68/78, fused with the lac-operon binding motif of 
LacI (Rep52-LacI) (Fig. 1 A and B). This modified Rep52 protein is prone to bind to lac-operon 
binding sequences present on the pHSV-lacO replicon and therefore allowed us to study the 
Rep helicase activity in absence of the endonuclease activity and independent of the interaction 
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between the AAV2 Rep DNA-binding domain and the RBS. The results shown in Fig. 1 (C and 
D) demonstrate that Rep52-LacI was indeed able to strongly inhibit the replication of pHSV-lacO, 
as cells containing mature stage IV RCs were not observed. By contrast, in cultures expressing 
Rep52, which lacks a DNA binding domain,  or Rep52K340H-LacI, which has a point mutation 
that inactivates the helicase activity (8, 25) and is fused to the DNA binding domain of LacI,  
28.3±7.6% or 14.7±6.1% of stage IV RCs were observed, respectively. Also, in the cultures 
transfected with the Rep52-LacI encoding plasmid the frequency of stage III RCs was reduced 
by approximately 50% while the frequency of cells showing diffuse EYFP-fluorescence (stage I; 
no RCs) was much higher when compared with the control cultures (no Rep, Rep52 and 
Rep52K340H-LacI). The distribution of stage I-IV RCs was comparable in cells transfected with 
the Rep52 and the Rep52K340H-LacI encoding plasmids, indicating that Rep52-LacI 
competition with EYFP-LacI did not interfere with detection of RCs. Moreover, while Rep68/78 
can efficiently inhibit HSV-1 DNA replication (12, 13), transfection of Rep52, Rep52-LacI, and 
Rep52K340H-LacI encoding plasmids did not affect HSV-1 DNA replication (data not shown). 
These results indicate that the AAV2 Rep helicase activity in absence of the Rep DNA binding 
and endonuclease activities can inhibit the replication of any DNA template as long as it can bind 
to the DNA. Of note, we have observed 5.3±9.2% and 17.3±4.6% of cells showing distinct foci 
when transfected with Rep52-LacI or the helicase mutant Rep52K340H-LacI respectively, which 
were not observed when transfected with the Rep52 or the empty backbone plasmid 
pcDNA3.1+. We considered this pattern as an artefact occurring from overexpression from the 
reporter plasmids. 
We addressed the second question, whether AAV2 Rep can bind to putative RBS on the HSV-1 
genome, initially by screening the HSV-1 (strain F) genome for the minimal consensus RBS 
motif GAGYGAGC as a prerequisite for the ability of Rep to bind to dsDNA templates via its 
DNA-binding domain (9). Such sites are indeed present and are shown in Fig. 2. All consensus 
RBS are located within coding sequences of genes found in the unique long (UL) segment of the 
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HSV-1 genome (Fig.2 A). Sequence alignment revealed that all putative HSV-1 RBS consist of 
two complete GAGC repeats with the exception of RBS No. 7, which contains a T in place of a C 
but still complies with the GAGYGAGC consensus sequence (Fig.2 B). Moreover, the regions 
upstream of the RBS-motif seem to be more conserved than the downstream regions (Fig.2 B). 
No consensus TRS (CCAACT) (18, 38) was found near the putative HSV-1 RBS. We next tested 
the capability of AAV2 Rep proteins to bind via the DNA-binding domain to putative HSV-1 RBS 
by electrophoretic mobility-shift assays (EMSA) using purified His-tagged Rep68 proteins. We 
designed 37-mer duplexed oligonucleotides harbouring selected putative RBS (No. 1-5), which 
were radioactively labelled with [y-32P]ATP. An oligonucleotide containing a random sequence 
from within the UL44 gene harbouring no putative RBS was used as the negative control. An 
oligonucleotide containing the RBS from the AAV2 inverted terminal repeat (ITR) was used as 
the positive control (Fig. 2 B). Approximately 5 fmol of each duplexed oligonucleotide was 
incubated with 0, 120, or 240 ng of Rep68 protein for 30’ at room temperature (RT) and then 
subjected to polyacrylamide gel electrophoresis. After 3h, the gel was dried and exposed to 
Fujifilm Imaging Plates, which were developed with a Fujifilm FLA-7000 Image Plate reader. We 
observed a dose-dependent shift from the unbound DNA template to the same level as the 
bound positive control (ITR) for every oligonucleotide (No. 1-5) examined (Fig. 3 A). As 
expected, the negative control (nc) did not show any bands at the level of the shifted DNA. Of 
note, the area of the shifted oligonucleotides (No. 1-5 as well as ITR) is characterized by multiple 
bands with different sizes. This may be due to the different oligomerization states Rep68 can 
form on ds DNA (28, 45, 46). To confirm that binding of Rep68 to the putative RBS is indeed 
specific, we performed EMSAs as described above, except that 5 fmol of non-labeled duplex ITR 
oligonucleotide was used as competitor. The ITR competitor DNA appeared to inhibit binding of 
Rep to the putative RBS oligonucleotides, as no shift was observed under these conditions 
(Fig.3 B). In order to investigate whether AAV2 Rep68 is able to bind to the consensus RBS on 
the HSV-1 genome also in HSV-1 infected cells, we performed chromatin-immunoprecipitation 
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(ChIP) assays. For this, Vero cells were transfected with plasmids expressing either the 
Rep68/78, or Rep52 proteins fused with enhanced green fluorescent protein (EGFP). The next 
day, the cells were infected with wt HSV-1 (strain F) at an MOI of 40. At 16 h after infection, the 
cells were fixed with 4% paraformaldehyde (PFA), sonicated for 10min (at 25% amplitude and 
duty cycle 10 on ice) and processed for ChIP using the GFP-Trap® kit (Chromotek). The 
immunoprecipitated DNA was then analyzed by quantitative (q)PCR using primers specific for 
the consensus RBS No. 1-5 (Suppl. Table. 1). Primers for amplification of a sequence from the 
HSV-1 genome harbouring no proximal RBS (US1) served as a negative control (Suppl. Table. 
1). The qPCR mix was the following: 0.25µl of each primer [10µM], 10µl of SYBR® Green mix 
(SYBR® Green PCR Master Mix, Applied Biosystems) and 2.5µl of DNA in a final volume of 20µl; 
The reaction was carried out as follows: 95°C for 3min, 39 cycles of 95°C for 15sec and 60°C for 
1min followed by a final elongation step at 95°C for 10min. The data was analyzed using the 
percent input method (as described by Life Technologies™) in which the signal from the qPCR 
reaction with the primers specific for the US1 sequence (negative control) served as the 
background and was set as 1. All other values were then normalized to the US1 value. The 
results are shown in Fig. 3C and can be summarized as follows: The AAV2 Rep68/78-GFP 
fusion protein is capable of binding to all HSV-1 consensus RBSs tested. Although there 
appears to be some variation in the affinities between the RBS No. 1-5 sequences, the values 
were all significantly higher than the value obtained with the US1 primers (no pRBS). On the 
other hand, the Rep52-GFP protein, which lacks the RBS binding domain, did not appear to bind 
to any of the RBS tested (data not shown). These results indicate that AAV2 Rep68/78 is indeed 
capable of interacting with the HSV-1 genome via its RBS binding domain. 
In this report we demonstrated that the AAV2 Rep68 proteins are capable of binding to pRBS on 
the HSV-1 ds DNA genome in silico, in vitro, and in HSV-1 infected cells. Our EMSA and ChIP 
data revealed that binding of Rep68 to consensus RBS is specific and requires the Rep DNA-
binding domain. Moreover, Rep68 is not able to bind directly to random HSV-1 dsDNA 
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sequences (UL44 and US1) that do not contain a putative RBS. In addition, we showed that the 
Rep helicase activity can inhibit replication of any DNA substrate it can bind to.  
Replicative stress is rapidly sensitized in the cell by numerous stress response factors and 
pathways such as DNA-damage response (DDR) or DNA-damage tolerance (DDT) (Reviewed in 
(47)). One of the best understood stress responses resembles the DDR pathway initiated by the 
sensor-kinase ataxia-telangiectasia mutated (ATM)- and Rad3-related (ATR), which is activated 
upon stalling of the replication fork (RF). At a stalled RF, the helicase activity of the mini-
chromosome maintenance protein (MCM2) is uncoupled from the replication complex and 
continues unwinding, which is generating a stretch of ssDNA recognized and covered by the 
replication protein A (RPA) (32–34). This leads to the activation of ATR, which then induces a 
DDR resulting in cell-cycle arrest allowing the cell to resolve the stalled RF (4, 29, 31, 48, 49). 
However, persisting replication stress can result in the collapse of the RF, associated with 
double-strand breaks (DSBs) and the consecutive inhibition of DNA replication (14, 27). 
We therefore hypothesize that binding of Rep to consensus RBS and the following helicase 
activity mimick a stalled RF, in particular when the Rep helicase activity is uncoupled from the 
replication activity, either because of the absence of a functional TRS or the absence of the 
endonuclease activity. Therefore it is likely that Rep-mediated unwinding of dsDNA is inducing a 
DDR which is similar to the one induced by a stalled RF. Support for this theory comes from 
previous observations that the AAV2 Rep68/78 proteins induce a DDR which is characterized by 
the activation of RPA and ATM, leading to a S-phase arrest (3, 12, 36, 37). However, in these 
studies the authors explain the activation of ATM as a response to nicks which were induced by 
Rep at TRSs located on the cellular chromatin. In contrast to this theory, we suggest that the 
activation of ATM might be due to Rep-induced dsDNA breaks caused by persistend stalling 
RFs. Indications for this theory comes from the simple fact that the existence of a putative RBS 
with a TRS in close proximity on the cellular genome is much less likely than a putative RBS 
without a functional TRS in close proximity. 
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If Rep indeed is inducing a stalled RF remains to be elucidated. Also, if the Rep helicase is 
indeed unwinding the HSV-1 DNA is a matter of current investigations. However, we 
demonstrate that the Rep helicase activity is inhibiting replication of dsDNA templates it can bind 
to and that Rep is indeed capable of binding to the HSV-1 genome at multiple consensus RBS.  
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FIGURE LEGENDS 
Figure 1. Inhibition of DNA replication by the AAV2 Rep helicase activity. (A) Schematic 
representation of the Rep constructs analyzed in this experiment. The functional domains of 
interest for this study are indicated. (B) Western analysis of Rep52, Rep52-LacI, and 
Rep52K340H-LacI. Vero cells (200’000) were transfected with 0.1µg of plasmids encoding 
Rep52, Rep52-LacI, or Rep52K340H-LacI, or the empty plasmid backbone pcDNA3.1+ (no 
Rep). After 24h the cells were harvested and processed for Western blotting using a Rep-
specific antibody (ms anti Rep-mAb, clone 303.9, Fitzgerald; 1:100). Actin staining served as 
loading-control. (C) HSV-1 DNA replication assay. Vero cells (150’000) were co-transfected with 
0.05µg of the HSV-1 replicon plasmid pHSV-LacO, 0.01µg of the reporter plasmid 
pSV2EYFPLacI and 0.05µg of a plasmid encoding either Rep52-LacI, the helicase deficient 
mutant Rep52K340H-LacI, wtRep52 or the empty plasmid backbone pcDNA3.1+ (no Rep). One 
day after transfection the cells were superinfected with wt HSV-1 (strain F) at an MOI of 5. After 
16 h, the cells were fixed with 4% paraformaldehyde (PFA), immunostained for Rep with a 
primary mouse (ms) anti Rep-mAb (clone 303.9, Fitzgerald, 1:100) and a secondary goat (gt) 
anti-ms IgG(H+L)–Alexa Fluor 594 (Molecular Probes®, 1:500) (red insets), and then subjected 
to confocal laser scanning microscopy (SP2 CLSM, Leica). The numbers of cells displaying 
pHSV-lacO RCs at stage I, II, III or IV, as well as the number of cells showing foci were 
determined. (C) Percentage of cells containing stage I, II, III, or IV RCs or foci evaluated from 
experiments shown in panel B. Error bars represent standard deviation (SD) from three 
independent experiments with 80-100 cells counted in each experiment. Asterisks indicate 
statistically significant differences based on a paired two-tail students t-test (* = p<0.05; ** = 
p<0.01). 
Figure 2. The HSV-1 genome contains nine putative Rep-binding sites. (A) The minimal 
AAV2 Rep-binding site motif GAGYGAGC was used to identify consensus Rep-binding sites 
within the HSV-1 (strain F) genome. The arrowheads facing down represent RBS located on the 
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plus-strand and the arrowheads facing up represent RBS located on the minus-strand. The RBS 
were numbered randomly from 1 to 9 as indicated. The HSV-1 genes harbouring a consensus 
RBS are highlighted. (B) Alignment of the minimal RBS motif GAGYGAGC (grey box), the AAV2 
ITR RBS, the nine putative HSV-1 RBS identified in panel A, and the negative control sequence 
(nc) within the UL44 gene. The illustration was generated using the prettyplot function of the 
online tool EMBOSS (http://pro.genomics.purdue.edu/emboss/) and represents the sequences 
of the oligonucleotides used for the electrophoretic mobility shift assays (EMSA; see Fig.3). 
Conserved nucleotides upstream and downstream of the GAGYGAGC motif are indicated with 
asterisks. The numbers on the right indicate the exact nucleotide (nt) position within the AAV2 
genome (ITR) or the HSV-1 genome (No. 1-9 and nc).  
Figure 3. Rep-binding assays. (A) Electrophoretic mobility shift assays (EMSA) were 
performed with purified Rep68 proteins and radiolabeled duplex oligonucleotides No. 1-5 
harbouring putative RBS, the negative control (nc) or the positive control (ITR) (Fig.2 B, bold 
numbers). The amount (ng) of Rep68 protein used is indicated at the top of the blot. (B) EMSA 
competition assays were performed with cold competitor DNA consisting of the positive control 
oligonucleotide (ITR). (C) Chromatin immuno-precipitation (ChIP) assays were performed with 
Vero cells (approx. 1.5x106 cells in a 6cm cell culture dish) transfected with 0.5µg of a plasmid 
encoding the Rep68-EGFP fusion protein (Rep68-GFP) and superinfected with wtHSV-1 (strain 
F) at an MOI of 40. At 16 h after infection the cells were processed for ChIP (as described in the 
text). The precipitated DNA was analyzed by qPCR using specific primers flanking the putative 
RBS No. 1-5 on the HSV-1 genome or primers flanking a sequence of the HSV-1 genome that 
contains no proximal putative RBS (no RBS) (see Supplementary Table.1). The data was 
quantified using the percentage input method (as described in the text) and the values were 
normalized to the no RBS-control, which was set as 1. Bars represent mean values and 
standard errors (SE) from 3-6 individual experiments. Asterisks indicate statistically significant 
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differences between the negative control (no RBS) and the putative RBS based on a paired two-
tail students t-test (* = p<0.05; ** = p<0.01). 
Supplementary Table 1. Primer pairs used for the ChIP assay. Forward and reverse primer 
sequences used for qPCR of precipitated DNA are listed. Primers were generated using the 
online tool Primer3® (22, 40). The efficiencies for all primer pairs were tested with serial dilutions 
of purified HSV-1 DNA (strain F) under the same qPCR conditions as used in Fig.3C. This data 
was used to standardize the ChIP protocol by including the efficiency coefficient for each primer 
pair in the percentage input (%-Input) method calculations. 
74
Fig. 1
A
C
B
DNA-binding domain (LacI)
K340H
Rep52
Rep52-LacI
Rep52K340H
-LacI
stage III stage IV focistage I stage II
R
ep
52
K3
40
H
-L
ac
I 14.7 ± 6.1%24.0 ± 1.0% 26.7 ± 2.3% 17.3 ± 2.3% 17.3 ± 4.6%
R
ep
52
-L
ac
I
47.0 ± 1.7% 39.3 ± 11.0% 8.3 ± 3.5% 5.3 ± 9.2%
not observed
pr
op
or
tio
n 
of
 c
el
ls
 %
Re
p5
2
Re
p5
2-L
ac
I
Re
p5
2K
34
0H
-La
cI
stage I
stage II
stage III
stage IV
foci
Rep ORF
ATPase/helicase domain (Rep)
N C
D
no
 R
ep
DNA-binding domain (Rep)
0
10
20
30
40
50
60
no
 R
ep
not observed
18.3 ± 2.9% 24.7 ± 2.1% 27.0 ± 7.0% 30.0 ± 6.6%
actin
Rep52
Rep40
Rep52-LacI
Rep40-LacI
Re
p5
2
no
 R
ep
Re
p5
2-L
ac
I
Re
p5
2K
34
0H
-La
cI
R
ep
52
not observed
19.7 ± 4.5% 28.0 ± 3.5% 24.0 ± 6.9% 28.3 ± 7.6%
p=0.05*
p=0.02*
75
Fig. 2
A
B
TRL TRSIRL IRSUL US
5‘
3‘
3‘
5‘UL31UL21UL19 UL29 UL36 UL42 UL50 UL52
1
Putative Rep-binding sites on the HSV-1 genome
ITR
No.
2 3 4 5
6789
1
Position (nt)
67040-67076
G
G
G
A
T
C
A
C
T
C
C
G
G
A
C
G
C
T
C
C
C
C
C
A
C
T
C
A
C
C
T
T
A
A
T
G
T
G
A
T
G
A
G
T
A
T
A
C
C
C
C
C
C
T
A
T
T
A
G
T
G
G
T
G A C C A
T
C
T
C
A
C
A
C
T
A
C
G
T
G
G
G
T
G
G
G
A
T
A
C
C
C
G
G
G
C
G
G
T
C
C
C
T
C
T
G
G
G
A
T
A
A
T
T
C
T
C
C
C
A
C
A
C
C
C
C
A
C
C
C
T
T
A
A
T
A
G
A
A
G
G
G
T
G
A
C
T
T
C
T
C
A
A
C
A
T
C
T
A
C
C
T
C
T
G
C
C
C
C
C
C
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
G
G
G
G
G
G
G
C
C
C
C
C
C
G
G
G
G
G
G
G
G
G
G
G
A
A
A
A
A
A
A
A
A
A
G
G
G
G
G
G
G
G
G
G
G
C
C
C
C
C
C
C
C
C
G
G
G
G
G
G
G
G
G
G
A
A
A
A
A
A
A
A
A
A
G
G
G
G
G
G
G
G
G
G
C
C
C
C
C
C
C
C
C
C
G
G
G
G
G
G
G
A
A
A
A
A
A
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
T
T
T
T
G
G
G
G
C
C
C
C
T
T
T
T
T
G
G
G
G
C
C
C
C
C
A
A
A
A
A
A
A
A
A
C
C
C
C
C
G
G
G
G
G
G
G
G
G
C
C
C
C
C
C
C
C
C
C
G
G
G
G
G
G
G
G
A
A
A
A
A
2
94024-940603
4
5
6
7
8
9
nc
107968-108004
109287-109323
109529-109493
74589-74553
59318-59282
43587-43551
45418-45454
39936-39972
81-117
Consensus RBS sequence alignment (5‘ to 3‘)
* * * * * * * *
76
Fig. 3
A
C
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 nc ITR
0 ng 120 ng 240 ng Rep68
Oligonucleotide
bo
un
d 
D
N
A
fre
e 
D
N
A
bo
un
d 
D
N
A
fre
e 
D
N
A
B
1 2 3 4 5
+- +- +- +- +- --
nc ITR
Rep68
Oligonucleotide
Competitor DNA (ITR)
240 ng
**
0
5
10
15
20
25
re
la
tiv
e
 v
al
ue
s 
[%
 I
np
ut
]
** *
* *
no RBS
pRBS
1 5432
77
# forward reverse
no RBS gcttccttgtttggagacca gtccagtcaaactccccaaa
1 cacgtgcagcatctggtc cgagcaacccacacacaat
2 atcgtgttgatctgctgcac gaggagatcgccatcgtg
3 ccctcaagttcttcctcacg ggagtcctggctgtctgttg
4 caaagcgcttcgaaactacc gggtgtgatagacccacagg
5 gctaaatggcgactccttcc cgatgtggtccggttgtag
Supplementary Table 1. primer pairs used for ChIP assay
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7.1. Background and Rationale 
 
In the past decade, HSV/AAV hybrid gene therapy vectors have been generated and used 
successfully to deliver a variety of transgenes to target cells in vitro and in vivo (1, 4, 5, 9, 
13). Despite this success, HSV/AAV hybrid vectors still are far away from being a reliable 
and robust therapeutic gene therapy tools in human medicine. Two main factors reduce the 
performance of HSV/AAV hybrid vectors: (i) the inevitable expression of the toxic rep genes 
is needed to establish site-specific integration of the transgene and (ii) the Rep-mediated 
inhibition of HSV-1 DNA replication, especially during vector production. The first factor is 
one of the main reasons for safety concerns since the AAV2 Rep proteins induce a cellular 
DDR and apoptosis (2, 7, 14, 15). The inhibition of HSV-1 replication on the other hand 
results in poor hybrid vector titers (9). To overcome these drawbacks HSV/AAV hybrid 
vectors were constructed which express little or even no Rep during packaging. However, in 
transduced cells providing the Cre recombinase, Rep was expressed upon site-specific 
recombination to establish site-specific integration of the transgene DNA (12). Since this 
strategy relies on the expression of the Cre recombinase in the target cells, the therapeutic 
applicability is limited. Therefore, the need for new strategies to overcome the drawbacks of 
HSV/AAV hybrid vectors is still amenable. 
Here, we describe the phenotype of a newly emerged Rep-helicase mutant (D371Y), which 
has the potential to overcome the aforementioned drawbacks of HSV/AAV hybrid vectors 
expressing the rep ORF during packaging and after transduction. In particular, we 
demonstrate that Rep78D371Y supports the simultaneous replication of both AAV2 and 
HSV-1 DNA replication. Moreover we found that overall Rep toxicity was drastically reduced 
in cells expressing the new mutant Rep78D371Y. These findings indicate that Rep78D371Y 
can potentially improve the performance of HSV/AAV hybrid vectors. 
 
7.2. Findings 
 
Expression levels of the wild-type and mutant rep genes. In order to characterize the 
phenotype of the Rep-helicase mutant D371Y, which harbors a Tyrosine (Y) instead of an 
Aspartic acid (D) at position 371, we compared three Rep constructs; (i) the wt Rep78 
consisting of the full-length Rep ORF, (ii) the Rep78 ORF with the helicase-null mutant 
K340H, which harbors a mutation within the Walker A motif of the ATPase helicase domain 
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(a Histidine instead of a Lysin at position 340) (3, 11) and (iii) the aforementioned Rep78 
helicase mutant D371Y (Fig. 7.1 A). All rep genes are under the control of the constitutively 
active CMV IE1 enhancer/promoter and cloned into the expression vector pcDNA3.1+. To 
estimate the expression levels, Vero cells were transfected with the corresponding plasmids 
and subjected to Western analysis 24 hrs post transfection using a Rep-specific antibody 
(Fig. 7.1 B). Actin staining served as a loading control. All three Rep constructs expressed 
the rep genes at comparable levels. The Rep78 and the Rep52 variants are indicated.  
Both Rep-helicase mutants Rep78D371Y and Rep78K340H allow HSV-1 DNA 
replication, whereas wt Rep78 does not. Effects of the different Rep constructs on HSV-1 
DNA replication were assessed using the HSV-1 TetO-TetR DNA visualization system (6). In 
brief, Vero cells were transfected with the plasmid pHSV-TetO, which harbors 35 TetR-
binding sites together with the different Rep expressing constructs. One day post 
transfection, the cells were superinfected with wt HSV-1 (MOI 2) to provide all replication 
factors necessary to replicate the pHSV-TetO replicon. The expression of a TetR-EYFP 
fusion protein allows the visualization of the pHSV-TetO replication compartments (RCs). 
The Rep-helicase mutants Rep78K340H and Rep78D371Y both allowed the formation of 
mature pHSV-TetO RCs, whereas the wt Rep78 did not (Fig. 7.2 A). In addition, a pHSVGFP 
packaging assay was utilized to quantify the effects of the different Rep constructs. Vero 2-2 
cells were transfected with the HSV-1 amplicon plasmid pHSVGFP together with a HSV-1 
helper DNA (fHSV BAC) providing HSV-1 replication factors and the Rep expressing 
constructs. Three days post transfection the pHSVGFP amplicons were harvested and 
titrated on Vero cells. Compared to the negative control, the wt Rep78 proteins reduced the 
pHSVGFP vector titers by 100-fold, while the effects of both Rep-helicase mutants were less 
pronounced (less than 10-fold) and at an equal level (Fig. 7.2 B). The inability of the 
helicase-null mutant Rep78K340H to inhibit HSV-1 DNA replication was expected and was 
described before (7). This led to the assumption that similar to Rep78K340H, the mutant 
Rep78D371Y may not provide helicase activity either and therefore may not be compatible 
with AAV2 DNA replication.  
Unlike Rep78K340H, the mutant Rep78D371Y supports AAV2 DNA replication. To test 
the capability of the Rep constructs to support AAV2 DNA replication we utilized the pAV2-
LacO DNA replication system. Vero cells were transfected with the AAV2 replicon pAV2-
LacO together with the different Rep expressing constructs and a plasmid expressing the 
LacI-EYFP fusion protein. One day post transfection, the cells were superinfected with wt 
HSV-1. Another day later the cells were fixed, stained with a Rep-specific antibody and the 
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formation of pAV2-LacO RCs was assessed. Surprisingly, unlike Rep78K340H, 
Rep78D371Y fully supported the formation of pAV2-LacO RCs (Fig. 7.3 A). To confirm the 
observed support for AAV2 DNA replication by Rep78D381Y, we utilized an AAV2 DNA 
replication assay based on Southern analysis. Vero cells were transfected with the AAV2 
replicon plasmid pAV2GFP together with the different Rep constructs and one day later 
superinfected with HSV-1 to provide helper factors for AAV2 replication. Three days post 
infection extra-chromosomal DNA was extracted, digested with DpnI to cut bacterial input 
DNA and subjected to Southern analysis using a GFP-specific probe (Fig. 7.3 B). Rescued 
monomeric (ITRm) and dimeric (ITRd) pAV2GFP replication intermediates (DpnI resistant) 
are indicated. As expected, the helicase null mutant Rep78K340H did not support the 
formation of any pAV2GFP intermediates, whereas the wt Rep78 and the mutant 
Rep78D371Y both did. 
Notably, the formation of HSV-1 RCs is dramatically reduced when either AAV2 is 
replicating, or the wt Rep proteins are present in the same cell (7, 8).These findings however 
suggest that the Rep78D371Y mutant may allow the simultaneous replication of HSV-1 and 
AAV2 DNA in the same cell. To test this hypothesis, we utilized the systems to visualize the 
formation of HSV-1 and AAV2 RCs simultaneously by co-transfecting Vero cells with the 
corresponding replicon plasmids pHSV-TetO and pAV2-LacO together with the different Rep 
constructs. As expected, the formation of AAV2 RCs was observed with the wt Rep78 but 
not with the mutant Rep78K340H, whereas the formation of HSV-1 RCs was observed with 
the mutant Rep78K340H, but not the wt Rep78. However, the mutant Rep78D371Y indeed 
allowed the simultaneous and comparable formation of RCs from both viruses AAV2 and 
HSV-1 (Fig. 7.4). 
The mutant Rep78D371Y is less toxic than the wt Rep78. In previous studies, we and 
others reported that the major AAV2 Rep68 and Rep78 proteins induce a DNA-damage 
response (DDR) in transfected cells characterized by the activation (i.e. phosphorylation) of 
the replication protein A (pRPA), the sensor-kinase ataxia-telangiectasia mutated (pATM) 
and the histone γH2AX (2, 7, 14, 15). We also demonstrated that the combined Rep DNA-
binding- and ATPase/helicase domain are necessary to induce the cellular DDR (7). 
Therefore we addressed the question whether the mutant Rep78D371Y is also able to 
induce a DDR in transfected cells. Vero cells expressing the different Rep constructs were 
fixed at 48 h after transfection and stained with antibodies specific for either pATM (S1981), 
pRPA32 (S4/S8) or γH2AX (S139). Rep expression was detected with Rep-specific 
antibodies. Rep- and GFP-positive cells were counted and scored for the staining of the 
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different DDR markers (Fig. 7.5 A-C). Interestingly, the DDR response is reduced 20-60% in 
cells expressing the Rep78D371Y protein when compared with the wt Rep78 expressing 
cells. As shown in a previous study, the DDR induced by Rep78K340H was reduced to basic 
levels when compared with the negative control (pcDNA-EGFP) (7). In a next step, we 
examined the capability of Rep78D371Y to induce apoptosis in transfected cells, since the 
Rep-domains responsible of inducing a DDR coincide with the domains responsible for 
inducing apoptosis (7). To do so, Vero cells were transfected with the different Rep 
constructs along with a GFP expressing plasmid to identify successfully transfected cells. 
Three days later the cells were stained with Cy5-conjugated annexin V and analyzed by 
screening of GFP-positive cells (flow cytometry) for the induction of apoptosis (Fig. 7.5 D). 
Similar to the mutant Rep78K340H proteins, the mutant Rep78D371Y proteins did not 
induce apoptosis, whereas the wt Rep78 proteins did. These results indicate that the overall 
toxicity of the mutant Rep78D371Y is clearly reduced compared to the wt Rep78. 
The titers of HSV/AAV hybrid vectors harboring the mutant Rep78D371Y are 10-fold 
higher than those of hybrid vectors harboring the wt Rep78.  HSV/AAV hybrid vectors 
have previously been generated to combine the advantages and to overcome the drawbacks 
of HSV-1 and AAV2 vectors (9, 10, 16). However, due to Rep-mediated toxicity and inhibiton 
of HSV-1 DNA replication, HSV/AAV hybrid vectors harboring the wt rep ORF were not 
promising because vector titers were too low (9). Since the newly characterized mutant 
Rep78D371Y proteins allow the simultaneous replication of both AAV2 and HSV-1 and in 
addition the overall toxicity is reduced, we included the mutation D371Y into the pre-existing 
HSV/AAV hybrid vectors, replacing the wt Rep78 ORF. Specifically, we cloned the complete 
rep ORF containing the mutation D371Y into the HSV/AAV hybrid vector backbone 
pHyGFPa resulting in the mutant hybrid vector pHyD371YGFPa. This hybrid vector next was 
packaged in Vero 2-2 cells as described above. Three days post transfection the hybrid 
vectors were harvested and titrated on Vero cells. The HSV/AAV hybrid vector harboring the 
wt rep ORF (pHyRaNGFPa) (9) and the HSV-1 amplicon vector harboring no AAV2 
elements (pHSVGFP) were used as controls. As predicted, the titers of the HSV/AAV hybrid 
vectors encoding the Rep D371Y mutation (pHyD371YGFPa) were up to 10-fold higher than 
those of hybrid vectors encoding the wt Rep (pHyRaNGFPa) (Fig. 7.6). However, the mutant 
hybrid vector titers were still approximately 10-fold lower than those of the standard HSV-1 
amplicon vectors. 
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7.3. Conclusions 
 
In this study, we elaborated the phenotypic profile of the novel AAV2 Rep helicase mutant 
Rep78D371Y. We assessed whether Rep78D371Y proteins are capable of promoting AAV2 
DNA replication. We found that unlike the helicase-null mutant Rep78K340H proteins, the 
Rep78D371Y proteins are fully compatible with AAV2 DNA replication. We also tested the 
capability of Rep78D371Y proteins to inhibit HSV-1 DNA replication. Interestingly, our results 
revealed that like the helicase-null mutant Rep78K340H, Rep78D371Y also lost the 
capability to inhibit HSV-1 DNA replication. In a next step, we assessed the induction of a 
DDR in Rep transfected cells. Specifically, we tested whether the mutant Rep78D371Y 
proteins induce the activation of the following DDR marker proteins: (i) the sensor-kinase 
ataxia-telangiectasia mutated (pATM), (ii) the replication protein A (pRPA) and (iii) the 
histone H2AX (γH2AX). Surprisingly, the levels of activated DDR proteins in Rep78D371Y 
expressing cells were 20-60% lower than in cells expressing wt Rep78. Moreover, we found 
that the Rep78D371Y proteins unlike their wt Rep78 counterparts do not induce apoptosis in 
cells. These findings suggest that overall toxicity of Rep78 is significantly reduced in cells 
expressing the mutant Rep78D371Y. The AAV2 mutant and wt Rep78 activities are 
summarized in Table 7.1. 
The phenotypic profile of Rep78D371Y had a beneficial impact on the production of next 
generation HSV/AAV hybrid gene therapy vectors. Due to the inability of Rep78D371Y to 
inhibit HSV-1 DNA replication, HSV/AAV hybrid vector titers were elevated up to 10-fold 
when expressing the mutant Rep78D371Y instead of the wt Rep78. In addition, the reduced 
Rep-mediated cell toxicity of Rep78D371Y proteins may improve the overall safety profile of 
the vector system. 
 
7.4. Materials and Methods 
 
Cells and viruses 
Vero and Vero 2-2 cells were maintained, wt HSV-1 (F-strain) was produced and titrated, 
and cells were infected as described in section 5 of this thesis. Transfections were 
performed using the Lipofectamine™ LTX and Plus™ reagents from Invitrogen™ according 
to the manufacturers’ protocol.  
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Plasmids 
The plasmids expressing the wt Rep78 (pcDNA.Rep78) and the mutant Rep78K340H 
(pcDNA.Rep78K340H) genes were described in section 5 of this thesis. The plasmid 
expressing the mutant Rep78D371Y (pcDNA.Rep78D371Y) was cloned by PCR as follows: 
A first round of PCR was performed using the pcDNA.Rep78 plasmid DNA as a template 
with primers reaching from the first BamHI-site (nt1040) to the AccI-site (nt1420) where in 
the reverse primer the GT substitution at position 1431 was introduced (for. primer: 
GCAGTGGATCCAGGAGGACCAGGCCTCATA / rev. primer: ACCAGATCACCATCTTGTA 
GACACAGTCGT). A second round of PCR was performed with primers reaching from AccI-
site (nt1413) to the XhoI-site (nt2225) (for. primer: CCCTTCAACGACTGTGTCT 
ACAAGATGGTG / rev. primer: CTTCAGAGAGAGTGTCC TCGAGCCAATCTG). The two 
PCR fragments were ligated between the BamHI and XhoI sites of pcDNA.Rep78. The 
empty plasmid backbone pcDNA3.1+ was purchased from Invitrogen™ (Cat.no. V790-20). 
The HSV/AAV hybrid vector plasmid pHyRaNGFPa was described elsewhere (9). In brief, 
the plasmid pRep harboring the full-length Rep ORF was cut with NotI and the overhang-
ends were blunt-end repaired with T4 DNA polymerase. This 2.5-kb fragment was inserted 
into the blunt-ended SphI site of pHSVNot resulting in pHyRa. In parallel, the BglII fragment 
was excised from the pAV2GFP plasmid which contains the ITR-flanked GFP cassette and 
was inserted into the BamHI site of pUC18-Not. The resulting plasmid pAV2GFP-Not was 
cleaved with NotI and the 2.3-kb fragment containing the ITR-flanked transgene egfp was 
inserted into the unique NotI site on pHyRa, forming pHyRaNGFPa. To generate the plasmid 
pHyRD371YGFPa, the same strategy was used as to generate pHyRaNGFPa, but instead a 
pRep plasmid was used harboring the mutation D371Y (pRepD371Y). pRepD371Y was 
cloned by ligating the PstI fragment from the pcDNA.Rep78D371Y template directly into the 
PstI cleaved target plasmid pRep. 
Western Blotting 
Western blotting was performed as described in section 5 of this thesis, except that the 
following expression plasmids were used: (i) pcDNA.Rep78, (ii) pcDNA.Rep78K340H, (iii) 
pcDNA.Rep78D371Y and (iv) the empty backbone plasmid pcDNA3.1+. 
Immunofluorescence analysis 
Visualization of AAV2 replication compartments and IF-staining of the AAV2 Rep proteins 
were performed as described in section 5 of this thesis and in reference (6). Visualization of 
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HSV-1 RCs was performed as described in section 6 of this thesis and in reference (8). In 
addition 0.5µg of the different Rep expressing plasmids were co-transfected with the 
corresponding HSV-1 or AAV2 visualization amplicons. Screening of cells expressing the 
different Rep expressing constructs pcDNA.Rep78, pcDNA.Rep78K340H or 
pcDNA.Rep78D371Y for the DDR markers pATM, pRPA and γH2AX was described before 
in section 5 of this thesis. 
HSV-1 amplicon and HSV/AAV hybrid vector packaging assay 
Packaging and titration of pHSVGFP amplicons was described in section 5 of this thesis. 
The different Rep expressing plasmids pcDNA.Rep78, pcDNA.Rep78K340H, or 
pcDNA.Rep78D371Y were co-transfected with the HSV-1 amplicon vector pHSVGFP or the 
HSV/AAV hybrid vectors pHyRaNGFPa or pHyRD371YGFPa together with the HSV-1 helper 
genome (fHSVΔpacΔ27). Harvesting and titration of vector stocks was performed as 
described in section 5 of this thesis. 
Southern Blotting 
The different Rep expressing plasmids pcDNA.Rep78, pcDNA.Rep78K340H, 
pcDNA.Rep78D371Y or the empty backbone plasmid pcDNA3.1+ were co-transfected 
together with the AAV2 replicon pAV2GFP and superinfected with wtHSV-1 (MOI 2) one day 
later. AAV2 replication intermediates were visualized by Southern analysis as described in 
section 5 of this thsis. 
Flow cytometry analysis 
Apoptotic cells expressing the different Rep constructs pcDNA.Rep78, pcDNA.Rep78K340H, 
pcDNA.Rep78D371Y and the empty backbone plasmid pcDNA3.1+ were stained and 
counted by flow cytometry as described in section 5 of this thesis. 
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7.5. Figure Legends & Figures 
 
Figure 7.1. The AAV2 Rep expression plasmids. (A) Schematic representation of the 
AAV2 Rep proteins analyzed in this study; (i) the wild-type (wt) Rep78, (ii) the helicase-
deficient mutant Rep78K340H and (iii) the helicase mutant Rep78D371Y. The 
ATPase/helicase domain (dark grey box) and the mutations (black lines) are indicated. A 
detailed scheme of the helicase domain (aa 225-490) is shown below. The mutation K340H 
is located within the Walker motif A whereas the mutation D371Y is located between the 
Walker motifs A and B. The exact locations within the Rep aa-sequence are indicated on the 
bottom of the scheme. (B) Rep expression levels. Plasmids encoding either the wt Rep78, 
the mutat Rep78K340H, the mutant Rep78D371Y or the empty vector plasmid pcDNA were 
transfected into Vero cells. One day post transfection, the cells were harvested and 
processed for Western analysis using a Rep-specific antibody. The Rep78- and the Rep52 
variants are indicated on the right. Detection of actin served as a loading control. 
Figure 7.2. Evaluation of the different Rep constructs for their ability to promote HSV-1 
replication. (A) Replication of an HSV-1 replicon is visualized with plasmid pHSV-TetO 
consisting of the HSV-1 oriS and a tetO-cassette containing 35x tetR binding sites. In 
presence of HSV-1 replication factors, the accumulation of pHSV-TetO replication products 
is visualized by binding of an EYFP-TetR fusion protein. Cells expressing the different Rep 
constructs (indicated on top) were analyzed for the ability to inhibit HSV-1 replication. The 
Rep proteins were stained with a Rep-specific antibody (red insets). Size bar; 5µm. (B) 
Effects of the Rep constructs on HSV-1 amplicon vector packaging. Vero 2-2 cells were 
transfected with the HSV-1 amplicon DNA pHSVGFP, packaging-defective HSV-1 helper 
DNA fHSVΔpacΔ27Δkn, HSV-1 ICP27 encoding plasmid pEBHICP27 and different Rep 
expression plasmids. 72 hrs post transfection the pHSVGFP amplicon vector particles were 
harvested and titrated on Vero cells. The data is shown as means ± SD from three 
independent experiments. Asterisks indicate statistically significant differences based on a 
paired two-tail students t-test (** = p<0.01). 
Figure 7.3. Effects of the different Rep constructs on AAV2 DNA replication. (A) 
Replication of an AAV2 replicon is visualized with plasmid pAV2-LacO, which is harbouring a 
LacO-cassette consisting of 40 LacI binding sites flanked by AAV2 ITRs. In presence of the 
different Rep constructs and HSV-1 helper factors, the accumulation of pAV2-LacO 
replication products is visualized by binding of an EYFP-LacI fusion protein. The Rep 
proteins were stained with a Rep-specific antibody (red insets). Size bar; 5µm. (B) Vero 2-2 
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cells were transfected with pAV2GFP and the different Rep constructs as indicated. One day 
post transfection, the cells were super-infected with HSV-1 (MOI 2) and 48hrs later subjected 
to HIRT DNA extraction. The extracted extrachromosomal DNA was digested with DpnI and 
analyzed by Southern blotting with a DIG-labeled probe specific for EGFP. The rescued 
monomeric (ITRm) and dimeric (ITRd) replication intermediates are indicated on the right. As 
a positive control, 0.1 ng of the excised (Bgl II digested) ITR cassette from pAV2GFP was 
loaded. 
Figure 7.4. Co-visualization of competing AAV2 and HSV-1 replication in the same cell. 
DNA Replication of AAV2 and HSV-1 was visualized in the same cell by transfecting Vero 2-
2 cells with the replicons pAV2-LacO and pHSV-TetO, respectively, together with the Rep 
constructs as indicated on the top. One day later, the cells were super-infeced with HSV-1 
(MOI 2). Replication products from pAV2-LacO were visualized with the fusion protein 
mRFP-LacI and replication products from pHSV-TetR were visualized with the fusion protein 
EYFP-TetR. Size bar; 2.5µm. 
Figure 7.5. Effects of the different Rep constructs on the cell. (A-C) Screening of the 
Rep constructs for their ability to induce a DNA-damage response. Vero cells were 
transfected with plasmids expressing either wtRep78, Rep78K340H or Rep78D371Y. The 
empty vector plasmid pcDNA-EGFP served as a negative control. After two days, the cells 
were fixed and stained with antibodies specific for Rep and either pRPA (S3/4), pATM 
(S1981) or γH2AX (S139). Rep+- or GFP+-cells were scored for staining of the DDR markers. 
(D) Screening of the Rep constructs for their ability to induce apoptosis in the transfected 
cell. Vero cells were transfected with plasmids as described in panels A-C together with an 
EGFP expressing plasmid. Three days later, the cells were stained with Cy5-conjugated 
annexin V and analyzed by flow cytometry with filters specific for EGFP (transfected cells) 
and Cy5 (apoptotic cells). The data is shown as means ± SD from three independent 
experiments. 
Figure 7.6. HSV/AAV hybrid vector replication and packaging. VERO 2-2 cells were 
transfected with the following vector plasmid DNAs: the HSV/AAV hybrid vector 
pHyRaNGFPa containing the wtRep ORF or the HSV/AAV hybrid vector pHyRD371YGFPa 
containing the D371Y helicase mutant Rep ORF. Packaging of the vectors into HSV-1 
virions was facilitated by co-transfecting a packaging-defective HSV-1 helper DNA 
fHSVΔpacΔ27Δkn and the HSV-1 ICP27 encoding plasmid pEBHICP27. Vector particles 
were harvested 3 days after transfection and titrated on Vero cells. Packaging of the HSV-1 
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vector plasmid pHSVGFP served as positive control. Mock infected Vero cells served as a 
negative control for the titration. The data is shown as means ± SD from three independent 
experiments. Asterisks indicate statistically significant differences based on a paired two-tail 
students t-test (*= p<0.05). 
Table 7.1. Summary of AAV2 Rep activities. The activities of the wt Rep78, the mutants 
Rep78K340H and Rep78D371Y were scored for their ability to (i) promote AAV2 replication, 
(ii) inhibit HSV-1 replication, (iii) induce a DDR and (iv) induce apoptosis; (-) no score, (+) 
minimal score, (++) intermediate score, (+++) high score. 
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Table 7.1
Rep AAV2 
replication
HSV-1 
replication
DNA damage 
response apoptosis
78 +++ - +++ +++
78K340H - ++ - -
78D371Y +++ ++ + -
Table 1. Summary of AAV2 Rep activities
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8. Discussion 
 
Inhibition of the helper virus is an essential step during the lytic replication cycle of AAV2. It is 
necessary to reduce and minimize helper virus DNA replication, which would compete in the co-
infected cell for resources, such as enzymes (e.g. polymerases) or energy sources (e.g. 
adenosine tri-phosphate; ATP), but also for spatial resources required for the development of 
replication centers (e.g. in the nucleus). The rationale behind the inhibition strategy lies within 
the challenge to inhibit helper virus replication, but at the same time still maintain the supply of 
helper functions from the inhibited virus. The fundamental differences in the nature of the various 
helper viruses require a broad range of strategies to inhibit helper virus replication. Some of the 
mechanisms AAV2 has developed to inhibit helper virus replication have been studied 
thoroughly and are well understood, as it is the case for Ad (5, 8, 26, 35). On the other hand, 
AAV2-mediated inhibition of HSV-1 replication has been documented on several occasions 
indeed, but much less is known about the exact inhibitory effects AAV2 exerts on HSV-1 
replication (2, 12, 14, 15, 17, 38). Nevertheless, several reports suggested that the AAV2 Rep 
protein is the main effector on AAV2-mediated inhibition of HSV-1 replication (14, 17), but none 
of these studies identified the mechanism of Rep-mediated inhibition of HSV-1 replication.  
The main objective of the present study was to address one fundamental question: what is the 
mechanism of AAV2 Rep-mediated inhibition of HSV-1 replication. We addressed this question 
as follows: In a first step, we characterized the level at which Rep is inhibiting HSV-1 replication. 
Next, we identified the functional domains of Rep necessary for inhibition of HSV-1 replication. 
Then, we created a link between the Rep domains identified to be responsible for inhibition of 
HSV-1 replication and the function these domains exert on the cellular level. In a final step, we 
asked the question, whether AAV2 Rep can interact directly with HSV-1 DNA in order to inhibit 
replication. 
The first step was accomplished by assessing the levels of infectious particles, the levels of 
replicated HSV-1 DNA and the levels of HSV-1 encoded gene products in presence of the AAV2 
Rep78 protein. We showed that the Rep-mediated inhibition of HSV-1 replication is dose-
dependent and likely occurs at the stage of HSV-1 DNA replication. The levels of infectious 
particles and replicated DNA decreased linearly with increasing amounts of transfected Rep78 
expression plasmids. However, the expression levels of HSV-1 genes were not uniformly 
inhibited. Rep78 had a stronger effect on the late (L) gene products VP16, VP22 and gC than on 
the immediate-early (IE) gene product ICP4 and the early (E) gene products UL9, UL5, UL42 
and ICP8, which was a clear indication that inhibition may occur at the stage of HSV-1 DNA 
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replication, which was in accordance with previous findings (12). In a second set of experiments 
we identified the Rep activities necessary for the inhibition of HSV-1 DNA replication. We 
determined that the Rep DNA-binding and ATPase/helicase activities present on the same Rep 
molecule are required and sufficient for inhibition, whereas the C-terminus and the 
endonuclease activities are not. We utilized a set of mutant Rep proteins lacking distinct 
activities or domains to assess production of infectious HSV-1 particles in transfected cells. The 
results demonstrated that the proteins Rep68, 78 and Rep78Y156F, which has a mutation within 
the RCR2 motif required for endonuclease activity (10), reduce infectious HSV-1 particle titers at 
around 100-fold, whereas Rep52, which lacks the DNA binding domain, and Rep78K340H, 
which is lacking helicase activity (3, 30), do not. In a subsequent experiment, we aimed to 
complement the required activities to inhibit HSV-1 replication by co-transfecting a plasmid 
encoding the wt Rep52 protein, which contains a functional ATPase/helicase domain but lacks 
the DNA-binding domain, and a plasmid encoding the mutant Rep78K340H, which contains a 
functional DNA-binding domain but lacks the helicase activity. However, these two Rep proteins 
were not able to cross-complement each other in order to restore inhibition activity. This result 
demonstrated that the DNA-binding and the ATPase/helicase activity are required to be present 
on the same Rep molecule.  
In a next step, we aimed to link the Rep-activities required for inhibition of HSV-1 replication with 
a mechanism. In theory, Rep could inhibit HSV-1 replication via a direct effect of Rep on HSV-1 
DNA replication, or else via an effect on cellular DNA. In fact, Rep is known to exhibit a variety of 
effects on the host cell such as induction of DNA damage responses, cell cycle arrest and 
apoptosis (3, 30–32). Of note, the Rep activities necessary to induce apoptosis and to inhibit 
HSV-1 replication perfectly coincide, which led us to the hypothesis that induction of apoptosis 
might be part of the mechanism how AAV2 is inhibiting HSV-1 replication. However, we 
demonstrate that induction of apoptosis is not the leading cause of inhibition of HSV-1 
replication. In particular, apoptosis is not induced in HSV-1 infected cells expressing Rep78 at 
72 hours post infection and in addition, caspase inhibitors did not abolish the Rep-mediated 
inhibition of HSV-1 replication. Therefore, we concluded that induction of apoptosis is not directly 
part of the inhibitory effect of Rep rather it is linked to it, most probably via a pathway upstream 
of apoptosis. One possibility could be the ability of Rep to induce DNA damage, which is a direct 
upstream inducer of apoptosis (3). The AAV2 Rep proteins have been documented to induce 
hyper-phosphorylation of ATM and H2AX in transfected cell (3, 32), while ATM has been shown 
to be essential for the Rep-mediated activation of H2AX. Specifically, Rep failed to induce 
activation of H2AX in ATM-null cells (3). H2AX is a histone protein, which is activated upon 
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dsDNA breaks and mediates recruitment of DNA repair proteins to the site of the lesion. ATM on 
the other hand is an effector kinase also activated upon dsDNA breaks and is activating a subset 
of downstream targets, which regulate the cell cycle and DNA damage repair (reviewed in (46)). 
In addition to the AAV2 Rep-induced hyper-phosphorylation of ATM and H2AX, we also 
observed Rep-mediated activation of RPA, a ssDNA-binding protein, which is involved in several 
cellular activities such as DNA replication, DNA repair and DNA damage checkpoint (reviewed in 
(49)). In fact, it has been documented that both viruses, AAV2 and HSV-1, can induce a DNA 
damage response (DDR) in the infected cell when entering a lytic replication cycle. While AAV2 
is inducing hyper-phosphorylation of ATM, H2AX and RPA (32), HSV-1 induces activation of 
ATM and H2AX only (18, 34, 42), but not RPA (40, 41). Moreover, it has been documented that 
activated RPA is sequestered into virus-induced chaperone enriched (VICE) domains during 
productive HSV-1 replication (42). Hence, we hypothesized that the AAV2 Rep-induced hyper-
phosphorylation of RPA could interfere with the DDR induced by HSV-1 and therefore lead to 
inhibition. To assess, if hyper-phosphorylation of RPA may inhibit HSV-1 replication, we 
determined HSV-1 replication efficiency in cells pre-treated with hydroxy urea (HU), 
camptothecin (CPT) or UV-inactivated AAV2, all inducing activation of RPA (9, 16, 20, 33). Our 
data indicated that induction of RPA is not resulting in reduced levels of HSV-1 replication, 
suggesting that phosphorylation and therefore activation of RPA is not the cause of Rep-
mediated inhibition of HSV-1 replication. Of note, even if HU-treatment was reducing virus titers 
significantly, we ruled out the possibility that phosphorylated RPA might be the cause, since HU 
is also depleting dNTP pools (1) and this effect would lead to overall reduced replication. 
After ruling out potential cellular mechanisms Rep may utilize to inhibit HSV-1 DNA replication, 
we considered a more direct mechanism as conceivable, because Rep might also interact 
directly with the HSV-1 DNA replication process. The AAV2 Rep proteins display site- and 
sequence-specific binding of dsDNA at Rep-binding sites (RBS), which is required for AAV2 
DNA replication as well as genomic integration. The RBS recognized by Rep is characterized by 
a simple stretch of GAGC tetra-nucleotide repeats, which vary in length and integrity (6, 7, 11, 
22, 23, 29, 43). The minimal sequence requirement for Rep to bind specifically to dsDNA is the 
motif consisting of the nucleotide sequence GAGYGAGC (6), but low-affinity Rep-binding is 
achieved even with a single GAGC repeat, followed by a stretch of G bases (7). Binding affinity 
of Rep to RBS is correlated with the number of GAGC repeats; the more repeats present, the 
higher the binding-affinity. The AAV2 genome contains two basic RBS located within the ITR, 
and within the p5 promoter with the much higher binding affinity of the RBS located on the ITR 
(11). If the minimal requirements for Rep-binding (GAGYGAGC) are applied to the human 
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genome, theoretically over 2x105 potential RBSs can be identified (45). Similar, if the same 
characteristics are applied to the HSV-1 genome, nine putative RBSs can be identified but no 
TRS in association with those putative RBSs. Of note, only the AAV2 origin of DNA replication 
(ITR) and the AAVS1 site on the human chromosome 19 are harboring a functional terminal 
resolution site (TRS) in close proximity to an RBS. Moreover, the RBS located at ITRs and 
AAVS1 are expected to possess the highest affinity for Rep, as they contain the most 
subsequent GAGC repeats (GAGCGAGCGAGC). However, after co-infection with a helper 
virus, Rep expression levels are high and Rep might also bind to RBSs with lower affinities, such 
as the putative RBS on the HSV-1 genome. The Rep helicase however relies on no sequence 
requirements, but if the DNA is blunt-ended, it needs to be bound to the substrate via the N-
terminal DNA-binding domain (44, 48).  
If the Rep-helicase indeed is the critical enzyme to inhibit HSV-1 DNA replication, it may be 
possible that it can inhibit replication of any DNA substrate it can bind to. To test this hypothesis, 
we tested the ability of a recombinant Rep molecule Rep52-LacI, which consists of the lac-
operon binding motif (LacI) instead of the Rep DNA-binding domain and the functional 
ATPase/helicase domain of Rep52, to inhibit replication of pHSV-LacO. This amplicon plasmid 
consists of an HSV-1 origin of DNA replication (oriS) and a cassette of 40 lac-inhibitor binding 
motifs (12). Indeed, we observed that HSV-1 induced formation of replication compartments 
(RCs) containing pHSV-LacO DNA was reduced significantly in cells expressing the recombinant 
Rep52-LacI protein. We also showed that either the protein Rep52K340H-LacI lacking helicase 
activity, or the wt Rep52 protein lacking the DNA-binding domain, were not affecting formation of 
pHSV-LacO RCs. Both observations are clear indications that the Rep helicase activity can 
affect replication of any DNA substrate it can bind to, independent of the Rep DNA-binding 
domain. Moreover, they indicate that Rep-helicase mediated inhibition of DNA replication is 
indeed specific. In a next step, we wanted to assess the capacity of Rep to bind the HSV-1 DNA 
at putative RBSs. We first identified putative RBSs (pRBS) on the HSV-1 genome by screening 
for the minimal consensus RBS motif GAGYGAGC (6, 7). We identified nine pRBS, which all are 
located on the unique long (UL) segment of the HSV-1 genome. Sequence alignment of the 
HSV-1 pRBS motifs revealed that they all consist of two complete GAGC repeats with the 
exception of one pRBS, which is consisting of one GAGT and one GAGC tetra-nucleotide, but 
still complies with the minimal Rep-binding motif. To confirm that the AAV2 Rep68 protein is 
capable of binding to these sites on the HSV-1 genome, we performed electrophoretic mobility 
shift assays (EMSA) with a randomly chosen set of five oligonucleotides, each harboring one 
pRBS from the HSV-1 genome. We clearly demonstrated that purified Rep68 proteins are 
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capable of specifically binding to all pRBSs on the HSV-1 genome tested in vitro, although with 
different binding affinities. These data were corroborated by a second set of experiments, which 
assessed binding of a Rep68-GFP fusion protein to HSV-1 pRBSs in the cell by chromatin 
immuno-precipitation assays (ChIP) followed by quantitative PCR (qPCR). The data showed that 
similar to the EMSA, Rep68-GFP is capable of binding to all tested pRBS identified on the HSV-
1 genome. This set of data confirmed that the AAV2 Rep68 protein indeed is capable of binding 
to pRBS on the HSV-1 genome, in silico, in vitro, and in the cell. 
In a follow-up study we presented the phenotypic profile of a newly emerged AAV2 Rep-helicase 
mutation (D371Y). In particular, we assessed the capability of the mutant Rep78D371Y protein 
to either promote AAV2- or inhibit HSV-1 DNA replication. Our results clearly demonstrate that 
the mutant Rep78D371Y is not inhibiting HSV-1 DNA replication to the same extent as the wt 
Rep78 does, but at the same time, unlike the helicase-null mutant Rep78K340H, the 
Rep78D371Y still supports AAV2 DNA replication. More precisely the formation of HSV-1 RCs 
was not promoted in cells expressing wt Rep78, but similar to the helicase-null mutant 
Rep78K340H, the mutant Rep78D371Y allowed the formation of HSV-1 RCs. On the other 
hand, the expected formation of AAV2 RCs was readily observed in cells expressing wt Rep78, 
but not in cells expressing the mutant Rep78K340H. Interestingly, the formation of AAV2 RCs 
was also observed with the helicase-mutant Rep78D371Y which was unexpected. These results 
were confirmed by Southern analysis to detect AAV2 replication intermediates and by HSV-1 
amplicon titration to assess HSV-1 replication. Moreover, we assessed the capability of the 
mutant Rep78D371Y to induce a DDR in transfected cells. The activation status of the following 
DDR proteins were analyzed in cells expressing the mutant Rep78D371Y: (i) the sensor-kinase 
ataxia-telangiectasia mutated (pATM), (ii) the replication protein A (pRPA) and (iii) the histone 
γH2AX. We found that the levels of activated DDR proteins were 20-60% lower in cells 
expressing the mutant Rep78D371Y compared to cells expressing the wt Rep78. In addition, as 
opposed to wt Rep78, the mutant Rep78D371Y did not induce apoptosis in transfected cells. 
Both findings are clear indications, that the overall toxicity of Rep78D371Y is dramatically 
reduced compared to the wt Rep78. The Rep activities tested in this study are summarized in 
Table 1. In a next step we inserted the mutant Rep78D371Y into HSV/AAV hybrid vectors by 
replacing the wt Rep ORF with the corresponding mutant Rep ORF. Titration of the newly 
generated mutant hybrid vectors revealed that Rep78D371Y did not inhibit replication of the 
hybrid amplicon DNA resulting in up to 10-fold higher hybrid vector titers when compared to 
titers of hybrid vectors harboring the wt Rep ORF. 
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9. Conclusions 
 
In the present study, we demonstrate that AAV2 Rep-mediated inhibition of HSV-1 DNA 
replication is not induced through a cellular mechanism, but rather is affecting the HSV-1 DNA 
replication process directly. We suggest that the Rep68/78 proteins are targeted to the HSV-1 
DNA via pRBS and that the Rep helicase activity can modify the bound DNA, which is then 
leading to inhibition of HSV-1 DNA replication.  
However, a conclusive mechanism how Rep is inhibiting HSV-1 DNA replication cannot be 
drawn directly from these facts, but our data still provide evidence for a conceivable strategy. 
Upon replicative stress, the cell is rapidly initiating a DDR, which is characterized by the type of 
stress. One of the responses is the DDR pathway initiated by ATM and ATR, which both are 
activated upon stalled replication forks (RF). During a stalled RFs, the mini-chromosome 
maintenance 2-7 (MCM2-7) complex is uncoupled from the cellular replication complex and 
continues unwinding the dsDNA template via its helicase activity, generating a stretch of ssDNA 
(25, 27, 28). This stretch of DNA is recognized and covered by the activated replication protein A 
(RPA), which is leading to the activation of ATR and the following cell-cycle arrest (Fig. 9.1 A) (4, 
21, 24, 47, 49). Importantly, persisting replicative stress can result in the collapse of the RF, 
which is associated with dsDNA breaks and the consecutive inhibition of DNA replication (13, 
19). 
In analogy to the MCM2-7 complex, the Rep proteins similarly may unwind dsDNA templates at 
sites where they can bind to, in particular when its replicative function is uncoupled from the 
helicase activity due to the lack of a functional TRS, such as it is the case for the pRBSs on the 
HSV-1 genome. The persisting Rep-helicase activity then would disallow the cell to recover the 
stalled RF and cause a collapse of the RF, which can lead to DSBs and the resulting inhibition of 
the DNA replication (Figure 9.1 B). This hypothesis is supported by previous findings that the 
AAV2 Rep proteins induce a DDR in transfected cells characterized by the activation of ATM 
and H2AX, which is leading to a cell cycle arrest (3, 30, 32). In addition, it may explain our 
observation of the AAV2 Rep induced DDR characterized by the activation not only of ATM and 
H2AX, but also of RPA. 
Our findings from the RepD371Y study revealed the potential of this novel Rep-helicase mutant 
as a reliable alternative for the wt Rep in HSV/AAV hybrid vectors. Low toxicity and the inability 
to inhibit HSV-1 DNA replication while retaining the capability to promote AAV2 DNA replication 
can overcome the most important drawbacks of HSV/AAV hybrid vectors. However, the 
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capability of Rep78D371Y to site-specifically integrate ITR-flanked transgenes into AAVS1 site 
of host chromosome 19 still needs to be elucidated. This property represents the most critical 
activity of Rep proteins in HSV/AAV hybrid vectors and therefore needs to be assessed 
thoroughly. Preliminary data from our lab demonstrated that HEK 293 cells transduced with the 
hybrid vector pHyRD371YGFPa (mutant RepD371Y) stably express the GFP transgene during a 
time period of more than eight month after transduction (data not shown). The same cells 
transduced with the HSV/AAV hybrid vector pHyRaNGFPa (wt Rep) were demonstrated to 
express the transgene gfp up to six month after transduction due to site-specific integration 
events occurring mostly at the AAVS1 site on chromosome 19 (15). These findings suggest that 
Rep78D371Y may retain the ability for site-specific integration.  
 
9.1. Figure Legend & Figure 
 
Figure 9.1 Mechanism of the ATR-mediated replication stress response. (A) Schematic 
representation of a stalled replication fork (RF). The parental DNA is unwound by the mini-
chromosome maintenance 2-7 (MCM2-7) complex and replicated by the polymerases Polε 
and Polδ which are bound to the processivity factor proliferating cell nuclear antigen (PCNA). 
When replication stalls at a damaged DNA strand (red star), the MCM2-7 complex is 
uncoupled from the replicative polymerases and continues unwinding the dsDNA 
downstream of the lesion. The resulting stretch of ssDNA is covered immediately by the 
replication protein A (RPA) and is recognized by ATR and its obligate binding partner ATRIP. 
This complex is initiating a DDR mediated primarily by the effector kinase CHK1 promoting 
fork stabilization and restart while preventing progression through the cell cycle. (B) 
Schematic representation of a stalled RF induced by the AAV2 Rep68/78 proteins. Upon 
binding of Rep68/78 at a putative Rep-binding site (pRBS) the helicase activity unwinds the 
dsDNA template similar to the MCM2-7 complex when uncoupled from the polymerases. The 
resulting stretch of ssDNA is recognized and processed by RPA and the ATR/ATRIP 
aggregate as described above and constitutes a block for the replication process resembling 
a stalled RF. 
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10. Outlook and Perspectives 
 
Whether Rep indeed is inducing a stalled RF still needs to be elucidated. Also, whether the Rep 
helicase activity is capable of unwinding the HSV-1 dsDNA has not yet been demonstrated and 
more work has to be done to answer these questions. Specifically, the development of a highly 
sensitive real-time in vitro helicase assay would help to assess whether Rep is able to unwind 
HSV-1 dsDNA templates. To conclusively corroborate our hypothesis how the AAV2 Rep 
proteins inhibit HSV-1 DNA replication, ultra high resolution microscopy, such as PALM, is 
necessary to identify the predicted stalled replication forks induced by Rep. 
As promising the Rep-mutant D371Y seems to be for the generation of novel HSV/AAV hybrid 
vectors as important it is to test the ability of this new Rep mutant to be compatible with site-
specific integration of transgenes into the AAVS1. Several possible strategies may be applied for 
this analysis: (i) chromosomal DNA extracted from stably transduced cells can be screened by 
PCR with specific primers detecting the junction between the ITR-flanked transgene sequences 
and the AAVS1 site (15) or (ii) linker-mediated PCR (LM-PCR) can be utilized to screen for any 
integration site in the host cell genome (39). In addition to the already improved performance of 
HSV/AAV hybrid vectors harboring the mutant Rep D371Y, the generation of a modified HSV-1 
helper genome lacking the pRBS may help to improve the generation of hybrid vector stocks in 
addition. Particularly, base modifications at the aforementioned pRBS on the HSV-1 genome 
disrupting the Rep-binding consensus sequence GAGYGAGC, but at the same time maintaining 
codon integrity, would result in a HSV-1 helper genome which would be completely resistant to 
Rep-mediated inhibition and therefore may improve HSV/AAV hybrid vector titers greatly. 
Moreover, the Rep-helicase mutant D371Y also may be applied in studies to assess the 
molecular interaction of AAV2 and HSV-1 specifically during DNA replication. The simultaneous 
replication of both viruses in the same cell may allow studying events such as the induction of 
DDR or apoptosis as well as the effect of these two viruses on the cell cycle (36, 37). 
Overall, we believe that the data introduced in the present thesis are contributing to the 
understanding of the interactions between AAV2 and its helper virus HSV-1 in the co-infected 
cell. Even if there is no direct contribution to public health care, the principle how two pathogenic 
agents are interacting with each other in the same cell provides a nice and easy-to-understand 
model to study kinetics and dynamics of such interactions. This knowledge may be useful to be 
adapted to systems and mechanisms of much higher complexity, where not only two pathogens 
are interacting in a cell or organism, which is more likely occurring in nature. Last but not least, 
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work on basic research in general provides a fundamental base for the development of next 
generation drugs, such as it was demonstrated impressively by the development of the recently 
licensed AAV-based gene therapy product Glybera. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
114
11. References (Chapters 8-10) 
 
1. Adams, R. L., and J. G. Lindsay. 1967. Hydroxyurea reversal of inhibition and use as a 
cell-synchronizing agent. J. Biol. Chem. 242:1314–1317. 
2. Bantel-Schaal, U., and H. Zur Hausen. 1988. Adeno-associated viruses inhibit SV40 
DNA amplification and replication of herpes simplex virus in SV40-transformed hamster 
cells. Virology 164:64–74. 
3. Berthet, C., K. Raj, P. Saudan, and P. Beard. 2005. How adeno-associated virus 
Rep78 protein arrests cells completely in S phase. Proceedings of the National Academy 
of Sciences of the United States of America 102:13634–13639. 
4. Boddy, M. N., B. Furnari, O. Mondesert, and P. Russell. 1998. Replication checkpoint 
enforced by kinases Cds1 and Chk1. Science 280:909–912. 
5. Casper, J. M., J. M. Timpe, J. D. Dignam, and J. P. Trempe. 2005. Identification of an 
adeno-associated virus Rep protein binding site in the adenovirus E2a promoter. Journal 
of Virology 79:28–38. 
6. Chiorini, J. A., S. M. Wiener, R. A. Owens, S. R. Kyostio, R. M. Kotin, and B. Safer. 
1994. Sequence requirements for stable binding and function of Rep68 on the adeno-
associated virus type 2 inverted terminal repeats. Journal of Virology 68:7448–7457. 
7. Chiorini, J. A., L. Yang, B. Safer, and R. M. Kotin. 1995. Determination of adeno-
associated virus Rep68 and Rep78 binding sites by random sequence oligonucleotide 
selection. J. Virol. 69:7334–7338. 
8. Di Pasquale, G., and J. A. Chiorini. 2003. PKA/PrKX activity is a modulator of 
AAV/adenovirus interaction. EMBO Journal 22:1716–1724. 
9. Fragkos, M., M. Breuleux, N. Clement, and P. Beard. 2008. Recombinant adeno-
associated viral vectors are deficient in provoking a DNA damage response. J Virol. 
"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citatio
n&list_uids=18463154 ". 
10. Francois, A., M. Guilbaud, R. Awedikian, G. Chadeuf, P. Moullier, and A. Salvetti. 
2005. The cellular TATA binding protein is required for rep-dependent replication of a 
minimal adeno-associated virus type 2 p5 element. Journal of Virology 79:11082–11094. 
11. Glauser, D. L., O. Saydam, N. A. Balsiger, I. Heid, R. M. Linden, M. Ackermann, and 
C. Fraefel. 2005. Four-dimensional visualization of the simultaneous activity of 
alternative adeno-associated virus replication origins. Journal of Virology 79:12218–
12230. 
115
12. Glauser, D. L., R. Strasser, A. S. Laimbacher, O. Saydam, N. Clément, R. M. Linden, 
M. Ackermann, and C. Fraefel. 2007. Live covisualization of competing adeno-
associated virus and herpes simplex virus type 1 DNA replication: molecular mechanisms 
of interaction. Journal of Virology 81:4732–4743. 
13. Hanada, K., M. Budzowska, S. L. Davies, E. van Drunen, H. Onizawa, H. B. 
Beverloo, A. Maas, J. Essers, I. D. Hickson, and R. Kanaar. 2007. The structure-
specific endonuclease Mus81 contributes to replication restart by generating double-
strand DNA breaks. Nat Struct Mol Biol 14:1096–1104. 
14. Heilbronn, R., A. Burkle, S. Stephan, and H. Zur Hausen. 1990. The adeno-associated 
virus rep gene suppresses herpes simplex virus-induced DNA amplification. Journal of 
Virology 64:3012–3018. 
15. Heister, T., I. Heid, M. Ackermann, and C. Fraefel. 2002. Herpes simplex virus type 
1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-
associated virus preintegration site, AAVS1, on human chromosome 19. Journal of 
Virology 76:7163–7173. 
16. Jurvansuu, J., K. Raj, A. Stasiak, and P. Beard. 2005. Viral transport of DNA damage 
that mimics a stalled replication fork. Journal of Virology 79:569–580. 
17. Kleinschmidt, J. A., M. Mohler, F. W. Weindler, and R. Heilbronn. 1995. Sequence 
elements of the adeno-associated virus rep gene required for suppression of herpes-
simplex-virus-induced DNA amplification. Virology 206:254–262. 
18. Lilley, C. E., C. T. Carson, A. R. Muotri, F. H. Gage, and M. D. Weitzman. 2005. DNA 
repair proteins affect the lifecycle of herpes simplex virus 1. Proceedings of the National 
Academy of Sciences of the United States of America 102:5844–5849. 
19. Lopes, M., M. Foiani, and J. M. Sogo. 2006. Multiple mechanisms control chromosome 
integrity after replication fork uncoupling and restart at irreparable UV lesions. Mol Cell 
21:15–27. 
20. Manthey, K. C., S. Opiyo, J. G. Glanzer, D. Dimitrova, J. Elliott, and G. G. Oakley. 
2007. NBS1 mediates ATR-dependent RPA hyperphosphorylation following replication-
fork stall and collapse. J Cell Sci 120:4221–4229. 
21. Martinho, R. G., H. D. Lindsay, G. Flaggs, A. J. DeMaggio, M. F. Hoekstra, A. M. 
Carr, and N. J. Bentley. 1998. Analysis of Rad3 and Chk1 protein kinases defines 
different checkpoint responses. EMBO J 17:7239–7249. 
22. McCarty, D. M., D. J. Pereira, I. Zolotukhin, X. Zhou, J. H. Ryan, and N. Muzyczka. 
1994. Identification of linear DNA sequences that specifically bind the adeno-associated 
virus Rep protein. Journal of Virology 68:4988–4997. 
116
23. McCarty, D. M., J. H. Ryan, S. Zolotukhin, X. Zhou, and N. Muzyczka. 1994. 
Interaction of the adeno-associated virus Rep protein with a sequence within the A 
palindrome of the viral terminal repeat. Journal of Virology 68:4998–5006. 
24. Namiki, Y., and L. Zou. 2006. ATRIP associates with replication protein A-coated 
ssDNA through multiple interactions. Proc. Natl. Acad. Sci. U.S.A. 103:580–585. 
25. Nedelcheva, M. N., A. Roguev, L. B. Dolapchiev, A. Shevchenko, H. B. Taskov, A. 
Shevchenko, A. F. Stewart, and S. S. Stoynov. 2005. Uncoupling of unwinding from 
DNA synthesis implies regulation of MCM helicase by Tof1/Mrc1/Csm3 checkpoint 
complex. J. Mol. Biol. 347:509–521. 
26. Needham, P. G., J. M. Casper, V. Kalman-Maltese, K. Verrill, J. D. Dignam, and J. P. 
Trempe. 2006. Adeno-associated virus rep protein-mediated inhibition of transcription of 
the adenovirus major late promoter in vitro. Journal of Virology 80:6207–6217. 
27. Nitani, N., C. Yadani, H. Yabuuchi, H. Masukata, and T. Nakagawa. 2008. Mcm4 C-
terminal domain of MCM helicase prevents excessive formation of single-stranded DNA 
at stalled replication forks. Proc. Natl. Acad. Sci. U.S.A. 105:12973–12978. 
28. Pacek, M., A. V. Tutter, Y. Kubota, H. Takisawa, and J. C. Walter. 2006. Localization 
of MCM2-7, Cdc45, and GINS to the site of DNA unwinding during eukaryotic DNA 
replication. Mol. Cell 21:581–587. 
29. Ryan, J. H., S. Zolotukhin, and N. Muzyczka. 1996. Sequence requirements for binding 
of Rep68 to the adeno-associated virus terminal repeats. Journal of Virology 70:1542–
1553. 
30. Saudan, P., J. Vlach, and P. Beard. 2000. Inhibition of S-phase progression by adeno-
associated virus Rep78 protein is mediated by hypophosphorylated pRb. EMBO Journal 
19:4351–4361. 
31. Schmidt, M., S. Afione, and R. M. Kotin. 2000. Adeno-associated virus type 2 Rep78 
induces apoptosis through caspase activation independently of p53. Journal of Virology 
74:9441–9450. 
32. Schwartz, R. A., C. T. Carson, C. Schuberth, and M. D. Weitzman. 2009. Adeno-
associated virus replication induces a DNA damage response coordinated by DNA-
dependent protein kinase. J Virol 83:6269–6278. 
33. Shao, R.-G. 1999. Replication-mediated DNA damage by camptothecin induces 
phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK 
complexes. The EMBO Journal 18:1397–1406. 
34. Shirata, N., A. Kudoh, T. Daikoku, Y. Tatsumi, M. Fujita, T. Kiyono, Y. Sugaya, H. 
Isomura, K. Ishizaki, and T. Tsurumi. 2005. Activation of ataxia telangiectasia-mutated 
117
DNA damage checkpoint signal transduction elicited by herpes simplex virus infection. 
Journal of Biological Chemistry 280:30336–30341. 
35. Timpe, J. M., K. C. Verrill, and J. P. Trempe. 2006. Effects of adeno-associated virus 
on adenovirus replication and gene expression during coinfection. Journal of Virology 
80:7807–7815. 
36. Vogel, R. 2013. Viral and Cellular Components of AAV2 Replication Compartments. 
TOVJ 7:98–120. 
37. Vogel, R., M. Seyffert, R. Strasser, A. P. de Oliveira, C. Dresch, D. L. Glauser, N. 
Jolinon, A. Salvetti, M. D. Weitzman, M. Ackermann, and C. Fraefel. 2011. Adeno-
Associated Virus Type 2 Modulates the Host DNA Damage Response Induced by 
Herpes Simplex Virus 1 during Coinfection. Journal of Virology 86:143–155. 
38. Wang, Y., S. M. Camp, M. Niwano, X. Shen, J. C. Bakowska, X. O. Breakefield, and 
P. D. Allen. 2002. Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid 
amplicon vector improves the stability of transgene expression in human cells by site-
specific integration. Journal of Virology 76:7150–7162. 
39. Ward, P., and C. E. Walsh. 2012. Targeted integration of a rAAV vector into the AAVS1 
region. Virology 433:356–366. 
40. Wilkinson, D. E., and S. K. Weller. 2004. Recruitment of cellular recombination and 
repair proteins to sites of herpes simplex virus type 1 DNA replication is dependent on 
the composition of viral proteins within prereplicative sites and correlates with the 
induction of the DNA damage response. Journal of Virology 78:4783–4796. 
41. Wilkinson, D. E., and S. K. Weller. 2005. Inhibition of the herpes simplex virus type 1 
DNA polymerase induces hyperphosphorylation of replication protein A and its 
accumulation at S-phase-specific sites of DNA damage during infection. Journal of 
Virology 79:7162–7171. 
42. Wilkinson, D. E., and S. K. Weller. 2006. Herpes simplex virus type I disrupts the ATR-
dependent DNA-damage response during lytic infection. Journal of Cell Science 
119:2695–2703. 
43. Wonderling, R. S., and R. A. Owens. 1997. Binding sites for adeno-associated virus 
Rep proteins within the human genome. J. Virol. 71:2528–2534. 
44. Wu, J., M. D. Davis, and R. A. Owens. 1999. Factors affecting the terminal resolution 
site endonuclease, helicase, and ATPase activities of adeno-associated virus type 2 Rep 
proteins. J. Virol. 73:8235–8244. 
118
45. Young, S. M., JR., D. M. McCarty, N. Degtyareva, and R. J. Samulski. 2000. Roles of 
adeno-associated virus Rep protein and human chromosome 19 in site-specific 
recombination. Journal of Virology 74:3953–3966. 
46. Zeman, M. K., and K. A. Cimprich. 2013. Causes and consequences of replication 
stress. Nat Cell Biol 16:2–9. 
47. Zeng, Y., K. C. Forbes, Z. Wu, S. Moreno, H. Piwnica-Worms, and T. Enoch. 1998. 
Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or 
Chk1. Nature 395:507–510. 
48. Zhou, X., I. Zolotukhin, D. S. Im, and N. Muzyczka. 1999. Biochemical characterization 
of adeno-associated virus rep68 DNA helicase and ATPase activities. Journal of Virology 
73:1580–1590. 
49. Zou, L., and S. J. Elledge. 2003. Sensing DNA damage through ATRIP recognition of 
RPA-ssDNA complexes. Science 300:1542–1548. 
  
119
12. Acknowledgments 
 
I kindly thank the following persons, who supported the realization of this thesis: 
Prof. Dr. Cornel Fraefel, who gave me the opportunity to make my PhD in his research group. I 
especially want to thank him for his continuous scientific support, for his great expertise and his 
patience throughout my PhD. I am also very grateful for the many opportunities to attend 
international and national scientific meetings and congresses. He has been always an 
encouraging mentor and supervisor. 
Dr. Daniel Glauser, for his excellent scientific support in the laboratory and for all the precious 
advices throughout my PhD. I am really grateful for his outstanding work in the laboratory, which 
was the groundwork for my PhD projects.  
Prof. Dr. Mathias Ackermann, for the valued support in his institute and for very helpful advices 
and scientific discussions. 
Prof. Dr. Urs Greber and Prof. Dr. Peter Beard for being co-supervisors in my PhD committee 
and for the great scientific support during PhD committee meetings. 
Dr. Kurt Tobler, Dr. Oleg Georgiev and Prof. Dr. Peter Wild for their outstanding experimental 
and scientific support and help. 
Bernd Vogt and Elisabeth Schraner for their excellent technical support in the laboratory. 
Prof. Dr. Michael Linden and Dr. Leticia Agundez Cortes for the continuous supply of purified 
Rep proteins. 
Especially I want to thank the following persons who contributed great support in any way during 
my PhD:  
Frau Dr. Andrea Laimbacher, Dr. Anna-Paula de Oliveira, Anita (Schnittchen) Meier, Dr. Bep 
Vetsch, Dr. Bruniña de Andrade Pereira do Visconde do Rio Branco, Cedric (Beer) Vogt, 
Christiane Dresch, Francesca Caccuri, Francesca Franzoso, Hitsch Lange, Marco (Carwash) 
Geisseler, Dr. Rebecca Vogel, (Dr.Dr.) Sophie Ramsauer (What?!) and all the persons I forgot to 
mention!                (Names in alphabetical order) 
 
 
120
Personally I kindly want to thank: 
My parents, who gave me the unique opportunity to study. Their tremendous support throughout 
my studies and especially during my PhD was a great motivation. Without their precious help 
this thesis would not exist. 
My sister and her family who contributed very valuable advices and critical discussions about 
science and research. They always have been a great inspiration for me. 
  
121
13. Curriculum Vitae 
 
Personal Dates 
 Last name:  SEYFFERT 
 First name:  Michael 
 Date of birth:  Nov. 1st, 1979 
 Place of birth:  Chur, Switzerland 
 Nationality:  Swiss 
 Address (private): Schwandenacker, 44 
    8052, Zurich, Switzerland 
    Phone:   079 647 19 39 
    E-Mail:   seyffert@gmx.ch 
 Address (work): Institute of Virology, University of Zurich, 
    Winterthurerstrasse 266a, 
    8057, Zurich, Switzerland 
    Phone:  +41 44 635 87 14 
    E-Mail:   mseyffert@vetvir.uzh.ch 
 
Education 
 1987-1992:  Primary School, Trimmis and Grüsch 
 1992-1993:  1st year of Secondary School, Grüsch 
 1993-2001:  Evangelische Mittelschule Schiers (EMS), Schiers 
 2002-2003:  Vetsuisse Faculty, University of Zurich; undergraduate student 
2003-2007: Mathematisch-naturwissenschaftliche Fakultät, University of Zurich, 
undergraduate student 
2007-2008:  Institute of Virology, University of Zurich, master student 
2008-2014:  Institute of Virology, University of Zurich, doctoral student 
 
Diplomas and Degrees 
 2001:   Matura (Type B) 
 2007:   Bachelor of Science (B.Sc.), Biology 
 2008:   Master of Science (M.Sc.), Molecular and Cellular Biology 
 
122
Research Experience 
 2007-2008:  Master student; Institute of Virology, University of Zurich 
 2008-2014:  Doctoral student; Institute of Virology, University of Zurich 
 
Working and Supervision Experience 
 2001-2002:   Veterinary assistant; Vetsuisse Faculty, University of Zurich 
2008-2014: Student course assistant (molecular biology, virology), Bachelor- 
and Master Student supervision; Institute of Virology, University of 
Zurich 
 
Research Interests 
 Molecular and applied virology 
 Microscopy 
 Cell biology 
 Gene therapy 
 Gene therapy vectors 
 
Publications 
   
Research articles 
1. Glauser DL, Seyffert M, Strasser R, Franchini M, Laimbacher AS, Dresch C, de 
Oliveira AP, Vogel R, Büning H, Salvetti A, Ackermann M, Fraefel C. Inhibition of 
herpes simplex virus type 1 replication by adeno-associated virus rep proteins 
depends on their combined DNA-binding and ATPase/helicase activities. 
J Virol. 2010 Apr; 84(8):3808-24. 
 
2. Vogel R, Seyffert M, Strasser R, de Oliveira AP, Dresch C, Glauser DL, Jolinon 
N, Salvetti A, Weitzman MD, Ackermann M, Fraefel C.  
Adeno-associated virus type 2 modulates the host DNA damage response 
induced by herpes simplex virus 1 during coinfection.  
J Virol. 2012 Jan; 86(1):143-55. 
 
 
 
123
3. Laimbacher AS, Esteban LE, Castello AA, Abdusetir Cerfoglio JC, Argüelles MH, 
Glikmann G, D'Antuono A, Mattion N, Berois M, Arbiza J, Hilbe M, Schraner EM, 
Seyffert M, Dresch C, Epstein AL, Ackermann M, Fraefel C. HSV-1 amplicon 
vectors launch the production of heterologous rotavirus-like particles and induce 
rotavirus-specific immune responses in mice.  
Mol Ther. 2012 Sep; 20(9):1810-20. 
 
4. Seyffert M, Glauser DL, Tobler K, Georgiev O, Vogel R, Vogt B, Agúndez L, 
Linden M, Büning H, Ackermann M, Fraefel C. 
AAV2 Rep68 can bind to consensus Rep-binding sites on the HSV-1 genome. 
Short-Form paper, JVI, manuscript in preparation, 2014. 
 
Review articles 
Vogel R, Seyffert M, Pereira Bde A, Fraefel C.  
Viral and Cellular Components of AAV2 Replication Compartments.  
Open Virol J. 2013 Oct 31; 7:98-120. 
 
  Book chapters 
Seyffert M, de Oliveira AP, Fraefel C, Vogel R.  
Multifluorescence Live Analysis of Herpes Simplex Virus Type-1 Replication. 
Herpes Simplex Virus: Methods and Protocols, Methods in Molecular Biology, 
vol. 1144, DOI 10.1007/978-1-4939-0428-0_16, © Springer Science+Business 
Media New York, 2014. 
 
Master Thesis 
Seyffert M.  
Mutational Analysis of AAV Rep Protein-Mediated Inhibition of HSV-1 Replication 
Master Thesis (M.Sc.), Institute of Virology, University of Zurich, 2008. 
 
124
